













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Investigating the effects of aspirin on cell 
invasion, epithelial-mesenchymal 
transition and cancer stem cell population 












Doctor of Philosophy 






I am the sole author of this thesis and all work has been completed by myself unless 





























Colorectal cancer (CRC) is the fourth most common cause of cancer related deaths 
in the UK with the prognosis dependent on the degree of tumour invasion and 
presence of metastasis at diagnosis. An important step in the invasion and 
metastasis of solid tumours is the loss of cell-cell junctions and the acquirement of a 
more motile mesenchymal phenotype which is facilitated by the epithelial-
mesenchymal transition (EMT). The presence of EMT is linked with a more 
aggressive, invasive tumour and subsequent poor prognosis. In addition to roles in 
motility and invasion, EMT can induce a cancer stem cell phenotype in a subset of 
tumour cells. Cancer stem cells (CSCs) are a subpopulation of cells capable of self-
renewal and maintaining a cellular population whilst displaying increased 
therapeutic resistance. Induction of EMT and CSCs can be regulated by common 
signalling pathways with expression of EMT transcription factors inducing CSCs 
expression. Understanding the signalling pathways regulating EMT and CSC 
formation in cancer is important for preventing of metastasis and combating 
therapeutic resistance.   
Aspirin’s role in cancer prevention has been established for a number of years with 
aspirin treatment reducing the incidence of CRC. Recently, evidence has emerged 
suggesting aspirin treatment may have post-diagnosis benefits and increase survival 
rates of CRC patients. A potential mechanism for the post-diagnosis benefit of 
aspirin is the inhibition of EMT and CSC formation which both facilitate tumour 
progression and metastasis. Aspirin has been demonstrated to suppress the 
migratory and invasive capacity of lung cancer cell lines by inhibiting EMT. Whilst 
aspirin has been shown to inhibit platelet-induced EMT in CRC, the direct effects of 
aspirin on EMT in CRC cell lines has not been established. I hypothesis that aspirin 
inhibits cell migration, invasion and EMT in CRC which results in a reduction in the 
CSC population and contributes to the clinical benefit of post-diagnosis aspirin. 
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Using CRC cell lines, I have demonstrated that aspirin treatment inhibits cell 
migration, invasion, motility and promotes an epithelial phenotype. These results 
have been confirmed in human organoids and mouse intestinal adenoma in vivo 
models. Aspirin also promotes a budding phenotype in Apc deficient organoids and 
reduces expression of stem cell markers in both mouse and human tissue. Aspirin 
inhibits the mTOR and Wnt signalling pathways in vivo which have the ability to 
regulate EMT and CSCs although signalling dependency has not been determined. 
Regardless, aspirin is decreasing the cancer stem cell population and promoting a 
non-invasive epithelial phenotype which may explain some of the previously 























Colorectal cancer (CRC) survival is dependent on the degree of invasion and spread 
at time of diagnosis. If the cancer has already spread to another organ, then the 
percentage of patients to survive five years is only 6.6% compared to almost 100% if 
the cancer is isolated to the inner lining of the bowel. This highlights the need to 
understand the mechanisms of invasion and the signalling pathways which regulate 
the spread of CRC. A key step in cancer cells becoming more invasive is the loss of 
normal junctions between cells and an increase in cell movement, known as the 
epithelial-mesenchymal transition (EMT). Cells which have undergone EMT can 
also gain features associated with stem cells such as the ability to maintain a cellular 
population and increased resistance to conventional cancer therapies. Therefore, 
understanding the signalling pathways which control this transition may provide 
new, specific treatments to prevent the spread of CRC.  
Aspirin’s role as a cancer prevention agent was first identified in patients treated 
with aspirin for vascular conditions. It was noted that these patients had a reduced 
risk of developing CRC. Recently, it has emerged that aspirin may also have a role 
in the treatment of CRC with aspirin treatment improving survival in CRC patients. 
The mechanism of action by which aspirin treatment improves survival in CRC 
patients is not fully understood. Aspirin-mediated inhibition of EMT and 
subsequent formation of cancer stem cells may explain some of the benefits of 
aspirin treatment. Aspirin has been demonstrated to decrease cell migration and 
invasion in lung cancer cells by inhibiting EMT. Therefore, I propose that aspirin 
can decrease cell migration, invasion and inhibit EMT in CRC which will reduce the 
formation of cancer stem cells and may help explain the survival benefits of aspirin.  
I have investigated the role of aspirin on CRC invasion, EMT and cancer stem cells 
using CRC cell lines, mouse models of intestinal adenomas and three dimensional 
organoids grown in the laboratory from patients with CRC. Aspirin suppresses the 
ability of CRC cells to migrate and invade by promoting an epithelial cell type. 
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Aspirin reduces the expression of stem cell markers and increases survival in mice 
with intestinal adenomas. Aspirin suppresses two signalling pathways, mTOR and 
Wnt, which are both capable of regulating EMT and cancer stem cells although their 
role in this research has not been confirmed. Regardless, aspirin is decreasing the 
cancer stem cell population and promoting a non-invasive phenotype which may 
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Chapter 1: Introduction 
 
This thesis details an investigation into the effects of aspirin on cell migration, 
invasion, motility, epithelial-mesenchymal transition and cancer stem cell 
population in colorectal cancer. The introduction will give an overview of colorectal 
cancer, including molecular pathogenesis and current management strategies. It will 
cover the current knowledge on the epithelial-mesenchymal transition, the 
association with a cancer stem cell population and the potential signalling pathways 
targeted by aspirin.  
 
 
1.1: Colorectal cancer 
 
1.1.1: Incidence and aetiology 
 
Colorectal cancer (CRC) is the third most common cancer worldwide with 1,361,000 
new cases recorded in 2012 (Ferley et al.). The highest estimated incidence rates are 
observed in Europe, North America and Oceania with the lowest rates in Africa 
(Ferley et al.). The reasons behind this regional variation are two-fold. Firstly, those 
populations with high CRC incidence rates have high obesity rates due to the 
popular western diet. The western diet is characterised by high consumption of red 
meat and processed foods with low consumption of fruit and vegetables. Secondly, 
the large majority of new colorectal cancer cases are detected in patients over 50 
years so countries with a large ageing population will have higher incidence rates 
(Cancer Research UK). Environmental and genetic factors are both important in the 
aetiology of sporadic CRC. Obesity, lack of physical exercise, smoking and alcohol 
consumption are all lifestyle risk factors for CRC (Cunningham et al., 2010). There is 
a substantial genetic influence with twin studies estimating around 35% heritability 
(Lichtenstein et al., 2000). There are a few well defined hereditary CRC syndromes 
such as Familial adenomatous polyposis (FAP) and Lynch syndrome (Cunningham 
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et al., 2010). FAP patients have a germline mutation of the Apc gene which results in 
formation of numerous adenomas throughout the colon which will ultimately 
become CRC without surgical intervention (O’Sullivan et al., 1998). Lynch 
syndrome results from DNA mismatch repair gene mutation and patients have an 
increased risk of several cancers including colon, stomach, endometrium, ureter and 
ovarian (Steinke et al., 2013). In addition to these autosomal dominant syndromes, a 
proportion of hereditary has been attributed to various risk loci identified by GWAS 
studies (Houlston et al., 2010).  
 
1.1.2: Environmental factors 
 
The main risk factors in the development of CRC are environmental with obesity, 
high red meat consumption, lack of physical exercise, alcohol and smoking all 
associated with increased CRC risk (Cunningham et al., 2010). The Western diet, 
characterised as high consumption of red meat and processed foods with low 
consumption of fruit and vegetables is primarily the reason for increased CRC 
incidence in the UK, USA and Australasia (Cunningham et al., 2010). Meta-analysis 
of sixteen studies, designed to determine the association with diet and CRC risk, 
claimed a 30% increased risk of developing CRC for those on a Western diet 
(Magalhães et al., 2012). A wider meta-analysis review of ten studies, designed to 
determine lifestyle risk factors for CRC, highlighted high alcohol consumption and 
smoking was associated with a 60% and 20% increased risk of developing CRC 
respectively (Huxley et al., 2009). In addition, physical activity had a protective 
effect with a 24% decreased risk of developing CRC (Huxley et al., 2009).  
The molecular mechanisms responsible for this increased CRC risk due to poor diet, 
obesity and lack of physical exercise are predominately due to an altered energy 
balance (Bultman, 2016). High blood glucose, observed in diabetic and obese 
patients, can drive cancer progression as cancer cells become glucose dependent 
(Bultman, 2016). This hypothesis is supported by the decreased CRC incidence 
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observed in patients treated with Metformin, a diabetic drug which lowers blood 
glucose levels (Zhang et al., 2011). Obese patients often have high levels of 
circulating insulin and insulin-like growth factor, due to an energy imbalance, 
which can upregulate the cell proliferation and cell survival pathways, specifically 
PI3K-AKT-mTOR signalling (Bultman, 2016). The PI3K-AKT-mTOR signalling 
pathway is often upregulated in CRC and is associated with cell proliferation after 
Apc loss in CRC models (Faller et al., 2015). The microbiota of the digestive system, 
a host of bacteria responsible for fermentation of non-digestible carbohydrates, has 
emerged as a key factor in CRC risk with diet effecting the composition of the 
microbiota (Louis et al., 2014). Red meat and fibre consumption have opposite 
effects on CRC risk which may be explained by the differences on the microbiota 
(Louis et al., 2014). An animal based diet results in an increased deoxycholic 
concentration, a bile acid linked to colorectal and liver cancer, whilst a plant based 
diet increases the concentration of short-chain fatty acids which have a protective 
effect on gut health (Louis et al., 2014). Alcohol consumption is associated with 
increased risk of several cancers including oesophageal, stomach, colon, liver and 
breast cancer (Haas et al., 2012). Alcohol metabolism produces acetaldehyde and 
increases reactive oxygen species (ROS) which are both carcinogenic due to DNA 
damaging effects (Haas et al., 2012).   
 
1.1.3: Genetic factors 
 
Twin studies have estimated the heritability of CRC at around 35% (Lichtenstein et 
al., 2000). There are a few autosomal dominant syndromes causing CRC such as 
Familial adenomatous polyposis (FAP) and Lynch syndrome. FAP is caused by a 
germline truncating mutation of the Apc gene at 5q21 and is characterised by the 
development of hundreds of adenomas throughout the colon which will progress to 
CRC (O’Sullivan et al., 1998). The Apc gene is a tumour suppressor gene which 
forms part of the β-catenin destruction complex thus regulates the levels of β-
catenin and subsequent canonical Wnt signalling within the cell (Behrens, 2005). In 
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addition to the classical FAP presentation, there is a subset of patients who develop 
less than a hundred adenomas at a later age and are described as having attenuated 
FAP (Ibrahim et al., 2014). Attenuated FAP is a result of a mutation at either the 5’ or 
3’ end of the Apc gene which, due to splicing variations, reduces the amount of non-
functional transcript (Ibrahim et al., 2014).  
Lynch syndrome, previously known as hereditary nonpolyposis colorectal cancer 
(HNPCC), is an autosomal dominant cancer syndrome caused by a mutation in the 
DNA mismatch repair genes (Steinke et al., 2013). Patients with Lynch syndrome 
usually present with a single CRC tumour, similar to sporadic CRC (Steinke et al., 
2013). However, patients are also at risk of developing cancers of other origins 
including endometrium, pelvis, ureter, ovarian and stomach (Steinke et al., 2013). 
Lynch syndrome is caused by mutation to a member of the mismatch repair genes; 
MLH1, MSH2, MSH6 or PMS2, which results in microsatellite instability and 
hypermutated tumours due to DNA repair failure (Raskov et al., 2014). 
In addition to these autosomal dominant cancer syndromes, a proportion of the 
heritability of CRC can be attributed to common low penetrance variants. Genome-
wide association studies (GWAS) identifies single nucleotide polymorphisms 
(SNPs) associated with a disease, in this case those associated with increased or 
decreased risk of CRC (Whiffin et al., 2014). Meta-analysis of several GWAS studies 
has identified a number of common low risk variants due to an increased statistical 
power (Whiffin et al., 2014).  These risk loci will be further evaluated and detailed in 
the laboratory to prove the legitimise of the loci for CRC risk. There is a genetic 
component to sporadic CRC with mutations to key signalling pathways discussed in 
chapter 1.1.7. Briefly, mutations in Apc, KRAS, PI3K and TP53 are common events 






1.1.4: Management of Colorectal cancer 
 
The primary treatment of non-metastatic colon cancer is surgical removal of the 
affected region of colon with either a right hemicolectomy, transverse 
hemicolectomy, left hemicolectomy or total colectomy (De Rosa et al., 2015). Rectal 
tumours can be treated with surgical removal if minimal invasion occurred (De 
Rosa et al., 2015). However, if local invasion is present then the addition of 
radiotherapy or chemotherapy to the treatment protocol improves survival rates 
and decreases recurrence rates (De Rosa et al., 2015). Metastatic colon or rectal 
cancer requires the addition of chemotherapy to the treatment protocol with 
FOLFOX (5-fluorouricil, leucovorin and oxaliplatin) or FOLFIRI (5-fluorouricil, 
leucovorin and irinotecan) (De Rosa et al., 2015). Monoclonal antibodies against 
EGFR are also approved for use in metastatic CRC, specifically cetuximab and 
panitumumab (Bertotti et al., 2015). There is a growing trend towards personalised 
treatments with the colorectal tumour’s individual mutations determining an 
effective treatment. The importance of determining mutations is demonstrated with 
EGFR antibody treatment which is commonly used to treat metastatic CRC but 
rendered ineffective by mutation to KRAS, PI3K, BRAF and PTEN genes (Bertotti et 
al., 2015).  
Early detection of colorectal tumours is important for effective management and 
improved prognosis. In Scotland, there is an established bowel screening 
programme in place with the guaiac-based faecal occult blood test offered to all 
members of the population over 50 years old. The guaiac-based faecal occult blood 
test detects faecal haemoglobin concentrations above 600ug/g of faeces (Tinmouth et 
al., 2015). The presence of faecal haemoglobin indicates the need for further clinical 
investigation with colonoscopy the primary diagnostic test to detect colorectal 
tumours. The guaiac-based faecal occult blood test is clinically specific but 
sensitivity is poor with false negatives common (Tinmouth et al., 2015). Despite 
these false negatives, faecal occult blood screening has been demonstrated to reduce 
CRC mortality (Hardcastle et al., 1996).   
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1.1.5: Prognosis and staging of colorectal cancer 
 
Worldwide there were 694,000 deaths attributed to colorectal cancer in 2012 which 
accounted for 8% of the total cancer related deaths (Ferley et al.). The prognosis for 
sporadic CRC is dependent on the stage of the tumour at diagnosis. Using the 
Dukes’ classification system, CRC tumours can be divided into four stages based on 
the amount of invasion present (Dukes, 1932). The tumour is restricted to the 
mucosal lining of the colon in Dukes’ A with invasion of the muscle layers occurring 
in Dukes’ B (Dukes, 1932). Involvement of the lymph nodes occurs in Dukes’ C with 
widespread metastasis in Dukes’ D (Dukes, 1932). As with all cancers, diagnosis at 
an earlier stage increases survival. CRC has a five-year survival rate of 94.6% if 
diagnosed while restricted to the innermost lining of the colon which drops to a 
meagre 6.9% if distant metastasis has occurred (Cancer Research UK). There are 
slight differences in survival rates between genders which along with incidence 
rates are detailed in Table 1.1. 
 
Stage Incidence Male Female 
All stages - 58% 61% 
Stage 1/ Dukes’ A 15% 95% 100% 
Stage 2/ Dukes’ B 22% 84% 86% 
Stage 3/ Dukes’ C 24% 63% 63% 
Stage 4/ Dukes’ D 22% 7% 8% 
 
Table 1.1: Incidence and five-year survival rates for colorectal cancer divided 
by gender and stage of diagnosis. Data specific to UK between 2002-2006 





The high survival rates for patients with Dukes’ A CRC highlights the need for early 
detection of tumours prior to invasion. The guaiac-based faecal occult blood test is 
the most widely used screening method and is available to all members of the UK 
population over 50 years old (Cunningham et al., 2010). A large proportion of 
sporadic CRC is preventable by lifestyle modification to counter the environmental 
risk factors such as obesity and lack of physical exercise. However, lifestyle 
modification can be difficult to achieve hence the need for chemoprevention and 
early detection. 
 
1.1.6: Biology of the human Intestines 
 
To begin to understand the dysregulated biology that occurs during cancer 
initiation and progression, it is important to have an appreciation of the normal 
anatomy and physiology of the human intestines (For review see; (De Santa Barbara 
et al., 2003; Pinto and Clevers, 2005; Spence and Mason, 1992; Tortora and 
Derrickson, 2010)).  
The small intestine stretches from the pyloric sphincter, found at the base of the 
stomach, to the ileocecal valve and is comprised of three regions; duodenum, 
jejunum and the ileum. The large intestine (or colon) connects to the ileum at the 
ileocecal valve and continues until the anus. The colon can be separated into the 
caecum, ascending colon, transverse colon, descending colon, sigmoid colon and the 
rectum. The walls of the intestine are comprised of four distinct layers; mucosa, 
submucosa, muscularis propria and serosa (Figure 1.1). The mucosa lines the 
intestinal lumen and is composed of a layer of simple columnar epithelium. External 
to this epithelium is a layer of connective tissue containing blood vessels, nerves 
and lymphoid tissue known as the lamina propria which is surrounded by a thin 
layer of muscle. The submucosa consists of connective tissue, blood vessels, nerves 
and lymphatic vessels. The muscularis propria is formed from two layers of muscle, 
an inner circular layer and an outer longitudinal layer, and is responsible for 
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peristalsis. The outermost layer of the intestine is the serosa which is a layer of 
connective tissue covered by a thin membrane known as the visceral peritoneum. 
The small intestine surface is covered in small finger-like projections, called villi, 
and small pits created in folds of the mucosa called the crypts of Lieberkühn. 
Combined these create a large surface area to maximise absorption. The colon has a 







Figure 1.1: Anatomy of the walls of the intestines. Diagrams of the anatomy of 
the small intestine (A) and colon (B) walls. Image obtained from Tortora & 





The epithelium of the intestine has a high turnover with 4-6 proliferative stem cells 
in each crypt base responsible for all cell production. These cells produce progenitor 
cells called transit amplifying cells which will undergo rapid proliferation. These 
cells, produced by the transit amplifying cells, will then migrate up the crypt and 
differentiate into one of seven possible cell types; Paneth cells, goblet cells, 
enteroendocrine cells, microfold cells, cup cells, tuft cells or enterocytes (Figure 1.2). 
This process of proliferation is balanced by that of apoptosis and cell shedding 
which occurs at either the tip of villi in small intestine or the top of the crypt in the 





Figure 1.2: Epithelium maintenance in small and large intestine. Diagram 
illustrating the epithelial renewal in small intestine (A) and colon (B). Stem cells 
produce transit amplifying cells (TA) which then produce all differentiated epithelial 




Enterocytes are the most common cell type and account for around 80% of all 
intestinal epithelial cells. They are responsible for the absorptive functions of the 
intestine. Enteroendocrine cells are much less abundant with only a few cells in the 
crypt base. They help regulate gastrointestinal motility via the production of 
hormones such as secretin. Goblet cells produce mucus which forms a protective 
barrier against the intestinal contents and can be easily identified by the presence of 
mucus granules within the cytoplasm. Paneth cells are found only in the small 
intestine and are situated at the base of the crypts below the stem cells. Paneth cells 
have an anti-microbial role with the production of peptides and enzymes such as 
defensins and lysozyme along with a central role in maintaining the stem cell niche 
(Porter et al., 2002). Microfold cells (M cells) are found in the epithelial layer 
overlying gut-associated lymphoid tissue (GALT) (Mabbott et al., 2013). M cells are 
important for the induction of immune responses in the GALT by transcytosis of 
antigen across the epithelium (Mabbott et al., 2013). Tuft cells are characterised by 
large, thick microvilli which protrude from the cell into the intestinal lumen but 
there function is unclear (Gerbe et al., 2012). Cup cells are predominately located in 
the ileum epithelium and there function is also unknown (Fujimura and Iida, 2001). 
M cells, cup cells and tuft cells are often ignored in the literature when discussing 
intestinal epithelium due to the poorly understood functions despite recent 
evidence that they are also derived from Lgr5+ stem cells (Gerbe et al., 2011; Lau et 
al., 2012).  
Stem cells are defined as a cell capable of self-renewal and maintaining a cellular 
population. In the small intestine, the intestinal stem cells have been identified as a 
small population of cells located at the crypt base between the Paneth cells (Barker 
et al., 2007). Initially, there were two central theories regarding intestinal stem cells. 
Firstly, that the fourth cell from the base of the crypt, termed 4+, is responsible for 
all cell proliferation (Potten, 1977). Secondly, that proliferation was in fact due to a 
few undifferentiated cells dispersed between Paneth cells in the crypt base, termed 
crypt base columnar cells (CBC cells) (Bjerknes and Cheng, 1999). Recently, it has 
been agreed that the CBC cells are responsible for maintaining epithelial cell 
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proliferation and that the 4+ cells act as a reserve stem cell population in the small 
intestine (Barker, 2014). In the colon, the stem cells are also located at the crypt base 
but there are no 4+ cells or Paneth cells present (Barker, 2014). The CBC cells are 
identified by their expression of a target gene of the Wnt signalling pathway, Lgr5 
(Barker et al., 2007). Leucine-rich repeat containing G protein-coupled receptor 5 
(Lgr5) is specifically expressed in CBC cells in the base of adult intestinal crypts 
(Barker et al., 2007).  Using lineage tracing in mice, it has been proven that Lgr5+ 
cells have the ability to maintain all cell types within the epithelial population in 
both small and large intestine (Barker et al., 2007). Transcriptional profiling of Lgr5+ 
cells identified a unique molecular signature with high expression of WNT 
signalling genes, such as SOX9 and TROY, and expression of other novel stem cell 
markers, such as OLFM4 and Smoc2 (Muñoz et al., 2012).  Olfactomedin-4 (OLFM4) 
is specifically and highly expressed by Lgr5+ cells (van der Flier et al., 2009). Due to 
the higher levels of expression, OLFM4 is a useful substitute marker for Lgr5+ cells 
in which Lgr5 expression is relatively low (van der Flier et al., 2009). Secreted 
modular calcium-binding matricellular protein-2 (Smoc2) expression correlated 
with that of the Lgr5+ stem cells and lineage tracing confirmed Smoc2 as a marker of 
intestinal stem cells (Muñoz et al., 2012) 
The 4+ reserve stem cells have a different gene expression profile to that of the CBC 
cells such as the expression of BMI1 and HOPX (Barker, 2014). Bmi1+ cells, which 
also express Paneth cell markers, are quiescent during normal homeostasis but able 
switch to a proliferative state in response to injury (Roth et al., 2012; Tian et al., 
2011). The relative quiescent nature of the BMI1+ cells plus the resistance to 
radiation is shared by HOPX+ cells which are also located at the 4+ location (Takeda 
et al., 2011). Lineage tracing has confirmed the validity of  BMI1 and HOPX as stem 
cell markers (Sangiorgi and Capecchi, 2008; Takeda et al., 2011). The presence of a 
reserve stem cell population adds another dimension to how the stem cell 
population regulate normal homeostasis, injury and potentially cancer. A list of 
stem cell markers in the small intestine, CBC and 4+ cells, and the colon as 





Small intestine Colon 
Crypt base columnar cells 4+ cells  
Lgr5 BMI-1 Lgr5 
OLFM4 HOPX OLFM4 
TROY  TROY 
SMOC2  SMOC2 
SOX9  SOX9 
 
Table 1.2: Stem cell markers for mouse small intestine and colon. List of mouse 
stem cell markers in small intestine, crypt base columnar cells (CBCs) and 4+ cells, 
and colon based on literature review. 
 
 
Intestinal stem cell function is dependent on the presence of a tightly regulated stem 
cell niche characterised by BMP, EGF, Notch and Wnt signalling (Sato and Clevers, 
2013). Bone morphogenic protein (BMP) inhibits stemness and in normal 
homeostasis is present in villi with inhibition of BMP signalling resulting in the 
formation of crypt-like structures within the villi of the small intestine (Haramis et 
al., 2004). Epidermal growth factor (EGF) promotes cellular proliferation in stem 
and transit amplifying cells (Sato and Clevers, 2013). Notch signalling is required to 
maintain the stem and transit amplifying cells in an undifferentiated state with 
Notch signalling inhibition resulting in the differentiation of proliferative cells into 
secretary goblet cells (van Es et al., 2005). The Wnt pathway is critical for stem cell 
proliferation and differentiation of Paneth cells (Sato and Clevers, 2013). Activation 
of the Wnt signalling pathway causes the nuclear localisation of β-catenin and 
activation of transcription of several genes required for cellular proliferation and 
cell survival (MacDonald et al., 2009).		
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Paneth cells express EGF and ligands for the Wnt and Notch signalling pathways, 
Wnt3a and DII4 respectively (Sato et al., 2011a). BMP signalling is expressed by 
adjacent mesenchymal cells (Haramis et al., 2004). There is also additional signalling 
produced by the stromal cells in the lamina propria layer under the intestinal stem 
cells (Sailaja et al., 2016). In the colon, the stem cell niche is less well defined with 
stromal cells and C-kit+ goblet cells proposed as sources of Wnt, EGF and Notch 
signals as no Paneth cells are present (Rothenberg et al., 2012). These four signalling 
pathways; Wnt, EGF, Notch and BMP, are critical to maintain the stem cell niche 
and normal intestinal stem cell homeostasis in both small intestine and colon (Sato 
and Clevers, 2013).    
 
 
1.1.7: Pathogenesis of colorectal cancer 
 
The pathogenesis of colorectal cancer involves the stepwise progression from 
normal mucosa to adenoma and eventually carcinoma due to an accumulation of 
mutations to oncogenes and tumour suppressor genes (Leslie et al., 2002) (Figure 
1.3). There are two main molecular pathways associated with colorectal 
carcinogenesis; the chromosomal instability pathway and the microsatellite 
instability pathway (Raskov et al., 2014). The chromosomal instability pathway 
(CIN) is the key pathway in the development of sporadic CRC and is the traditional 
stepwise progression from adenoma to carcinoma due to mutations of tumour-
suppressor genes and oncogenes (Pino and Chung, 2010). The microsatellite 
instability pathway (MIS) occurs when mutations of the mismatch repair genes 









Figure 1.3: Adenoma-carcinoma sequence in the colon. Diagram of adeno-
carcinoma sequence in CRC by either microsatellite instability or chromosomal 
instability pathways. Diagram borrowed from Walther review of genetic events in 
CRC progression (Walther et al., 2009). 
 
In sporadic CRC, CIN is the predominant molecular pathway accounting for around 
84% of tumours (Cancer Genome Atlas Network, 2012). The mutational background 
of these tumours are relatively consistent with the Apc (81%), TP53 (60%), KRAS 
(43%) and PIK3CA (18%) genes amongst the most frequently mutated (Cancer 
Genome Atlas Network, 2012). Analysis of 224 sporadic colorectal tumour samples 
by the Cancer Genome Atlas Network identified a subset of hypermutated tumours 
which account for around 16% of all sporadic CRC in which the microsatellite 
instability pathway is responsible for carcinogenesis (Cancer Genome Atlas 
Network, 2012).  This group of hypermutated tumours had a median of 728 
mutations compared to the non-hypermutated with a median of 58 mutations 
(Cancer Genome Atlas Network, 2012). Hypermutation is a consequence of 
mutations within the DNA mismatch repair pathways, specifically MLH1 silencing 
and polymerase ε (POLE) mutation (Cancer Genome Atlas Network, 2012). 
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Mutations of the TGF-β family genes, ACVR2A and TGFBR2, and the mismatch 
repair genes, MSH3 and MSH6, are especially common in hypermutated CRC 
tumours (Cancer Genome Atlas Network, 2012).  
The Apc gene, a classic tumour suppressor gene, controls canonical Wnt signalling 
within the cell by regulating the levels of β-catenin and is frequently the initiating 
mutation in sporadic CRC (Behrens, 2005). The majority of Apc mutations are point 
mutations which result in the translation of a truncated and non-functional Apc 
protein (Schneikert and Behrens, 2007). Inactivating mutations in the Apc gene 
results in unregulated β-catenin and subsequent dysregulated Wnt signalling 
(Behrens, 2005). The loss of functional Apc protein results in a hyperproliferative 
phenotype in Apcflox/flox mice and intestinal adenomas in ApcMin/+ mice (Schneikert 
and Behrens, 2007). Familial adenomatous polyposis (FAP) is caused by a germline 
mutation in the Apc gene which has 100% penetrance and will lead to an 
accumulation of small adenomas throughout the colon and ultimately progress to 
CRC (O’Sullivan et al., 1998).  
The canonical Wnt signalling pathway centres around the regulation of β-catenin 
and its subsequent activation of Wnt target gene expression (Figure 1.4) 
(MacDonald et al., 2009). Degradation of cytoplasmic β-catenin is coordinated by a 
complex of axin, adenomatous polyposis coli (Apc), casein kinase 1 and glycogen 
synthase kinase-3β (GSK-3β) (MacDonald et al., 2009). When Wnt signalling is 
switched off, β-catenin is present only at the adherens junctions with any 
cytoplasmic β-catenin degraded (MacDonald et al., 2009). Activation of the Wnt 
signalling pathway is caused by the binding of Wnt ligands to the frizzled receptor 
and LRP5/6 co-receptors (MacDonald et al., 2009). This binding disrupts the β-
catenin destruction complex, by binding axin and GSK-3β, creating an accumulation 
of cytoplasmic β-catenin (MacDonald et al., 2009). Unregulated β-catenin 
translocates to the nucleus where it acts as a coactivator of the DNA bound T cell 
factor/ lymphoid enhancer factor (TCF/LEF) (MacDonald et al., 2009). TCF/LEF 
represses gene expression by an interaction with the transcription repressor 
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transducin-like enhancer protein 1 (TLE1) which promotes chromatin compaction 
and histone deacetylation (MacDonald et al., 2009).  The binding of β-catenin to 
TCF/LEF causes the displacement of TLE1 and the binding of further co-activators 
to activate expression of Wnt target genes which are varied, including a host of 





Figure 1.4: The Canonical Wnt signalling pathway. In the absence of Wnt 
signalling, β-catenin is only present at the adherens junctions with E-cadherin. All 
free cytoplasmic β-catenin is degraded by the β-catenin degradation complex 
composed of Apc, Axin, Casein kinase 1 and GSK-3β. In presence of Wnt stimulus, 
the Wnt ligands bind to Frizzled receptor and LRP5/6 co-receptor. This interaction 
results in the binding of Axin and GSK-3β thus preventing the destruction of free 
cytoplasmic β-catenin. Free β-catenin shuttles to the nucleus and binds to TCF/LEF 
to initiate transcription of Wnt target genes. Diagram based on a review of Canonical 































After the activation of the Wnt signalling pathway, by Apc mutation, subsequent 
mutations to other signalling pathways such as KRAS, PIK3CA and TP53 can occur 
in sporadic CRC to facilitate CRC carcinogenesis (Leslie et al., 2002). KRAS gene 
encodes the GTPase protein K-Ras which is involved in cellular proliferation, 
differentiation and cell survival (Morkel et al., 2015). These effects can be attributed 
to roles in the MAPK and PIK3/Akt/mTOR signalling pathways (Morkel et al., 2015). 
KRAS is an oncogene with gain of function mutations frequently occurring in CRC 
(Morkel et al., 2015). KRAS mutations are more common in the late adenomas (~40-
50%) compared to the early adenomas (~10%) which highlights its role in CRC 
progression (Morkel et al., 2015). The presence of KRAS mutations indicates a 
resistance to epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, 
which are commonly used for metastatic CRC treatment (Lièvre et al., 2006). The 
downstream signalling of EGFR remains active despite inhibitors due to presence of 
mutant K-Ras (Lièvre et al., 2006). 
PIK3CA gene encodes the catalytic subunit for PI3K which is a key signalling hub in 
the PI3K/Akt/mTOR pathway (Cathomas, 2014). The PI3K/Akt/mTOR pathway is 
responsible for cell metabolism with key roles in proliferation, survival, apoptosis 
and migration (Cathomas, 2014). PIK3CA mutation results in an dysregulated 
PI3K/Akt/mTOR pathway and is associated with poor survival in CRC patients 
(Kato et al., 2007). The importance of this pathway is highlighted by the poor 
prognosis associated with the tumour suppressor gene, PTEN, which is a direct 
antagonist to the PI3K/Akt/mTOR pathway (Atreya et al., 2013). Similar to KRAS 
mutations, PI3KCA and PTEN mutations predict poor clinical response to EGFR 
inhibitors (Therkildsen et al., 2014).  
TP53 is the most frequently mutated tumour suppressor gene across all cancers. 
TP53 encodes the protein p53 which regulates cell division and prevents the 
proliferation of cells which contain mutations by either repairing DNA damage or 
targeting the cell for apoptosis (Naccarati et al., 2012). Loss of p53 function is a late 
event in colorectal carcinogenesis associated with carcinoma progression (Naccarati 
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et al., 2012). This is illustrated by a low frequency of TP53 mutations in adenomas 
(~16%) compared to colorectal carcinomas (~50-60%) (Naccarati et al., 2012). These 
are a sample of the most commonly mutated genes in sporadic CRC but other  
signalling pathways such as TGF-β are also frequently mutated with 10% of CIN 
and 51% of MSI sporadic CRC tumours containing SMAD4  and TGFBR2 mutations 
respectively (Cancer Genome Atlas Network, 2012).  
 
1.1.8: Metastatic colorectal cancer 
 
The survival statistics in CRC demonstrates that metastasis is associated with low 5-
year survival thus highlights the importance of determining the mechanisms and 
signalling associated with CRC metastasis. The formation of metastasis from solid 
tumours requires local invasion, intravasation, systemic transportation, 
extravasation and colonisation (Chambers et al., 2002). Primary tumour growth 
triggers angiogenesis, the formation of new blood vessels, to meet the metabolic 
requirements of the growing tumour (Sethi and Kang, 2011). Tumour cells can gain 
entrance to the circulatory system, termed intravasation, directly via these new 
blood vessels which exhibit poor vascular integrity or indirectly via the lymphatic 
drainage (Sethi and Kang, 2011). Tumour cells must survive the circulatory system 
before reaching the secondary organ where tumour cells are stopped in the small 
capillaries due to size restriction (Chambers et al., 2002). These cells may leave the 
circulatory system, termed extravasation, and proliferate to form secondary 
tumours or remain dormant (Chambers et al., 2002). The vascular flow determines 
the secondary sites for metastasis in CRC, the liver and the lungs, with blood from 
the intestines passing through the liver before entering the venous system and 
passing through the lungs (Chambers et al., 2002).  
Understanding the mechanisms of metastasis and the underlying signalling 
pathways driving invasion and metastasis is critical for the development of new 
targeted treatments. A key molecular mechanism implicated in metastasis is the 
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epithelial-mesenchymal transition (EMT). Cells undergoing EMT lose epithelial 
characteristics, such as apical-basal polarity and cell-cell junctions, whilst gaining 
mesenchymal characteristics, such as increased motility and invasive capabilities 
(Cao et al., 2015). EMT has been demonstrated in tumour buds of CRC and is 
associated with aggressive, invasive tumours and subsequent poor prognosis 
(Galván et al., 2015). In addition to EMT facilitating invasion and metastasis, cells 
undergoing EMT have been demonstrated to have an increased resistance to both 
chemotherapy and radiotherapy (Cao et al., 2015).  Cancer stem cells (CSCs) and 
EMT are closely linked progresses with both implicated in metastasis and 
chemoresistance (Jordan et al., 2006). CSCs are defined by functional characteristics 
such as self-renewal, proliferation and ability to initiate and propagate tumour 
growth (Jordan et al., 2006). CSCs of breast origin demonstrate this relationship with 
increased expression of mesenchymal markers and EMT transcription factors in 
circulating CSCs suggesting EMT facilitates the induction of CSCs in epithelial 
cancers (Bonnomet et al., 2012).  A detailed description of EMT and CSCs is 















1.2: Epithelial-mesenchymal transition 
 
Epithelial-mesenchymal transition is characterised as the loss of epithelial features 
and the acquirement of a more motile, mesenchymal phenotype (Hay, 1995) (Figure 
1.5). Typically, epithelial cells are organized as sheets of polarised cells with the cell-
to-cell junctions important to maintain structural integrity (Kalluri and Neilson, 
2003). Mesenchymal cells are generally more spindle shaped and lacking both 
polarity and cell-to-cell junctions which allows them to migrate through the 
basement membrane (Kalluri and Neilson, 2003). These two phenotypes represent 
either end of the spectrum with most cells retaining characteristics of both during 
this progression (Hay, 1995). This is a reversible process with mesenchymal-
epithelial transition (MET) possible and occurs in cancer with the formation of 
secondary epithelial metastasis (Kalluri and Weinberg, 2009). EMT can be measured 
in cells and tissue by evaluating the expression of epithelial and mesenchymal 
markers plus expression of the transcription factors which drive this process 





Figure 1.5: Overview of the epithelial-mesenchymal transition. Epithelial cells 
are polarized and organized into sheets of cells with cell-cell junctions whereas the 
mesenchymal cells are spindle shaped with no cell-cell junctions.  
 
 





EMT is a normal physiological process with roles in embryogenesis (Hay, 1995) and 
organ fibrosis (Iwano et al., 2002) along with a pathogenic role in epithelial cancer 
progression (Thiery, 2002) (Figure 1.6). Type 1 EMT’s are those associated with 
embryo implantation and embryogenesis, of which there are many (Kalluri and 
Weinberg, 2009). An example of a type 1 EMT is the migration of cells from the 
primitive streak in the embryo which allows the differentiation of the mesoderm 
and endoderm layers in the embryo (Hay, 1995). Type 2 EMT’s are associated with 
organ fibrosis in response to chronic inflammation (Iwano et al., 2002). In response 
to tissue damage, a local EMT occurs which allows the formation of fibroblasts and 
resulting organ fibrosis which is maintained until the inflammatory stimulus is 
removed (Iwano et al., 2002). The 3rd type of EMT occurs in solid epithelial tumours 
and allows tumour cells to invade beyond the basement membrane and disseminate 
throughout the body (Thiery, 2002). Once the cells reach the secondary sites they 
can revert back to an epithelial population by undergoing MET so the metastases 






Figure 1.6: Type 3 EMT associated with cancer invasion and metastasis. 
Epithelial cells (green) from the primary tumour undergo EMT to become more 
motile mesenchymal cells (red). The mesenchymal cells can travel to secondary 
sites via circulatory or lymphatic systems. Cells undergo MET to form epithelial 




1.2.1 Markers of epithelial-mesenchymal transition 
 
To investigate EMT progression, expression levels of epithelial and mesenchymal 
markers are determined. Expression of adherens junction proteins, specifically E-
cadherin and the catenins, are the hallmark markers for epithelial cells. 
Mesenchymal cells have altered localisation of the adherens and tight junctional 
proteins plus an increased expression of transcription factors and cytoskeletal 
proteins associated with cellular motility. All epithelial and mesenchymal markers 




Epithelial Mesenchymal  
E-cadherin N-cadherin 
Zona-occludens 1 Vimentin 






Table 1.3: Epithelial and mesenchymal markers. All epithelial and mesenchymal 








Given the importance of the cell junction proteins in EMT, an overview of the 
adherens and tight junctions structure and differences noted during EMT is 
required to appreciate any observed alterations. The adherens junctions, composed 
of cadherin and catenin proteins, links neighbouring cells (Figure 1.7) (Farquhar and 
Palade, 1963). E-cadherin is a major component of the adherens junctions and links 
the adherens junctions to the actin cytoskeleton (Baum and Georgiou, 2011). E-
cadherin is composed of five extracellular domains, a transmembrane domain and a 
large cytoplasmic tail (Baum and Georgiou, 2011). Homophillic interactions between 
neighbouring cells’ extracellular domains link the cells together with the 
cytoplasmic tail linking with the actin cytoskeleton via the catenins: α, β and p120 
(Baum and Georgiou, 2011). The link to the actin cytoskeleton is formed by α-
catenin which binds to both β-catenin and the actin filaments (Dufour et al., 2013). β-
catenin and p120-catenin bind directly to E-cadherin’s cytoplasmic tail thus linking 
the adherens junctions to the actin cytoskeleton (Dufour et al., 2013). Other proteins 
can bind to α-catenin such as vinculin which is required to strengthen the junction 
(Dufour et al., 2013). p120-catenin is involved in stabilising the adherens junctions 
with knockdown of p120-catenin resulting in loss of cell-cell adhesion (Davis et al., 
2003). There is also a role for p120-catenin in stabilization of the actin filaments via 
RhoA and Rac1 signalling (Davis et al., 2003). β-catenin’s primary role in the cell is 
as the effector of the canonical Wnt signalling pathway (Niehrs, 2012). 
Adherens junctions are highly dynamic structures and are regularly formed, broken 
and reformed (Kowalczyk and Nanes, 2012). This dynamism is required for normal 
cell growth, division and movement (Kowalczyk and Nanes, 2012). E-cadherin is the 
key component in the adherens junctions and loss of E-cadherin expression is a 
hallmark of EMT (Kalluri and Weinberg, 2009). E-cadherin and the adherens 
junctions are calcium mediated with a changes in extracellular calcium disrupting 
the adherens junctions (Le et al., 1999). E-cadherin is removed from the cell surface 
by either clathrin- or caveolin- mediated endocytosis (Le et al., 1999). When in the 
cytoplasm, E-cadherin can either be degraded or re-cycled back to the adherens 
junctions depending on the requirements of the cell (Le et al., 1999). E-cadherin 
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expression is therefore a balance of degradation, recycling and synthesis (Le et al., 
1999). During EMT E-cadherin is replaced by the mesenchymal cadherin, N-
cadherin, a phenomenon known as cadherin switching (Maeda et al., 2005). N-
cadherin is reported to be crucial for the increased cellular motility acquired during 








Figure 1.7: Adherens junctions. Simplified diagram of the Adherens junctions 
based on Baum & Georgiou review (Baum and Georgiou, 2011). Cells are 
connected by the extracellular domain of E-cadherin. E-cadherin is connected to the 
actin filaments and cytoskeleton by β-catenin and α-catenin with p120-catenin 





















In collaboration with the adherens junctions, the tight junctions help maintain 
cellular contacts and structural integrity. The tight junctions have no extracellular 
space between the plasma membranes of joined cells (Farquhar and Palade, 1963). 
Tight junctions are composed of claudins, zona-occludens, occludin and junctional 
adhesion molecule proteins (Figure 1.8) (Niessen, 2007). The transmembrane 
components of the tight junctions are the claudins, occludins and junctional 
adhesion molecule-1 (JAM-1), with the zona-occludens family acting as the 
scaffolding proteins and a connection to the actin filaments (Niessen, 2007). Several 
other proteins such as cingulin and membrane-associated guanylate kinase (MAGI) 
seem to have regulatory roles at the tight junctions although there exact functions 
are unclear (Niessen, 2007). Under normal physiological conditions, zona occludens-
1 (ZO-1) and claudin-1 have roles in maintaining the tight junctions but during 
cancer progression they can shuttle to the nucleus and correlate with EMT 
progression (Dhawan et al., 2005; Polette et al., 2007). Claudin-1 has been linked to 
the activation of pro-matrix metalloproteinase 2 (MMP2) associating it with invasion 
and metastasis (Miyamori et al., 2001). Claudin-1 may also play a role in β-
catenin/TCF signalling underscoring its dysregulation in CRC (Dhawan et al., 2005). 
The cellular location of ZO-1 and claudin-1 may be more relevant than overall 
expression as both proteins serve as either epithelial or mesenchymal markers 
depending on the location of the protein, either at the cell membrane or in the 
nucleus.  
Vimentin and α-smooth muscle actin (α-SMA) are important mesenchymal markers 
with elevated expression correlating with EMT progression. Vimentin belongs to the 
intermediate filament family and acts to maintain structural integrity of 
mesenchymal cells (Ivaska et al., 2007). It is also required for cellular motility with 
vimentin knockdown causing impaired wound healing and defects in fibroblast 
migration (Ivaska et al., 2007). α-SMA is a structural protein which is ususally found 
in vascular smooth muscle and myofibroblasts (Wang et al., 2006a). It is regulated 
by serum response factor (SRF) whose activity is enhanced by increased actin 
47 
 
polymerization caused by RhoA (Wang et al., 2006a). Hence α-SMA is increased in 







Figure 1.8: Tight junctions. Simplified diagram of tight junctions based on the 
review from C.M Niessen (Niessen, 2007). Cells are connected by junctional 
adhesion molecule 1 (JAM-1), claudins and occludins. These proteins are 
connected to the actin filaments by the zona-occludens proteins. Cingulin and MAGI 
have a regularly role at the tight junctions and only bind to JAM-1 and the claudins 
respectively. The exact composition of tight junctions can vary with some protein 























1.2.2: Regulation of epithelial-mesenchymal transition 
 
Several transcription factors (snail, slug, twist and ZEB1) are increased during EMT 
and all act to suppress E-cadherin transcription along with other individual 
functions (Moreno-Bueno et al., 2008). Slug and snail suppress the transcription of 
E-cadherin by binding to E-boxes in the gene’s promoter (Naber et al., 
2013).Overexpression of either slug or snail enhances the invasion of cells and 
causes cells to undergo EMT in a similar manner to TGF-β stimulated EMT (Naber 
et al., 2013). Twist is a critical developmental transcription regulator which is 
involved in EMT (Yang et al., 2004). Twist overexpression initiated EMT both by 
suppression of E-cadherin and by increasing several mesenchymal markers (Yang et 
al., 2004). Twist activation also increases expression of the extracellular matrix 
degredation proteins, MMP2 and MMP9, whilst repressing their direct antagonists, 
TIMPs (Tania et al., 2014). ZEB1 is present in Apc-mutated CRCs, where there is 
dysregulated Wnt signalling as ZEB1 acts as an effector of the β-catenin/TCF 
signalling thus inducing EMT (Sánchez-Tilló et al., 2011). Expression of ZEB1 
correlates with increased tumour aggressiveness and increased metastasis (Tania et 
al., 2014). ZEB1 is inhibited at the mRNA level by a family of microRNAs, miR-200, 
which in turn induce MET (Zhang and Ma, 2012). These transcription factors are the 
key regulators of  EMT in colorectal cancer but they can be activated by numerous 
pathways including EGF, FGF, TGF-β, PDGF, Wnt, Notch, Akt, c-MET, Ras, NF-κB, 
















Figure 1.9: Regulation of the epithelial-mesenchymal transition in cancer. 
Summary diagram of some key upstream signalling pathways involved in the 
regulation of EMT (A) and the downstream signalling effecting the transcription 
factors; snail, slug, Zeb1 and twist (B). EMT transcription factors downregulate E-





MicroRNAs are small non-coding RNAs which regulate expression of target 
proteins by binding to the complementary sequences of the target mRNA leading 
either cleavage of the mRNA or translation inhibition (Zhang and Ma, 2012). There 
are various microRNAs which are reported to regulate EMT, invasion and 
metastasis in CRC. Several of these microRNAs have tumour suppressor functions 
by directly targeting the EMT transcription factors with miR-381, miR-200 and miR-
34 inhibiting Twist, ZEB1 and Snail respectively (He et al., 2016; Hur et al., 2013; 
Kim et al., 2011). Other microRNAs promote EMT by direct suppression of E-
cadherin as observed with miR-9 (Ma et al., 2010). There are also microRNAs 
involved in motility, invasion and the acquirement of a stem cell phenotype which 
will be discussed in the relevant chapters. 
EMT can be induced in vitro by several growth factors such as HGF, FGF, PDGF, 
EGF and TGF-β. There are several common signalling pathways which can regulate 
growth factor induced EMT such as c-MET, PI3K/Akt/mTOR, Notch, TGF-β, NF-κB 
and Wnt. The induction of EMT in the epithelial Madin-Darby canine kidney 
(MDCK) cell line by hepatocyte growth factor (HGF) identified the c-MET signalling 
pathway as an EMT regulator (Naldini et al., 1991; Stoker et al., 1987). HGF binds to 
and phosphorylates c-MET which results in the recruitment of various signalling 
effectors such as PI3K, RAS and SRC (Organ and Tsao, 2011). By activating these 
pathways, c-MET can regulate cell proliferation, cell motility and EMT induction 
(Organ and Tsao, 2011). The role of c-MET in cancer pathogenesis is complex with 
activation of c-MET noted in several cancers including colorectal (Hiscox et al., 
1997). An interesting observation in solid tumour progression is the activation of c-
MET by hypoxia inducible factor 1α (HIF1α) which could help explain induction of 
EMT and dissemination of cancer cells as tumours grow (Organ and Tsao, 2011). 
Phosphatidylinositol 3-kinase (PI3K) signalling pathway is upstream of Akt and 
mTOR (Cho, 2014). There are 3 classes of PI3Ks with class 1A the most relevant for 
cancer biology with roles in cellular proliferation, survival and motility (Cho, 2014). 
Class 1A PI3Ks activates Akt via the generation of phosphatidylinositol-3,4,5-
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triphosphate (PIP3) (Cho, 2014). This activation is antagonised by the tumour 
suppressor PTEN (Cho, 2014). Akt activates the mTOR complex 1 which is a key 
signalling hub regulating cellular proliferation and survival based on the energy 
balance of the cell (Cho, 2014). PI3K activity can be induced by TGF-β (Schlegel et 
al., 2015) and PDGF (Jechlinger et al., 2006) either directly or indirectly via c-MET. 
Mutations in the PIK3CA gene, which encodes the catalytic subunit of PI3K, and the 
PTEN gene occur frequently in CRC (Cancer Genome Atlas Network, 2012). 
Induction of EMT by PI3K can either be due to Akt or mTOR activity with both 
implicated in EMT and cancer progression. An increase in Akt activity correlates 
with cadherin switching caused by snail expression which is a hallmark of EMT 
(Hao et al., 2012). Regulation of EMT by mTOR has been demonstrated, with the 
RhoA and Rac1 GTPases the effectors (Chen et al., 2014; Gulhati et al., 2011). 
Activation of Akt and mTOR signalling pathway has been associated with the 
induction of EMT and an increase in the cancer stem cell population in various 
types of cancer. Overexpression of twist results in EMT induction, the acquirement 
of stem cell characteristics and the activation of Akt signalling in breast and cervical 
cancer cell lines (Li and Zhou, 2011). Activation of Akt by TNF-α signalling results 
in the repression of GSK-β which increases Snail expression and subsequent EMT 
induction in CRC cell lines (Wang et al., 2013a). EMT regulation by the mTOR 
signalling pathway has been demonstrated in several cancers including colorectal 
and prostate cancer (Chen et al., 2014; Gulhati et al., 2011). The knockout of raptor 
and rictor, the crucial components of mTORC1 and mTORC2 respectively, inhibited 
EMT in CRC cell lines and metastasis in vivo (Gulhati et al., 2011). These effects 
were determined to be RhoA and Rac1 dependent in both colorectal and prostate 
cancer (Chen et al., 2014; Gulhati et al., 2011).   
In renal cell carcinoma, macrophages promote EMT and stem cell characteristics by 
activation of the Akt and mTOR signalling pathways (Yang et al., 2016). Co-culture 
of renal cell carcinoma cell lines with macrophages increased expression of 
mesenchymal and stem cell markers (Yang et al., 2016). These effects were blocked 
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when the Akt/mTOR signalling pathway was inhibited (Yang et al., 2016). F-box and 
WD repeat domain containing 7 (FBXW7) is involved in several cellular processes 
including proliferation, motility and tumorigenesis (Wang et al., 2013b). Depletion 
of FBXW7 induces EMT and cancer stem cell characteristics in colorectal cancer cell 
lines (Wang et al., 2013b). These effects can be prevented by mTOR inhibition and 
thus induction of EMT and stem like characteristics are mTOR dependent (Wang et 
al., 2013b). Inhibition of the PI3K/mTOR signalling pathways reduces expression of 
stem cell markers and characteristics in CRC (Chen et al., 2015a).  
The Notch signalling pathway regulates cellular fate by balancing cellular 
proliferation, differentiation and apoptosis (Miyamoto and Rosenberg, 2011). There 
are four Notch genes (1-4) and five ligands (Jagged1 and 2 plus Delta-like 1,3 and 4) 
(Miyamoto and Rosenberg, 2011). In normal intestinal homeostasis, Notch1 and 
Jagged1 expression is highest in the proliferative zone of the crypts with Notch 
signalling critical for maintenance of stem cell functions (Miyamoto and Rosenberg, 
2011). Notch1 is highly expressed in colorectal tumours with expression of Notch1 
correlating with EMT in CRC cell lines (Fender et al., 2015). Overexpression of 
Notch1 in CRC cell lines results in an increase in slug expression which represses 
transcription and subsequent expression of E-cadherin (Fender et al., 2015).  
The transforming growth factor β (TGF-β) signalling pathway has tumour 
suppressive functions in the normal cell which include inhibiting cell proliferation 
via MYC inhibition (Drabsch and ten Dijke, 2012). However, during tumour 
development TGF-β becomes a potent growth factor which promotes invasion, EMT 
and metastasis (Drabsch and ten Dijke, 2012). TGF-β signalling occurs through 
Smad proteins and mutations in Smad4 are common in colorectal cancer (Saitoh, 
2015). Other growth factors, such as EGF, FGF and TNF-α, can enhance TGF-β 
signalling in cancer cells (Saitoh, 2015). TGF-β regulates EMT by inducing snail 
expression in cancer cells (Saitoh, 2015). This mechanism is Ras dependent with 
oncogenic Ras resulting in an increase in TGF-β mediated snail expression and 
subsequent EMT induction (Saitoh, 2015).  
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The NF-κB family is a group of transcription factors with 5 members found in 
mammalian species, namely NF-κB1, NF-κB2, RelA, RelB and c-Rel (Min et al., 
2008). NF-κB family transcription factors have important roles in innate and 
adaptive immune responses (Min et al., 2008). NF-κB has the ability to induce EMT 
with overexpression of NF-κB proteins in cancer cell lines inducing ZEB1 and 
vimentin expression (Chua et al., 2007). Twist and snail gene transcription can be 
directly regulated by NF-κB (Min et al., 2008). Along with EMT induction, NF-κB 
can induce invasion by the expression of the metalloproteinases, MMP2 and MMP9 
(Min et al., 2008). This is achieved by activating transcription of MMP9 and post 
translational processing of MMP2 (Min et al., 2008).  
Wnt signalling, illustrated by nuclear β-catenin, is active in cells at the invasive front 
of the CRC tumours in collaboration with decreased E-cadherin, a hallmark of EMT 
(Basu et al., 2016). Wnt signalling can directly induce EMT by the downregulating 
glycogen synthase kinase-β (GSK-β), a component of the β-catenin destruction 
complex, which is an inhibitor of the EMT transcription factor, Snail (Zhou et al., 
2004). The activation of Wnt signalling can also directly impact E-cadherin 
expression levels at the cell membrane and the associated adherens junctions (Huels 
et al., 2015a).  Activation of Wnt removes β-catenin from the adherens junctions and 
shuttles it to the nucleus which results in the turnover of the adherens junctions and 
decreased E-cadherin at the cell membrane (Huels et al., 2015a). E-cadherin has been 
shown to act as a buffer for excessive Wnt signalling by maintaining β-catenin as the 
adherens junctions thus preventing nuclear shuttling and the transcription of Wnt 
target genes (Huels et al., 2015a). Wnt signalling is associated with the formation 
and maintenance of cancer stem cells by promoting EMT (Basu et al., 2016). An 
increase in colorectal cancer stemness and metastasis can be achieved by activating 
the canonical Wnt pathway, demonstrated by the removal of inhibitors of the 
Wnt/β-catenin pathway (Liu et al., 2016; Wangpu et al., 2015). 
In addition to roles in cancer stem cells and EMT, the Wnt pathway also regulates 
other genes associated with motility and invasion. There is an increased expression 
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of a Wnt target gene, Fascin1, at the invasive front of CRC tumours which is an actin 
bundling protein involved in cellular motility (Vignjevic et al., 2007). The Wnt/β-
catenin target gene, L1, is located in invasive CRC cells and linked with liver 
metastasis (Haase et al., 2016). L1, a transmembrane protein and member of the 
immunoglobulin like cell adhesion family, has increased expression at the invasive 
front of CRC tumours and co-expressed with nuclear β-catenin (Haase et al., 2016). 
L1 expression is associated with increase in specific stem cell markers, such as 
SMOC2, and an increase in NF-κB with roles in cell motility, invasion and 
metastasis (Haase et al., 2016). Activation of Wnt promotes proliferation and 
invasion with close associations to EMT and the acquirement of a cancer stem cell 
population.  
 
1.2.3 Epithelial-mesenchymal transition in colorectal cancer 
 
The presence of epithelial-mesenchymal transition in colorectal cancer has been 
demonstrated by gene expression data and histological analysis of CRC tumours. 
Microarray data from colorectal tumours identified an EMT gene expression 
signature as the most dominant pattern and associated EMT with CRC progression 
(Loboda et al., 2011).  Subdivision of CRC based on gene expression (Melo et al., 
2013) or histological characteristics (Ueno et al., 2014) demonstrates a correlation 
between EMT, CRC progression and poor prognosis. Tumour budding and 
destruction of the basement membrane are important steps in CRC invasion and 
metastasis with both correlating with poor survival (Galván et al., 2015; Spaderna et 
al., 2006). Tumour buds have increased expression of the extracellular matrix 
degradation proteins, MMP-2 and MMP-9, plus a decrease in epithelial markers due 
to transcriptional repression from TWIST (Galván et al., 2015). The loss of basement 
membrane structural integrity is combined with a decrease of E-cadherin and an 
increase in mesenchymal markers, specifically ZEB1 (Spaderna et al., 2006).  
Colorectal tumours undergo EMT to facilitate invasion and metastasis with the 
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presence of EMT associated with a more aggressive tumour and subsequent poor 
prognosis.  
Recently, there have been a number of publications investigating EMT regulation in 
CRC with both the WNT and mTOR pathways and several microRNAs described as 
EMT regulators. An investigation of differences in gene expression from primary 
CRC tumours and the corresponding liver metastases revealed an association 
between miR-200c and the switch from EMT to MET (Hur et al., 2013).  A member 
of the miR-200 family, miR-200c, expression correlates with a decrease in ZEB1 and 
Vimentin and an increase in E-cadherin expression illustrating the link with EMT 
(Hur et al., 2013). There is a decrease in miR-200c and increase in mesenchymal 
markers at the invasive front of primary CRC tumours with higher expression of 
miR-200c and decreased mesenchymal markers in established liver metastases 
associated with a mesenchymal-epithelial transition occurring in the establishment 
of secondary tumours (Hur et al., 2013).  Expression of miR-200c was also described 
as reduced in oxaliplatin resistant CRC cell lines, illustrating a link with EMT and 
chemo-resistance (Tanaka et al., 2015). Wnt signalling is the most commonly 
mutated pathway in CRC and has key roles in initiation, progression and metastasis 
including regulation of EMT (Behrens, 2005; Guo et al., 2016). The mTOR signalling 
pathway has been demonstrated to regulate EMT via RhoA/Rac1 signalling in colon 
and prostate cancer (Chen et al., 2014; Gulhati et al., 2011). 
 
 
1.2.4: Cancer stem cells 
 
The acquirement of a cancer stem cell phenotype is closely associated with cells 
undergoing the epithelial-mesenchymal transition. A common theme between CSCs 
and EMT is the cell’s ability to hijack normal physiological signalling pathways in 
order to facilitate tumour growth and spread. An overview of intestinal stem cell 
markers and role in normal physiology is described in chapter 1.1.6. Cancer stem 
cells (CSCs) were first characterised in haematological cancers and are defined by 
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some common functional characteristics such as self-renewal, proliferation and the 
ability to initiate and maintain tumour growth (Jordan et al., 2006).  A subset of 
cells, CSCs, gain tumour initiating mutations and are responsible for the initial 
tumour growth (Jordan et al., 2006). As subsequent mutations arise, a new 
population of CSCs are formed which explains the clonal expansion of tumours 
(Jordan et al., 2006). There is increasing evidence that CSC’s CSCs are more resistant 
to conventional cancer treatments, both radiotherapy and chemotherapy (Rycaj and 
Tang, 2014; Zhang et al., 2015). Colorectal cancer stem cells can be identified by the 
expression of stem cell markers including Lgr5, CD44, CD133, Bmi-1, Oct4, c-myc 
and Nanog (Jordan et al., 2006). In addition, aldehyde dehydrogenase 1 (ALDH1) 
activity has been demonstrated to be a robust marker of intestinal stem cells (Huang 
et al., 2009). Their tumorigenic potential is evaluated by colony forming assays or 
xenotransplantation into immunocompromised mice (Jordan et al., 2006).  
The four signalling pathways responsible for the stem cell niche in normal intestinal 
homeostasis are Wnt, Notch, EGF and BMP (Sato and Clevers, 2013). The Wnt 
signalling pathway is frequently dysregulated in sporadic CRC with mutation of the 
Apc gene often the initiating mutation in colon adenoma formation (Behrens, 2005). 
In normal intestinal crypts there is a Wnt gradient with the peak expression in the 
stem cell compartment and decreasing Wnt expression higher up the crypt (Sato 
and Clevers, 2013). This signalling gradient is required to regulate proliferation and 
differentiation in the crypt with dysregulated Wnt signalling resulting in a 
hyperproliferative phenotype (Sansom et al., 2004). In CRC cells, activation of the 
Wnt signalling pathway can directly induce EMT by downregulating glycogen 
synthase kinase-β (GSK-β) which is a member of the β-catenin destruction complex 
and an inhibitor of the EMT transcription factor, Snail (Zhou et al., 2004). Notch1 is 
overexpressed in CRC tumour samples with overexpression of Notch1 in CRC cell 
lines corresponding with an EMT and an induction of CSC markers (Fender et al., 
2015). The EGF signalling pathway has been reported to be essential for the 
initiation and maintenance of CSCs in vitro (Feng et al., 2012). Expression of BMPs 
promotes EMT, tumorigenicity and the acquirement of cancer stem phenotype in 
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breast cancer cell lines by activation of the Smad signalling pathway (Garulli et al., 
2014).  
The transcription factors regulating EMT also have roles in the promotion of a 
cancer stem cell phenotype (Wang et al., 2015b). ZEB1 represses E-cadherin and 
promotes Bmi-1 expression which is a stem cell marker found primarily in 4+ cells 
of the intestinal crypt (Scheel and Weinberg, 2012). ZEB1 is regulated by miR-200 as 
part of a negative feedback system with miR-200 suppressing stemness via ZEB1 
inhibition (Scheel and Weinberg, 2012). Bmi-1 expression can also be activated 
directly by twist1 and snail (Kurrey et al., 2009; Wu et al., 2012). Twist expression is 
associated with decrease in CD24 and increased expression of CD44, marking an 
induction of a stem cell phenotype (Wang et al., 2015b).  Snail promotes stemness by 
directly binding to a number of stem associated gene promoters including Nanog, 
Tcf4, KLF4 and GPC3 (Kurrey et al., 2009). This demonstrates that the EMT inducing 
transcription factors can also regulate a number of genes associated with the cancer 
stem cell phenotype.  
 
 
1.2.5: Role of epithelial-mesenchymal transition and cancer stem 
cells in therapeutic resistance 
 
An increasing number of studies have linked the induction of EMT with the 
acquirement of therapeutic resistance. The stem cell like features gained during 
EMT, such as increased cell proliferation and survival, all contribute to this increase 
in resistance to conventional cancer therapies. Tumour cell lines have increased 
therapeutic resistance when transfected with EMT genes such as TGF-β and twist 
(Sui et al., 2014). The acquirement of multidrug resistance (MDR) in cancer is 
associated with the removal of chemotherapy drugs from the resistant cells by the 
ATP binding cassette transporters (ABC transporters) (Saxena et al., 2011). These 
ABC transporters contain binding sites for the EMT transcription factors; snail and 
twist (Saxena et al., 2011). A decrease in the expression of EMT transcription factors, 
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twist and Zeb1, results in a reduction of ABC transporter proteins and an increased 
sensitivity to chemotherapy treatment (Saxena et al., 2011).  
The role of the EMT transcription factors, specifically snail, in therapeutic resistance 
have been demonstrated by the knockdown of snail in resistant cell lines (Kaufhold 
and Bonavida, 2014). Knockdown of snail induced apoptosis in adriamycin resistant 
melanoma cells and sensitised lung adenocarcinoma cells to cisplatin (Kaufhold and 
Bonavida, 2014). Resistance to radiation has also been attributed to snail expression 
in ovarian cancer cells (Kaufhold and Bonavida, 2014).  Radioresistance is a common 
attribute of cancer stem cells with an increased expression of cancer stem cells 
associated with a poor response to radiotherapy (Marie-Egyptienne et al., 2013). 
This increase in cancer stem cells and the associated EMT has been linked to the 
increased expression of hypoxia inducible factor - 1α (HIF-1α) (Marie-Egyptienne et 
al., 2013). Hypoxic tissue expresses higher levels of HIF-1α which induces EMT and 
a cancer stem cell phenotype and results in an increased radioresistance compared 
to non-hypoxic tissue (Marie-Egyptienne et al., 2013). The induction of EMT and an 
acquirement of a cancer stem cell phenotype correlates with an increased resistance 
to chemotherapy and radiotherapy in cancer cells. Therefore, understanding the 
mechanisms and signalling pathways contributing to EMT is crucial for the 












Aspirin, acetylsalicylic acid, is a non-steroidal anti-inflammatory drug (NSAID) 
which is commonly used to relieve pain and inflammation. The clinical benefit of 
aspirin in CRC pathogenesis was first discovered in clinical trials investigating low-
dose aspirin treatment as a preventative for vascular events such as thrombosis. 
Aspirin was demonstrated to be an effective chemopreventative, an agent that 
inhibits the initiation of cancer, with a  twenty year follow up study for five of these 
trials, total of over 4000 patients in control and aspirin cohorts, revealing a 40-50% 
risk reduction in fatal colorectal cancer in the aspirin treated groups (Rothwell et al., 
2010). Low dose aspirin, between 75 and 300mg, reduced both the incidence and 
mortality of colorectal cancer (Rothwell et al., 2010). An aspirin mediated reduction 
in CRC incidence has been noted after just 1-year of daily low dose aspirin, but 
there are cumulative effects with an increased duration of aspirin treatment 
corresponding with an increased risk reduction (Din et al., 2010).  
To evaluate the effects of aspirin on those patients with a history of colon adenomas, 
a randomised double-blind trial was conducted (Baron et al., 2003). Patients were 
given either a placebo, 81mg aspirin or 325mg aspirin daily for at least one year then 
colonoscopy performed (Baron et al., 2003). The 81mg of aspirin had the largest 
effect with a 19% reduction in colon adenoma incidence and a 40% reduction in the 
incidence of advanced lesions (Baron et al., 2003). Analysis of gene environment 
interactions using GWAS data highlighted two SNPs at chromosome 12 and 15 
which are associated with the use of aspirin and CRC risk (Nan et al., 2015). These 
SNPs are yet to be validated but may help identify a population where aspirin is a 
chemo-preventative. There is conclusive evidence from large datasets that low dose 
aspirin treatment reduces the incidence of fatal colorectal cancer. 
There is substantial evidence that aspirin can prevent colorectal cancer but the 
benefits of post-diagnosis aspirin are more controversial.  Analysis of a case control 
cohort of 4,794 colorectal cancer patients observed that post diagnosis aspirin had 
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no benefit on either cancer specific or all cause cancer mortality (Cardwell et al., 
2014). However, a separate meta-analysis of eleven different studies reported that 
post-diagnosis aspirin reduced mortality by 16% in colorectal cancer patients (Li et 
al., 2014). Pre-diagnosis aspirin had no effect on mortality in this study which is 
expected as any tumour forming in the presence of aspirin is unlikely to respond to 
aspirin treatment (Li et al., 2014). Meta-analysis of five clinical trials investigating 
aspirin’s prevention of thrombosis, previously used in CRC prevention studies, 
reported a significant decrease in the risk of developing metastasis and a decrease in 
the overall mortality rates when patients treated with aspirin (Rothwell et al., 2012). 
Tumours expressing high levels of COX-2 and tumours with mutated PI3KCA 
benefited the most from aspirin treatment and may be used as potential biomarkers 
for aspirin responding tumours (Li et al., 2014). Further literature reports that post-
diagnosis aspirin increases survival in patients with PI3KCA mutant CRC but has 
little effect on tumours with wild type PI3KCA (Liao et al., 2012).  Whilst there has 
been no large clinical trial of aspirin as an adjuvant treatment in CRC management, 
it is becoming apparent from several small studies that aspirin treatment can 
increase survival in CRC but may be mutation dependent.   
 
 
1.3.1 Cox-dependent mechanism of action 
 
The original nature paper described aspirin’s mechanism of action as an inhibition 
of prostaglandin synthesis which we now know is due to an inhibition of the cyclo-
oxygenase enzymes (Vane, 1971). Aspirin irreversibly inhibits both cyclo-oxygenase 
1 and 2 (COX1 and COX2) enzymes by acetylation which prevents the synthesis of 
prostaglandins, prostacyclins and thromboxanes from arachidonic acid (Roth et al., 
1975). This inhibition accounts for aspirin’s anti-inflammatory, anti-pyretic, anti-
thrombotic and analgesic effects. The infrequent use of aspirin is very safe with side-
effects, such as nausea and vomiting unlikely. Prophylactic use of aspirin, under 
325mg per day, is associated with an increased risk of side effects with between 1 to 
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9 cases per 1000 of gastro-intestinal bleeding and 0.5 to 1.5 cases per 1000 of peptic 
ulcers (Thorat and Cuzick, 2015). The estimated rates of fatal gastro-intestinal 
bleeding due to prophylactic aspirin use in the UK population is between 0.05 to 
0.95 cases per 1000 patients (Thorat and Cuzick, 2015). In addition to gastro-
intestinal effects, aspirin can cause haemorrhagic stroke due to extracranial bleeding 
with incidence rates of between 0.2 to 3 cases per 1000 patients on prophylactic 
aspirin (Thorat and Cuzick, 2015). The incidence rates were age and sex dependent 
with incidence increased with age and in males (Thorat and Cuzick, 2015).  
Whilst the role of aspirin-mediated cox inhibition is understood in normal 
physiology, the role of aspirin and the cox enzymes have in cancer progression has 
only recently been investigated. Both cyclooxygenase enzymes, COX-1 and COX-2, 
are overexpressed in colorectal cancer yet there use as a predictive marker of 
prognosis has been controversial. COX-2 has been claimed to predict prognosis in 
CRC with increased expression linked with invasion and metastasis due to 
increased prostaglandin E2 synthesis (PGE2) (Soumaoro et al., 2004). However, 
another published study of 747 patients determined that COX-2 expression had no 
impact on survival (Fux et al., 2005). A randomized trial treating patients with stage 
three CRC with the specific COX-2 inhibitor, Rofecoxib, showed no difference in 
overall survival (Midgley et al., 2010). While Celecoxib, another specific COX-2 
inhibitor, has been demonstrated to inhibit cellular proliferation and induce 
apoptosis with several of these effects were determined as COX-2-independent (Xie 
et al., 2012). It seems unlikely that aspirin’s effects in cancer prevention and 
treatment are due entirely to COX inhibition as it would then be expected that 
specific COX-2 inhibitors would offer significantly better protection and treatment 
for CRC which is untrue.  
Aspirin is a well characteristic anti-thrombotic with low-dose aspirin used to treat 
vascular conditions. Aspirin acetylates platelet cyclooxygenase which results in the 
inhibition of thromboxane formation and subsequent inhibition of platelet 
aggregation (Schrör, 1997). Platelets have been demonstrated to enhance metastatic 
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potential of tumour cells by promoting adhesion, shielding tumour cells from the 
immune system and production of growth factors such as platelet-derived growth 
factor (PDGF) and transforming growth factor-β (TGF-β) (Labelle et al., 2011).	
Expression of Thrombin by tumour cells induces platelet aggregation which is 
thought to aid metastasis and indeed inhibition of Thrombin in mice with 
melanoma blocked lung metastasis (Lou et al., 2015). The co-culture of CRC cell 
lines with platelets results in CRC cells becoming more mesenchymal and enhances 
their metastatic potential (Guillem-Llobat et al., 2016). This was associated with 
CRC cells having increased migratory capacity and undergoing EMT (Guillem-
Llobat et al., 2016). Pre-treating the platelets with aspirin before co-culture 
prevented this induction of EMT and the aggregation of platelets observed in vivo 
(Guillem-Llobat et al., 2016).  
 
 
1.3.2 Cox-independent mechanism of action 
 
It is likely that a benefit of aspirin, over other specific inhibitors, is the numerous 
pathways which are targeted and the crosslinking of those pathways which avoids 
signal redundancy (Figure 1.20). Three of the main cox-dependent signalling 
pathways inhibited by aspirin in cancer progression is the NF-κB, Wnt and mTOR 
signalling pathways. Nuclear factor-kappaB (NF-κB) is a transcriptional regulator 
for a number of genes involved in cell growth and apoptosis (Stark et al., 2007). 
Aspirin treatment induces the nuclear translocation of NF-κB in CRC cell lines and 
mouse intestinal tissue to induce apoptosis and decrease cell proliferation (Stark et 
al., 2007). Treatment of breast cancer cell lines with aspirin prodrugs also induced 
the nuclear translocation of NF-resulting in the inhibition of cancer stem cell 




The loss of Apc and dysregulation of the Wnt signalling pathway is key in the 
development of colorectal cancer. Aspirin treatment of CRC cell lines decreases β-
catenin and TCF expression thus inhibiting the non-canonical Wnt signalling 
pathway (Bos et al., 2006). This inhibition was demonstrated to be GSK-3β 
independent and protein phosphatase 2A (PP2A) dependent (Bos et al., 2006). PP2A 
effects Wnt signalling by the de-phosphorylation of Apc and Axin proteins (Gala 
and Chan, 2015). Prostaglandin E2 (PGE2), which is inhibited by aspirin mediated 
COX inhibition, inhibits Wnt signalling by stabilizing β-catenin expression through 
phosphorylation of GSK-3β and β-catenin (Gala and Chan, 2015). It is clear from the 
literature that aspirin treatment inhibits the Wnt signalling pathway and its 
associated cellular effects by decreasing β-catenin/TCF signalling in CRC which may 
help explain aspirin’s beneficial effects in CRC initiation following Apc loss.  
Aspirin inhibits the mTOR signalling pathway by both AMPK dependent and 
independent mechanisms which results in a decrease in global protein synthesis and 
an increase in autophagy in CRC cell lines (Din et al., 2012). This inhibition of mTOR 
was also demonstrated in human patients with aspirin treatment corresponding to a 
decrease in mTOR marker expression in rectal mucosa (Din et al., 2012). Aspirin’s 
inhibition of PGE2 production may also influence mTOR activity as PGE2 increases 
cyclic AMP (cAMP) which in turn activates mTOR signalling via AMPK (Gala and 
Chan, 2015).  Given the cellular processes which mTOR signalling regulates, 
including cell growth, survival, EMT and motility, it is clear that aspirin-mediated 
mTOR inhibition could help explain the effects of aspirin in cancer initiation and 












Figure 1.10: Aspirin-mediated effects on signalling pathways. List effects 
attributed to aspirin-mediated inhibition on the cellular signalling pathway, both cox-


































I hypothesis that aspirin is inhibiting the migration, invasion and motility of 
colorectal cancer cells via the inhibition of the epithelial-mesenchymal transition. 
This inhibition of the epithelial-mesenchymal transition reduces the cancer stem cell 




I. Investigate the effects of aspirin on the migration of CRC cells 
II. Investigate the effects of aspirin on the invasion of CRC cells 
III. Investigate the effects of aspirin on the cellular motility and associated 
motility pathways in CRC cells 
IV. Investigate the effects of aspirin on the epithelial-mesenchymal transition in 
CRC cells 
V. Establish a protocol for the culture of organoids from both murine and 
human tissue 
VI. Investigate the effects of aspirin on the budding of Apc deficient organoids 
VII. Investigate the effects of aspirin on the stem cell population in organoids 
VIII. Investigate the effects of aspirin on the stem cell population and epithelial-
mesenchymal transition using in vivo mouse models of intestinal neoplasia 
IX. Investigate the effects of aspirin on the Wnt and mTOR signalling pathways 







Potential clinical impact of research 
This research should help address the molecular impact of aspirin on CRC 
progression specifically related to cell migration, invasion and EMT. By 
understanding the signalling pathways effected by aspirin in this context this 
should help indicate which patients would benefit from aspirin treatment based on 



















Chapter 2: Materials and Methods 
 
 
2.1: Cell lines and reagents 
 
2.1.1: CRC cell line culture 
 
Colorectal cancer cell lines (HCT-116, Colo205, SW480, RKO, LS-174T, DLD-1, HT-
29 and Caco-2) are available from the European Collection of Authenticated Cell 
Cultures (ECACC). Telomerase immortalised mouse fibroblasts (TIFs) were kindly 
provided by John Dawson (IGMM, Edinburgh). Cells were grown as a monolayer in 
Dulbecco’s modified Eagle medium (DMEM) (Life Technologies) supplemented 
with 10% foetal calf serum and 1% penicillin/streptomycin. Cells were passaged 
when confluent, every 3-4 days, using trypsin/EDTA solution and maintained in 5% 
CO2 at 37°C. Cells were counted prior to experimentation using a Coulter counter 
(Beckman). Cell stocks were frozen in DMEM supplemented with 10% DMSO and 
stored in liquid nitrogen containers. The mutational background of a selection of 
CRC cell lines was determined by a review of the Sanger Institute Catalogue of 
Somatic Mutations in Cancer website and the latest literature (Ahmed et al., 2013; 















Cell line β-catenin KRAS BRAF PIK3CA PTEN TP53 
HCT-116 S45del G13D WT H1047R WT WT 
Colo205 N287S WT V600E WT WT Y103_L111>L 
SW480 WT G12V WT WT WT R273H;P3095 
RKO WT WT V600E H1047R WT WT 
HT-29 WT WT V600E P449T WT R273H 
DLD-1 WT G13D WT E545K;D549N WT S241F 
LS-174T S45F G12D WT H1047R WT WT 
Caco-2 G245A WT WT WT WT E204X 
 
 
Table 2.1: Mutational background of colorectal cancer cell lines. The mutational 
status of a selection of CRC cell lines based on the latest literature. MSI, 
microsatellite instable, MSS, microsatellite stable, CIN, chromosomal instability, WT, 




Cell line MSI status CIN Apc 
HCT-116 MSI - WT 
Colo205 MSI + T1556fs*3 
SW480 MSS + Q1338 
RKO MSI - WT 
HT-29 MSS + E853*, T1556fs*3 
DLD-1 MSI -  R709M, R727M, K975N, K993N, 
I1417fs*2 
LS-174T MSI - WT 




2.1.2: Aspirin preparation 
 
Aspirin stock solution, 0.5M, is prepared by dissolving 4.505grams of acetyl-salicylic 
acid (Sigma-Aldrich) in 50mls distilled water. The pH of the solution is adjusted 
with the addition of sodium hydroxide solution until stable at 7.0. Aspirin solution 
is passed through a 0.2μm syringe filter and stored in aliquots at -20°C.   
 
2.2: CRC cell line assays 
 
2.2.1: Growth curves 
 
Growth curves were completed over a 72-hour period. Cells were plated at 1x104 
cells/cm2 in a 6 well plate with separate duplicate wells prepared for the 24, 48 and 
72 hour counts. Every 24 hours, cells from duplicate wells were re-suspended and 
counted using a coulter counter. Treatment was added to media at 0 hours and left 
on cells for the duration of the experiment. The growth inhibition IC50 was 
determined from the growth curves. The IC50 was calculated by linear regression 
using the 24, 48 and 72 hour values.  
 
2.2.2: Wound healing assays 
 
Wound healing assays were performed by two different methods, either creating a 
scratch in a cellular monolayer or growing cells in an insert to create a cell free gap. 
For the scratch assay method, cells were plated at 6x104cells/cm2 in normal growth 
media in 6 well plates. Following 24 hours of cellular growth, a wound was created 
using a p200 pipette tip. Cells were seeded in Ibidi cell culture inserts (Thistle 
Scientific) at 4x104cells per insert. Cells were grown until an estimated 90% 
confluency, between 24-36 hours of cellular growth. Removal of the insert left a cell 
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free gap without causing cellular damage. After creation of a cell free gap, through 
either a scratch or insert, the protocol for both methods is identical. Cells were 
washed with PBS before fresh DMEM was added with either 0.5% or 10% serum. 
Treatment was added and images taken at 0, 24 and 48 hours by a Zeiss Axiovert 
100 microscope using 4x objective. The area of the wound was measured and the 
corresponding percentage wound closure calculated using Image J software. 
 
2.2.3: Inverse invasion assays 
 
 The inverse invasion assay is a matrigel based assay in which cells can be stained 
with a live cell dye allowing the distance and speed of invasion to be determined by 
confocal microscopy. A thin layer of matrigel was pipetted into Polycarbonate 
membrane transwell inserts (Corning) with 8μm pore size and left to solidify. The 
inserts were flipped over and 2x104 cells were seeded on the base of the insert. After 
cellular attachment the inserts were flipped back to original state and placed in a 24 
well plate. Serum free media was added to the cells and media containing 10% 
foetal calf serum was placed inside the insert upon the matrigel layer to act as a 
chemo-attractant. After a 5-day incubation, cells were stained with Calcein AM 
permeant cell dye (Thermofisher) which is a live cell dye that stains the whole cell 
green. The assay was imaged by Nikon C1+ confocal microscope with a 20x 
objective. Optical sections were scanned at 15μm intervals from the filter up through 









2.2.4: Organotypic invasion assays 
 
Organotypic collagen based invasion assays were used as previously described 
(Timpson et al., 2011).  
 
Stage 1: Preparation of collagen solution from rat tail tendons 
Rat tails were washed in ethanol, tendons were dissected and placed in 0.5M acetic 
acid for 48 hours. Collagen was precipitated out of solution with the addition of 10% 
NaCl before re-dissolved in 0.25M acetic acid. Solution was dialyzed against 
17.5mM acetic acid using 12-14kD Visking dialysis tubing (Medicell International) 
for 4 days. Collagen solution was stored at 4°C. 
 
Stage 2: Set up of 3D matrix for invasion 
Glutamine free minimum essential media (MEM) (Life Technologies) was added to 
the collagen solution and then neutralized with the addition of NaOH. Telomerase 
immortalised fibroblasts were pelleted, suspended in foetal calf serum then added 
to the collagen solution. The matrix was solidified in 6 well plates and incubated in 
DMEM media for 4-6 days. During this incubation the gels shrink to one third of 
their original size and can fit into the well of a 24 well plate.   
 
Stage 3: Invasion assays 
Gels were transferred to 24 well plates and CRC cells plated on surface of the gel at 
1x104 cells/well. Once cells had grown to confluence, 1-2 days, gels are placed on 
stainless steel grids (Sigma-Aldrich). It is important that only the bottom surface of 
the gel is in contact with media as this creates a nutrient gradient which promotes 
invasion. Cells are left to invade for 7 days with media changed every 2 days. The 
gels are fixed in 4% paraformaldehyde overnight at room temperature and 
embedded in paraffin. Sections from the paraffin embedded gels are stained with 
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haematoxylin and eosin. Cells were imaged on Zeiss Axioplan 2 microscope using a 
10x objective and counted using Image J software.  
 
2.2.5: Motility assays 
 
Cells were seeded at 3x103 cells/cm2 in normal growth media in 96 well plates. 
Following 24 hours of cellular growth, media was removed and fresh DMEM added 
containing either 0.5% or 10% serum. Treatment was added to the cells, 4 wells per 
condition, and images taken on a live cell imaging microscope, Zeiss Axiovert 200. 
A 10x objective was used and ten cells per well were tracked with images captured 
every 30 minutes for 24 hours. Cell movement was measured using a manual 
tracking plugin for Image J. Quantification of accumulated and euclidean distance 
was calculated and graphs plotted using a chemotaxis plugin for Image J. 
 
2.2.6: Spheroid formation assays 
 
Spheroid formation assays were performed using Corning costar ultra-low 
attachment (Sigma-Alrich) 60mm culture dishes and 96 well plates. Cells were 
washed in PBS and 60,000cells/cm2 seeded in spheroid formation media. Spheroid 
formation media is composed of DMEM/F12 media (Life Technologies), 1x B27 
(Invitrogen), 50ng/ml EGF (Sigma-Aldrich) and 5μg/ml insulin (Sigma-Aldrich). 
Spheres formed in suspension and media was half changed every 2 days. Protein 
extraction and immunofluorescence was completed on pelleted spheroids using 








2.3: Protein  
 
2.3.1: Protein extraction 
 
Cells were seeded at 3x104 cells/cm2 24 hours prior to treatment. On completion of 
treatment, cells were washed in ice cold PBS and pelleted. For whole cell lysis, the 
pellet was lysed in whole cell lysis buffer for 45 minutes on ice then spun at 
13000rpm for 20 minutes. The supernatant contained all cellular proteins and was 
stored at -80C. For cytoplasmic and nuclear fractioned extractions, cell pellets were 
lysed in cytoplasmic lysis buffer for 10 minutes then pelleted at 3000rpm for 5 
minutes with the supernatant, containing all the cytoplasmic proteins, removed and 
stored at -80°C. The nuclear pellet was lysed in hypotonic buffer for 30 minutes on 
ice then spun at 13000rpm for 20 minutes with the supernatant, containing all 
nuclear proteins, removed and stored at -80°C. Lysis buffer recipes are detailed in 

















Whole cell lysis buffer Cytoplasmic lysis 
buffer 
Nuclear lysis buffer 
20mM Tris pH 7.5 20mM Tris pH 7.5 20mM Hepes pH 8 
150mM NaCl 0.1mM EDTA 0.4M NaCl 
1mM EDTA 2mM MgCl2 25% glycerol 
1mM EGTA 2ug/ml Aprotinin 1mM EDTA 






50mM NaF 10ug/ml Trypsin inhibitor 0.5mM DTT 
5mM beta glycerol 
phosphate 
1% NP40 2ug/ml Aprotinin 
50nM calyculin A 50nM beta-2-
metcapethanol 
2ug/ml Leupeptin 
1mM Na3VO4 1mM PMSF 0.3ug/ml 
benzamindichloride 
1x PhosSTOP, Roche 
complete protease 
inhibitors 
1x PhosSTOP, Roche 
complete protease 
inhibitors 
1x PhosSTOP, Roche 
complete protease 
inhibitors 
  1mM PMSF 
  10ug/ml Trypsin inhibitor 
 
Table 2.2: Protein extraction lysis buffer recipes. Detailed recipe for whole cell, 











2.3.2: Western blotting 
 
Protein samples were separated by sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PDVF) 




Protein concentration of the extractions was quantified using Bradford’s protein 
assay (Bio-Rad) with bovine serum albumin (BSA) solution used to create the 
standard curve. Protein samples were incubated in laemmli buffer (Bio-Rad) at 95-
105°C for 5 minutes before loaded into wells on polyacrylamide gels. The chemical 
composition of gels and buffers is detailed in Table 2.3. Protein samples were run at 
120V for 20 minutes, this allowed samples to migrate to the bottom of the stacking 




Proteins were transferred from the gel to a PDVF membrane (Thermofisher) which 
had been pre-soaked in 100% ethanol for 5 minutes.  This was completed by semi-
dry transfer in which the gel and membrane are sandwiched between sheets of 
paper soaked in semi-dry transfer buffer. Transfer is completed at 15V for 30 
minutes. Post transfer, membranes were briefly washed in 0.1% tween/PBS then 




Primary antibodies were diluted in 3% bovine serum albumin/ 0.02% sodium azide/ 
PBS solution and membranes incubated overnight at 4°C. Membranes were briefly 
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washed in 0.1% tween/PBS then incubated with a secondary antibody for 1 hour at 
room temperature. Secondary HRP-conjugated antibodies were diluted in 5% non-
fat milk/ 0.1% tween/ PBS solution. Details of antibodies used are detailed in Table 
2.4. Membranes were washed in 0.1% tween/ PBS solution on a shaker for 3 x 15 
minute periods. Antigen-antibody complexes were visualised by 
chemiluminescence using western blotting luminal reagent (Santa-Cruz 
Biotechnology). Membranes were incubated in luminal reagent for 1 minute at room 





Buffer (pH 6.8) 
4x Resolving 





6.05g Tris Base 18.15g Tris Base 30g Tris Base 5.8g Tris Base 
2ml 20% SDS 2ml 20% SDS 144g Glycine 2.9g Glycine 
pH adjusted with 
addition of HCl 
pH adjusted with 
addition of HCl 
50mls 20% SDS 1.85mls 20% SDS 
Up to 100ml with 
dH2O 
Up to 100ml with 
dH2O 




   Up to 1litre with 
dH2O 
 
 Stacking gels (x2) 10% Running gels (x2) 
dH2O 4.955ml 7.4ml 
4x stacking/ resolving 
buffer 
1.825ml 3.8ml 




Temed 7.5ul 10ul 
 
Table 2.3: Recipe for PAG gels and SDS-PAGE buffers. Detailed recipes for 4x 
stacking buffer, 4x resolving buffer, 10x running buffer, semi-dry transfer buffer, 
stacking gels and 10% running gels. Recipe for 10% running gels as an example 
with 40% acrylamide and distilled H2O volumes altered to create higher or lower 





Primary Antibody Dilution Species Company 
E-cadherin (24E10) 1:1000 Rabbit Cell Signalling Technology 
N-cadherin (D4R1H) 1:250 Rabbit Cell Signalling Technology 
Vimentin (D21H3) 1:500 Rabbit Cell Signalling Technology 
Claudin-1 (D5H1D) 1:1000 Rabbit Cell Signalling Technology 
Snail (C15D3) 1:250 Rabbit Cell Signalling Technology 
Slug (C19G7) 1:250 Rabbit Cell Signalling Technology 
ZO-1 (D7D12) 1:500 Rabbit Cell Signalling Technology 
ROCK1 (C8F7) 1:500 Rabbit Cell Signalling Technology 
Cofilin (D3F9) 1:1000 Rabbit Cell Signalling Technology 
Phospho-cofilin (ser3) 
(77G2) 
1:500 Rabbit Cell Signalling Technology 




1:250 Rabbit Cell Signalling Technology 
alpha-smooth muscle 
actin  
1:1000 Rabbit Abcam 
Anti-GPCR GPR49 
(Lgr5) (EPR3065Y) 
1:500 Rabbit Abcam 
β-catenin 1:1500 Mouse BD Transduction 
Laboratories 
GAPDH (GT239) 1:1000 Mouse GeneTex 
Lamin B (C-20) 1:500 Goat Santa Cruz Biotechnology 
β-actin (C4) 1:5000 Rabbit Santa Cruz Biotechnology 
 
Secondary Antibody Dilution Company 
Rabbit IgG HRP linked 1:3000 GE Healthcare 
Mouse IgG HRP linked 1:3000 GE Healthcare 




Table 2.4: Antibodies used for western blotting. Detailed list of primary and 










Cells were seeded at 3x104 cells/cm2 on glass coverslips 24 hours prior to treatment. 
On completion of treatment, cells were fixed in 4% paraformaldehyde (Thermo 
Scientific) for 15 minutes at room temperature. After washing with PBS, cells were 
incubated in permeabilization buffer for 10 minutes then blocking buffer added for 
1 hour, all at room temperature. Permeabilization buffer consists of 0.2% Triton X 
diluted in PBS. Blocking buffer is 3% goat serum and 3% bovine serum albumin 
diluted in PBS. Primary and secondary antibodies were diluted in 0.5% goat serum 
0.1% Tween20 in PBS. E-cadherin (Cell signalling) or ZO-1 (Cell signalling) 
antibody, diluted 1:100, was incubated overnight at 4°C. After washing with 0.1% 
tween/ PBS, cells were incubated with Alexafluor488 rabbit antibody (Life 
Technologies) at 1:1000 for 1 hour at room temperature. F-actin was stained with 
Alexfluor488 phalloidin (Life Technologies) at 1:200 overnight at 4°C. Following 
washing with 0.1% tween/ PBS, cells were mounted with Vectashield mounting 
medium plus DAPI (Vector laboratories). Cells were imaged on Zeiss Axioplan 2 
using 10x, 40x and 100x objectives. To verify specificity of primary antibody 
staining, cells were incubated in secondary antibody only and imaged with minimal 















Figure 2.1: Immunofluorescence secondary antibody controls. No primary 
antibody incubation only rabbit secondary-488 antibody incubation. Images of 

















Paraffin embedding and sectioning was performed by either the Beatson institute 
histology department or the IGMM histology department.   
 
Stage 1: Deparaffinise and rehydrate sections 
Sections were deparaffinised by 3 x 5 minute washes in 100% xylene. Then 
sequentially washed in decreasing concentrations of ethanol, specifically 3 x 2 
minute washes in 100% ethanol followed by 2 minute washes in 90% and 70% 
ethanol. Sections were placed under running tap water for 5 minutes to fully 
rehydrate. 
 
Stage 2: Antigen retrieval 
Antigen retrieval was achieved by submerging sections in boiling 1X citrate buffer 
(Thermofisher) for 30 minutes, then left in solution for further 30 minutes while 
solution cools. Sections were washed in distilled water.  
 
Stage 3: Endogenous blocking 
Endogenous blocking was achieved by incubation in 3% hydrogen peroxide (Sigma-
Aldrich) for 10 minutes followed by 1 hour incubation with 5% goat serum 0.1% 
Tween20 in PBS at room temperature. 
 
Stage 4: Primary antibody 
Primary antibodies used are detailed in Table 2.5.  The primary antibody was 
diluted in 5% goat serum 0.1% Tween20 in PBS and incubated overnight at 4°C. 





Stage 5: Secondary antibody 
For most of the proteins stained incubation for 1 hour at room temperature with 
either rabbit (DAKO) or mouse (DAKO) HRP secondary antibody was sufficient 
although for p-S6 and p-4E-BP1 an amplifying secondary was required. The rabbit 
ABC amplification kit (Vector laboratories) contained a rabbit secondary antibody 
and amplification reagents. Sections were incubated for 30 minutes with antibody 
and 30 minutes with ABC amplification reagents. Sections were then washed in 
0.1% Tween20 in PBS. 
 
Stage 6: Visualisation of positivity and counterstaining 
Signal was detected using 3,3’-Diaminobenzidine (DAB) peroxidase substrate kit 
(Vector laboratories). After visualisation of positivity, sections were rinsed in water 
then counterstained for 1 minute with Harris haematoxylin. Sections were washed 
under running water for 5 minutes.  
 
Stage 7: Mounting of immunohistochemistry slides 
Sections were dehydrated in 3 x 2 minute washes in 100% ethanol and cleared in 3 x 
5 minute washes in 100% xylene before mounting using DPX mounting medium. 
All slides were imaged using a Hamamatsu nanozoomer.  
To verify the specificity of primary antibody staining, sections of mouse tissue were 











Antibody Dilution Species Secondary  Company 
E-cadherin 1:200 Rabbit HRP linked Cell Signalling 
Technology 

















1:500 Rabbit HRP linked Sigma-Aldrich 
β-catenin 1:300 Mouse HRP linked BD Biosciences 
Lysozyme 1:1000 Rabbit HRP linked Dako 
Sox-9 1:500 Rabbit HRP linked Millipore 
BrdU 1:200 Mouse HRP linked BD Biosciences 
 
Table 2.5: Immunohistochemistry primary antibodies. Detailed list of all primary 
antibodies used for immunohistochemistry, antibody dilution, species, secondary 



















Figure 2.2: Immunohistochemistry secondary antibody control. Images of 
small intestine and colon tissue with no primary antibody incubation. 






2.4.1: RNA extraction 
 
Cells were seeded at 3x104 cells/cm2 in 6 well plates 24 hours prior to treatment. 
Following treatment, RNA was extracted using Ribopure RNA purification kit 
(Thermofisher). Media is removed and cells lysed in 1ml of TRI reagent per 10cm2 of 
adherent cell monolayer. After incubation for 5 minutes at room temperature, the 
solution is transferred to an eppendorf and 200ul of chloroform added. Solution is 
vortexed, incubated at room temperature for 5 minutes then spun at 12000g for 10 
minutes. This process separates the mixture into three phases with RNA isolated in 
the upper aqueous phase. The aqueous phase is transferred to a fresh eppendorf 
and 200ul of 100% ethanol added. The sample is placed in a filter cartridge and spun 
at 12000g for 30 seconds which binds the RNA to the filter. Further washes are 
completed before RNA is recovered in a small volume of elution buffer. RNA 
extractions are quantified using a nanodrop and stored at -80°C.  
 
2.4.2: cDNA synthesis 
 
RNA was DNase treated by incubation with RQ DNase 1 and RQ1 10x React Buffer 
at 37°C for 30 minutes. The reaction was stopped by the addition of DNAstop 
solution and further incubation at 65°C for 10 minutes. Synthesis of cDNA was 
completed by addition of cDNA reaction mixture (M-MLVRT, M-MLVRT 5x react 
buffer, Random primers, 10mM dNTP and RNasin) and incubation at 37°C for 1 
hour followed by 95°C for 5 minutes. Plates with stock cDNA were stored at -20°C. 









DNase treatment Per well Company 
RQ1 DNase 1  1µl Promega 
RQ1 10x React Buffer  1µl Promega 
RNA 1µg - 
dH2O up to 10µl - 
 
cDNA synthesis Per well Company 
M-MLVRT 5x react buffer  4µl Promega 
M-MLVRT  1µl Promega 
Random primer  1µl Promega 
10mM dNTP  2µl Promega 
RNasin  1µl Promega 
dH2O 1µl - 
 
Table 2.6: DNase and cDNA synthesis reaction mixtures. Detailed recipes of 
DNase and cDNA synthesis reaction mixtures per well and list of companies 















2.4.3: Quantitative real time polymerase chain reaction (qRT-PCR) 
 
Quantitative real time PCR was completed on Lightcycler 480 (Roche) using the 
SYBR green master mix (Bio-Rad). The reaction mix is detailed in Table 2.7. The 
qRT-PCR template and the primer sequences are detailed in Table 2.8. Expression of 
target genes was normalised to the expression of the house keeping gene, GAPDH. 
 
qRT-PCR reaction Per well 
SYBR green select 2x master mix  5µl 
20µM F + R primers 1µl 
dH2O 2µl 
Diluted 1:10 cDNA  2µl 
 
Table 2.7: qRT-PCR reaction mixture. Detailed recipe for qRT-PCR reaction 



















A: qRT-PCR template 
 Cycles Temperature Time 
Pre-incubation 1 95°C 5 minute  
Amplification 60 95°C 10 seconds 
60°C 10 seconds 
72°C 10 seconds 
Melting Curve 1 95°C 5 seconds 
65°C 1 minute 
97°C Continuous 0.11°C/second 
Cooling 1 40°C 30 seconds 
 
B: Primer sequences 
Gene Sequence 
GAPDH - F 5′- GCACCGTCAAGGCTGAGAAC-3′ 
GAPDH - R 5′-TGGTGAAGACGCCAGTGGA-3′ 
CDH1 – F 5′-ATTCTGATTCTGCTGCTCTTG-3′ 
CDH1 - R 5′-AGTAGTCATAGTCCTGGTCTT-3′ 
SNAIL1 – F 5′-CAGACCCACTCAGATGTCAA-3′ 
SNAIL1 - R 5′-CATAGTTAGTCACACCTCGT-3′ 
LGR5 – F 5’-GAGTCAACCCAAGCCTTAGTATCC-3’ 
LGR5 - R 5’-CATGGGACAAATGCAACTGAAG-3’ 
TROY – F 5’-CTGGATTTGAAGTTTGTCTG-3’ 
TROY – R 5’-CGTGTTTATTCCTGCTACTC-3’ 
OLFM4 - F 5’-GCCACTTTCCAATTTCAC-3’ 
OLFM4 – R 5’-GAGCCTCTTCTCATACAC-3’ 
TCF7 – F 5’-CACCACAGGAGGAAAAAGAAATG-3’ 
TCF7 – R 5’-CAAGGAGGGCAACAGAAGATAC-3’ 
 
Table 2.8: qRT-PCR template and primer sequences. Detailed reaction protocol 
for qRT-PCR experiment (A) and list of primer sequences (B). Primer sequences for 





RNAscope is a RNA is situ hybridization method which allows visualisation and 
quantification of RNA transcripts in formalin fixed tissue (Wang et al., 2012). All 
reagents were purchased from Advanced Cell Diagnostics. Tissue was probed for 
Lgr5 RNA expression as there was no effective immunohistochemistry antibody for 
Lgr5 protein available at time of experiment. RNAscope was completed using 2.0 
HD red detection kit following manufacturer’s protocol which is illustrated in 
Figure 2.3 by flow diagram. Paraffin embedded sections were baked at 60°C for 1 
hour before being deparaffinised and rehydrated by sequential washes in 100% 
xylene, 100% ethanol and distilled water. Antigen retrieval and endogenous 
blocking was achieved by incubation with three pretreatment solutions. The Lgr5 
probe was hybridized for 2 hours at 40°C. Amplification of the signal was achieved 
by the sequential hybridization of six different solutions. The slides were 
counterstained with Gills haematoxylin and blued with 0.02% ammonia water. 
Samples were mounted and imaged with the nanozoomer slide scanner. To validate 
the quality of RNA and specificity of the protocol, tissue was incubated with 
negative and positive control probes. The positive control probe detects mouse 















Sections cut by IGMM histology department 
Bake slides at 60°C for 1 hour 
Deparaffinisation in xylene, dipped in 100% ethanol and air-dried 
Pre-treatment 1-3 
Hybridize the Lgr5 probe for 2 hours at 40°C  
Hybridize Amps 1-6 
Detection of signal with Fast Red solution  
Counterstain in Gills Haematoxylin solution and blued with 0.02% ammonia water 
Mount samples with EcoMount mounting medium. 
Slides imaged by Hamamatsu nanozoomer.  
 
 
Figure 2.3: RNAscope protocol. Simplified flow diagram of RNAscope protocol as 








Figure 2.4: RNAscope negative and positive control probes. Negative (A) and 
positive (B), PPIB, RNAscope control probe incubation on small intestine, colon and 
Hela cell monolayer. 
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2.5: Organoid culture 
 
The culture of colonic organoids from human tissue has been described 
previously(Sato et al., 2011b). All organoid crypt culture solutions and organoid 
media formulations are detailed in Table 2.9 and Table 2.10 respectively.  
 
ADF+++ Volume Company 
Advanced DMEM/F12  485ml Life Technologies 
1000x Glutamax  5ml Life Technologies 
1M Hepes  5ml Life Technologies 
Penicillin/Streptomycin 5ml Life Technologies 
 
10x complete chelation 
solution (CCS) 
Volume Company 
10x PBS 500ml Life Technologies 
Sucrose 75g Sigma-Aldrich 
D-sorbitol 50g Sigma-Aldrich 
1x complete chelation 
solution 
Volume Company 
dH2O 450ml - 
10x CCS 50ml - 
DL-dithiotreitol 40mg Sigma-Aldrich 
 
Digestion Media Volume Company 
ADF+++ 50ml - 
Collagenase 50mg Sigma-Aldrich 
Hyaluranidase 1μg Sigma-Aldrich 





Table 2.9: Organoid crypt culture solutions. Detailed recipe for ADF+++, 
complete chelation solution and digestion media which are require for the initial 
culture of normal mucosa and adenoma organoids. Reagents purchased from 














ADF+++ - 11.5ml 11.5ml - 




500mM 30µl 30µl Sigma-Aldrich 
Nicotinamide 1M 120µl 120µl Sigma-Aldrich 
Gastrin 1µM 120µl 120µl Sigma-Aldrich 
EGF 50µg/ml 12µl 12µl Sigma-Aldrich 
Mouse 
Noggin 
100µg/ml 12µl 12µl Preprotech 
A83-01 500µM 12µl 12µl Sigma-Aldrich 
SB202190 10mM 12µl 12µl Sigma-Aldrich 
PGE2 100µM 12µl 12µl Sigma-Aldrich 
Human R-
spondin 
500µg/ml 24µl 24µl R&D 
Human Wnt-
3a 
200µg/ml 6µl - R&D 
RhoKi 
(Y27632) 










ADF+++ - 11.75ml 11.75ml - 
EGF 50μg/ml 12μl 12μl Sigma-Aldrich 
Mouse 
Noggin 
100μg/ml 12μl 12μl Preprotech 
Mouse R-
spondin 
50μg/ml 240μl 240μl R&D 
Mouse Wnt-
3a 
200μg/ml - 6μl R&D 
 
 
Table 2.10: Organoid media formulations. Detailed recipe for human colon 
normal mucosa and adenoma media. Detailed recipe for mouse small intestine and 




2.5.1: Human colonic organoids 
 
Human colonic normal mucosa and adenomas were removed during surgery and 
transported to laboratory in PBS on ice. Mucosa was cut into strips and washed 
three times with 1xCCS. Mucosa was incubated in 20mls of 1xCCS with 5mM EDTA 
for 1 hour at 4°C on rotating wheel. After incubation vigorous shaking results in 
release of crypts into supernatant. Supernatant was collected and 5ml of foetal calf 
serum added. Crypts are pelleted and washed in ADF+++ three times to remove 
debris and single cells. Crypts were suspended in 70% matrigel (BD Biosciences), 
diluted with ADF+++, at 500crypts/50ul of matrigel. Multiple droplets of matrigel 
were pipetted into each well of a 24 well plate. The plate is inverted and placed in 
an incubator for 30 minutes for matrigel to solidify. Human colon normal media 
was added, 500μl per well, and changed every 2-3 days. Organoids were passaged 
when the centres of the organoids became dark indicating an accumulation of 
cellular debris which would lead to the destruction of the organoid if not passaged. 
To passage organoids, they need to be removed from the matrigel by mechanical 
disruption which can be achieved with p1000 and p200 pipettes. The organoids are 
washed then disrupted by passing through a 21-gauge needle. After further 
washing, the organoids can be re-plated as previously detailed. Depending of 
growth of organoids, they can be passaged between 1:1 to 1:4.  
 
2.5.2: Human colonic adenoma 
 
Human colonic adenoma crypt culture varies from that of normal mucosa. 
Adenomas are placed in 10ml digestion media and cut into small segments with a 
scalpel. This mixture is incubated at 37°C for 1 hour on a shaker. The solution is 
forced through a 70μm cell strainer twice to remove fibrous tissue. The adenoma 
cells are then washed and plated using the same protocol as normal mucosa with 




2.5.3: Mouse organoid culture 
 
Mouse organoids are set up using a similar protocol to human colonic normal 
mucosa. Mouse intestines were cut into small segments with scissors and incubated 
in 1xCCS/EDTA solution. Small intestine requires incubation with 1xCCS + 2mM 
EDTA for 30mins, whilst mouse colon requires 1xCCS + 25mM EDTA for 30mins. 
The crypts are removed, washed and plated as previously described for human 
colonic normal mucosa organoids. Mouse organoid media requires only a few 
growth factors compared to human, with the formulations detailed in Table MM9. 
Organoids from wild-type mouse small intestine and Apcflox/flox mouse small 
intestine were kindly provided by Kevin Myant (IGMM, Edinburgh).  
 
2.6: In vivo mouse models 
 
2.6.1: ApcMin/+ mouse model 
 
ApcMin/+ mice have a nonsense mutation at codon 850 resulting in a truncated protein 
(Heyer et al., 1999). ApcMin/+ heterozygotes develop numerous adenomas throughout 
the intestines with the large majority in the small intestine. Symptoms of the 
adenoma burden are blood in faeces and signs of anaemia such as pale feet. 
Lifespan of the mice can vary but is usually around 100-150 days. Tissue was 
analysed from three separate aspirin treated ApcMin/+ cohorts, one cohort completed 
by our research group in Edinburgh and two cohorts completed in collaboration 
with the Owen Samson group at the Beatson institute in Glasgow. The gender 
distribution of each mouse cohort is detailed in Table 2.11. The aspirin dosage used 
in the mouse experiments were either 400mg/kg by oral gavage or 2.6mg/ml in 
drinking water. Based on an average 20g mouse which drinks 3mls per day these 
doses equate to 8mg and 7.8mg aspirin respectively. These doses were based on 
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previous experiments from the literature and equate to approximately 33mg/kg 
human dosage. 
 
 Control Aspirin 
Cohort Male Female Male Female 
4-week 3 3 2 3 
Ageing 6 2 6 2 
7-day 0 5 1 3 
Apcflox/flox 2 0 3 0 
 
 
Table 2.11: Gender distribution of mouse aspirin treatment cohorts. The 
number of male and female mice in each the control and aspirin treatment cohorts. 
 
1) 4-week treatment cohort 
The 4-week treatment cohort was composed of 13 wild-type mice and 13 
ApcMin/+ mice. These groups of 13 were split into 6 control mice, 6 aspirin 
treated mice and 1 rapamycin treated mouse. Mice were 6 weeks old when 
treatment began and lasted 4 weeks. Mice were administered either distilled 
water or 400mg/kg aspirin by oral gavage daily with the exception of the 2 
rapamycin treated mice. These mice received a single intraperitoneal 
injection of 2.5mg/kg of rapamycin 48 hours prior to culling. A single aspirin 
treated ApcMin/+ mouse had to be culled before the experiment was 
completed. The animal appeared ill with skin lesions commonly found when 
mice have been fighting. There were no symptoms of anaemia, associated 
with high tumour burden or any signs of aspirin toxicity.  
 
All mice were culled by cervical dislocation by trained technicians. 
Immediately after culling, the small intestine, colon and liver were dissected. 
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A small portion of each tissue was snap frozen in liquid nitrogen for future 
RNA and protein extraction. The majority of tissue was fixed in 10% neutral 
buffer formalin for histological analysis. The intestines were fixed on 
wooden skewers overnight at room temperature then washed and stained 
with methylene blue dye to highlight the adenomas. The stained intestines 
were imaged by Nikon eclipse T-is macroscope so counts and sizing of 
adenomas could be completed at a later date. Tissue was placed in ethanol 
for 2-3 days which removed most of the dye. Intestines were swiss-rolled 
and embedded in paraffin along with a section of the liver.  
 
2) Ageing cohort 
The ageing cohort was composed of 16 ApcMin/+ mice, 8 aspirin treated and 8 
untreated controls. Treatment was individualised with treatment initiated 
once symptoms of tumour burden were present, specifically pale feet, and 
continued until the mice’s health deteriorated and they had to be culled. 
Aspirin was administered via the drinking water which contained 2.6mg/ml 
of aspirin. Mice were culled by schedule 1 methods. Intestines and liver were 
dissected, fixed and paraffin embedded for histological analysis. 
 
 
3) 7-day treatment cohort 
The 7-day treatment cohort was composed of 9 ApcMin/+ mice, 4 aspirin 
treated and 5 untreated controls. Treatment was individualised with 
treatment initiated once symptoms of tumour burden were present, 
specifically pale feet, and continued for 7 days. Aspirin was administered via 
the drinking water which contained 2.6mg/ml of aspirin. Mice were culled 
by schedule 1 methods. Intestines and liver were dissected, fixed and 





2.6.2: Apcflox/flox mouse model 
 
All Apcflox/flox mouse experiments were completed by Tam Jamieson (Beatson, 
Glasgow). Conditional knockout of the 15 coding exons of the Apc gene in the 
intestines was achieved with VilCreER (el Marjou et al., 2004). Recombination was 
induced by one intraperitoneal injection of 80mg/kg tamoxifen, administered on two 
consecutive days.  
1) Apcflox/flox cohort 
The Apcflox/flox cohort was composed of 5 mice, 2 controls and 3 aspirin 
treated mice. Aspirin was administered via the drinking water which 
contained 2.6mg/ml of aspirin for 4 days. Mice were culled by schedule 1 
methods. Intestines and liver were dissected, fixed and paraffin embedded 
for histological analysis. There were an additional 2 wild-type control mice 
which were culled and processed in parallel with the Apcflox/flox mice to 
determine alterations due to Apc knock out. 
 
2.6.3: 5-bromo-2’-deoxyuridine (BrdU) staining 
 
BrdU is a synthetic thymidine analog which is incorporated into newly synthesised 
DNA allowing measurement of cellular proliferation. BrdU injection and staining 
was completed at the Beatson institute in the ApcMin/+ ageing and Apcflox/flox mouse 
cohorts. BrdU is administered to live mice by intraperitoneal injection 2 hours prior 
to cull then visualised by immunohistochemistry using an anti-BrdU antibody.  
 
2.7: Data analysis and statistics 
 
2.7.1: Quantification of immunofluorescence 
 
Using Image J, the mean grey value was determined from the FITC images. The 
number of cells per image were manually counted from the corresponding DAPI 
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image. Differences in the mean grey value per cell were then used to evaluate 
expression differences.   
 
2.7.2: Quantification of immunohistochemistry  
 
For the adenoma grading, images of all adenomas in a mouse cohort were captured 
with a 10x objective, re-numbered and randomised to minimise unconscious bias. 
Staining intensity was graded as either negative, light, moderate or dark and 
assigned number zero to three respectively. The percentage of adenoma cells with 
that staining intensity was determined. The total score was a sum of the percentage 
of cells multiplied by the grading of intensity. For example, an adenoma with 50% 
moderately stained cells (50 x 2), 30% lightly stained (30 x 1) and 20% negative 
staining (20 x 0) would have a score of 130. Once all adenomas had been assigned a 
score, adenomas were grouped back into their original treatment groups. This 
quantification method was established after consultation with Professor Mark 
Arends, an experienced pathologist. Where possible statistics for 
immunohistochemistry grading is based on the mean score per mouse. However, 
due to low adenoma numbers in the 4week treatment cohort, statistics are based on 




All statistics and graphs were produced using Microsoft excel software. All 
graphical error bars represent the standard error value of the sample set. Data 
distribution was evaluated on histogram to establish normality of data. Statistical 





Chapter 3: The effect of aspirin on cell migration, 





Cancer cell movement is closely associated with the epithelial-mesenchymal 
transition (EMT) with EMT induced cancer cell migration critical in the 
establishment of distant metastasis (Chambers et al., 2002). Therefore, cancer cells 
undergoing EMT are a therapeutic target in the treatment of cancer and prevention 
of metastasis. CRC cells can move as groups of cells or individuals as demonstrated 
by collective cell migration and single cell migration respectively (Brabletz et al., 
2001; Nabeshima et al., 1999). Collective migration as an epithelial sheet is 
developmentally common and is illustrated by the migrations of the lateral line 
primordium in zebrafish (Arboleda-Estudillo et al., 2010). In collective cell 
migration, neighbouring cells maintain the cell-cell junctions and high E-cadherin 
expression which has been observed in human squamous cell carcinomas (Wicki et 
al., 2006). Cell-cell contacts, especially the adherens junctions, are important to 
maintain cohesion to the leader cells (Mayor and Etienne-Manneville, 2016). Single 
cell migration is a result of induction of EMT with the subsequent loss of cell-cell 
junctions and acquirement of a more motile phenotype which is coordinated by the 
EMT transcription factors (Nieto, 2011). There are similarities between single cell 
and collective movement with front to rear polarity across the cells and the GTPases 
facilitating movement (Mayor and Etienne-Manneville, 2016). 
The mechanisms and signalling in cell invasion is similar to cell migration with both 
collective cell invasion and single cell invasion observed in colorectal cancer 
(Brabletz et al., 2001; Nabeshima et al., 1999). In collective cell invasion, the leader 
cell, also known as a tip cell, exhibits a mesenchymal phenotype with the following 
cells remaining epithelial and maintaining cell-cell contacts (van Zijl et al., 2011). 
The loss of E-cadherin and expression of N-cadherin is directly linked to an 
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increased cellular motility as N-cadherin activated cytoskeletal re-arrangement via 
Rac1 and Cdc42 signalling (Cavallaro and Christofori, 2004). In single cell invasion, 
the cell induces EMT and becomes mesenchymal which facilitates rearrangement of 
the cytoskeleton via the GTPases and expression of extracellular matrix degradation 
components, specifically the matrix metalloproteinases; MMP2 and MMP9 (van Zijl 
et al., 2011). Induction of MMPs expression can be indirectly regulated by the EMT 
transcription factors such as snail, ZEB 1 and twist (Peinado et al., 2007).  
The signalling controlling both migration and invasion is predominately the 
GTPases, RhoA, Rac1 and Cdc42, which control the cytoskeleton re-arrangements 
and are responsible for coordinating cytoskeletal arrangements and subsequent cell 
motility (Yamazaki et al., 2005). The RhoA and Rac1 pathway is of specific interest 
as they are proven as regulate EMT and cellular motility in colorectal and prostate 
cancer  (Chen et al., 2014; Gulhati et al., 2011).  RhoA is predominately responsible 
for stress fibre assembly and cell body contraction (Parri and Chiarugi, 2010).These 
effects are regulated by the Rho-associated kinases (ROCK1 and ROCK2) which 
phosphorylate myosin regulatory light chain 2 (MLC2), regulating cell body 
contraction, and the LIM kinases 1 and 2 (LIMK1/2), regulating stress fibre 
formation (Rath and Olson, 2012). Phosphorylated LIMK1/2 inhibits the 
phosphorylation of cofilin which leads to reduced actin turnover and F-actin 
stabilisation (Wang et al., 2006b). Rac1 can also phosphorylate both MLC2 and 
LIMK1/2 by p21 activated kinase 1 (PAK1) (Parri and Chiarugi, 2010). Rac1 activity 
is essential for lamellipodium extension and regulation of actin polymerization by 
activating the actin related protein 2/3 complex (Arp2/3) (Parri and Chiarugi, 2010) 
(Figure 3.1).  
These common signalling pathways governing cell migration, invasion and motility 
have been linked to EMT induction in both colon and prostate cancer (Chen et al., 
2014; Gulhati et al., 2011). Therefore, I hypothesis that an inhibition of EMT would 
correlate with a reduction in cell migration, invasion and motility.  The focus of this 
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work was to investigate the effect of aspirin treatment on cell migration, invasion, 






Figure 3.1: RhoA and Rac1 motility pathway. Simplified diagrammatic 










3.2: Colorectal cancer cell line characterisation 
 
As part of the preparatory work, it was important to determine which CRC cell lines 
would be the most appropriate to investigate EMT with regards to basal protein 
expression of EMT markers and sensitivity to aspirin. Due to their previous use in 
EMT studies, it was decided to proceed with HCT116 cells as the predominant cell 
line and SW480 cells as a secondary cell line (Gulhati et al., 2011). With the aim of 
using three CRC cell lines for the project, a panel of CRC cell lines were 
characterised to determine which additional cell line would be the most suitable to 
investigate EMT. I examined the basal and aspirin treated expression levels of the 
epithelial marker, E-cadherin, and the mesenchymal markers, snail and claudin-1, in 
Colo205, Caco-2, DLD-1 and LS-174T cell lines using western blotting (Figure 3.2). 
The lack of E-cadherin protein expression in LS-174T cells meant that they were 
excluded as E-cadherin is the hallmark epithelial marker. Caco-2 cells expressed E-
cadherin, snail and low levels of claudin-1 protein but no response to aspirin 
treatment was detected. This lack of response may be due to the different tissue of 
origin as the Caco-2 cell line was derived from a tumour of the small intestine rather 
than a colorectal tumour. Aspirin exposure increased E-cadherin expression in 
Colo205 cells and decreased claudin-1 expression in both Colo205 and DLD-1 cell 
lines. Based on these preliminary results it was decided that Colo205 and DLD-1 


















Figure 3.2: Expression of EMT markers in a panel of colorectal cancer cell 
lines. Expression of E-cadherin, snail and claudin-1 in Colo205, Caco-2, DLD-1 and 
LS-174T cell lines treated with 5mM aspirin for 24 hours. Densitometry results 
normalised to β-actin expression. Aspirin treated results expressed as fold change 
of protein expression compared to untreated control cells. This is representative of 










Growth curves were preformed to determine aspirin sensitivity in the four CRC cell 
lines; Colo205, DLD-1, HCT116 and SW480 cells (Figure 3.3). The inhibitory 
concentration (IC50) was determined over 24, 48 and 72 hours (Table 3.1). HCT116 
and Colo205 cells grow well in both absence and presence of aspirin with IC50 over 
24 hours of 7.43mM and 7.73mM respectively. DLD-1 cells had a similar 24 hour 
IC50 value of 7.42mM but with lower basal levels of proliferation. SW480 cells had 
the lowest basal levels of proliferation and were more sensitive to aspirin with a 24 
hour IC50 of 5.55mM. These IC50 values are high and while cells may survive high 
concentrations of aspirin for short periods it is expected that the viability of the cells 
would be significantly impaired at these concentrations and would eventually lead 
to cell death. Therefore, the use of growth curves is less sensitive compared to 
functional assays to determine viable cells or apoptosis rates after aspirin treatment. 
The IC50 values decrease in all CRC cell lines as the duration of treatment increases. 
I used the SW480 cells in several experiments as they expressed a number of 
mesenchymal markers uncommonly detected in the more epithelial CRC cell lines. 
Along with HCT116 and SW480 cells, it was decided the third cell line would be 


















Figure 3.3: Growth curves and IC50 of colorectal cancer cell lines. Growth 
curves for HCT116 (A), SW480 (B), Colo205 (C) and DLD-1 (D) cell lines in normal 
growth media with 10% serum over 72 hours. Counts are the mean of two 




Cell line 24hour IC50 (mM) 48hour IC50 (mM) 72hour IC50 (mM) 
HCT116 7.43 3.96 2.93 
SW480 5.55 2.57 1.87 
Colo205 7.73 5.66 3.82 
DLD-1 7.42 5.84 3.27 
 
Table 3.1: Inhibitory concentration (IC50) values of CRC cells. The IC50 values 
for CRC cell lines were calculated from growth curves after determining the 
equation (y = ax + b) of the line. As a number of the values are higher than the 
















3.3: Aspirin inhibits CRC cell migration 
 
Aspirin’s effect on cellular migration was assessed by wound healing assays. 
Initially, these assays were performed by both the scratch and insert method to 
investigate any effects cell destruction, caused by the scratch, had on wound closure 
results. There were only negligible differences in wound closure detected between 
these methods in our cell lines, so all future experiments were completed as scratch 
assays as these were more reproducible. Aspirin decreased the percentage wound 
closure in HCT116, Colo205 and SW480 cells at both low and high dose aspirin, 
0.5mM and 3mM (Figure 3.4-3.6). The low proliferation rate in SW480 cells was 
reflected in the wound closure assays with a low percentage of closure over 48 
hours in untreated cells. Despite these low migration rates, aspirin still decreased 
the percentage wound closure in SW480 cells. These results highlighted a concern 
that proliferation rates may confound the migration results. To assess this, these 
assays were repeated in low serum media, 0.5%, where proliferation should be 
inhibited and therefore less of a factor. The results in low serum wound healing 
assays were consistent with those in the normal growth media giving confidence 


















Figure 3.4: Aspirin inhibits cellular migration in HCT116 cells. Brightfield 
images of scratch assays at 0 and 48 hours in media containing 0.5% serum (A) and 
10% serum (C). Corresponding graphs of percentage wound closure at 24 and 48 
hours in media containing 0.5% serum (B) and 10% serum (D). All images taken 
with 10x objective. Combined data from three independent experiments each 
containing three technical replicates. Error bars represent standard error. P-value 







Figure 3.5: Aspirin inhibits cellular migration in Colo205 cells. Brightfield 
images of scratch assays at 0 and 48 hours in media containing 0.5% serum (A) and 
10% serum (C). Corresponding graphs of percentage wound closure at 24 and 48 
hours in media containing 0.5% serum (B) and 10% serum (D). All images taken 
with 10x objective. Combined data from three independent experiments each 
containing three technical replicates. Error bars represent standard error. P-value 








Figure 3.6: Aspirin inhibits cellular migration in SW480 cells. Brightfield images 
of scratch assays at 0 and 48 hours in media containing 0.5% serum (A) and 10% 
serum (C). Corresponding graphs of percentage wound closure at 48 hours in media 
containing 0.5% serum (B) and 10% serum (D). All images taken with 10x objective. 
Combined data from three independent experiments each containing three technical 
replicates. Error bars represent standard error. P-value determined by students 





3.4: Aspirin inhibits CRC cell invasion 
 
To model cellular invasion in vitro I have used both matrigel and collagen based 
assays, namely the inverse invasion assay and the organotypic invasion assay 
respectively. The inverse invasion assay is commonly used to model cell invasion in 
vitro and allows immunofluorescence staining of cells during invasion. HCT116 and 
SW480 cells were allowed to invade matrigel for 5 days (Figure 3.7). However, 
neither cell line exhibited any sign of invasion. These assays were repeated in the 
presence of growth factors and high serum chemo-attractant but no CRC cell line 
ever invaded. Therefore, the alternative collagen based assay, organotypic invasion 




Figure 3.7: Inverse invasion assays with HCT116 and SW480 cell lines. Z-
sections through matrigel at 15μm intervals using confocal microscope with 4x 
objective. Live cells stained with Calcein dye and visualised as green using FITC 




HCT116 and Colo205 cells invaded the collagen gels without any external stimuli. 
Aspirin inhibits both the percentage of cells invading and the distance of invasion in 
HCT116 and Colo205 cells (Figures 3.8, 3.9). The organotypic invasion assays were 
performed under normal serum conditions, 10% serum, as the invasion 
quantification method corrected for any differences in proliferation rates. An 
additional benefit of the organotypic assays is the opportunity to complete 
immunohistochemistry staining on the paraffin embedded gels. HCT116 gels were 
stained with E-cadherin and vimentin antibodies to determine the role of EMT in 
cellular invasion (Figure 3.10). The invading cells had decreased E-cadherin which 
reflects the lack of cell-cell contacts. A proportion of the invading cells expressed 
vimentin which was absent in all non-invading cells. This suggests that some 
invading cells have become more mesenchymal although the fact that vimentin was 
only present in a subset of the invading cells illustrates its expression is not required 
for invasion. In addition to EMT markers, I completed immunohistochemistry and 
immunoblotting for the matrix-metalloproteinases, MMP2 and MMP9, which are 
involved in degrading the extracellular matrix to facilitate cellular invasion. 
Unfortunately, I was unable to detect any expression of either MMP2 or MMP9 in 


















Figure 3.8: Aspirin inhibits cellular invasion in HCT116 cells. Brightfield images 
of organotypic gels stained with haematoxylin and eosin (A). Corresponding graphs 
for percentage of invasion (B) and distance of invasion (C). All images captured by 
Nanozoomer slide scanner with 10x objective. Combined data from three 
independent experiments each containing two technical replicates. Error bars 











Figure 3.9: Aspirin inhibits cellular invasion in Colo205 cells. Brightfield images 
of organotypic gels stained with haematoxylin and eosin (A). Corresponding graphs 
for percentage of invasion (B) and distance of invasion (C). All images captured by 
Nanozoomer slide scanner with 10x objective. Combined data from three 
independent experiments each containing two technical replicates. Error bars 











Figure 3.10: Expression differences in invading and non-invading cells. 
Immunohistochemistry staining for E-cadherin and Vimentin in non-treated HCT116 
cells in an organotypic invasion assay. All images captured by Nanozoomer slide 















3.5: Aspirin inhibits single cell motility 
 
Single cell motility assays, performed by time-lapse imaging of cell movement, were 
completed on HCT116 and Colo205 cells under low serum, 0.5%, and normal serum, 
10%, conditions (Figure 3.11, 3.12). The distance cells travelled was manually 
tracked with both the accumulated and euclidean distance calculated. Accumulated 
distance is the total distance travelled by the cell over a 24hour period. Eucluidean 
distance is the direct distance from the cell’s start position at 0 hours to its final 
position at 24 hours. Directionality of movement can then be determined by 
comparing the accumulated and eucluidean distances. In HCT116 and Colo205 cells, 
cells travelled randomly with no directional bias. This was consistent across all non-
treated and treated cells. Aspirin decreased both the accumulated and euclidean 
distance cells covered in 24 hours in HCT116 and Colo205 cells under normal serum 
conditions. However, under low serum conditions aspirin only inhibited the cellular 
motility of Colo205 cells with no change in HCT116 cell motility detected. This may 
be explained by an overall inhibition of cellular motility due to serum starvation. As 
illustrated by a decrease in cellular motility in untreated HCT116 cells in low serum 
compared to those in normal serum conditions. Therefore, serum starvation is 
reducing basal motility, in HCT116 cells, to a low level which means further 













Figure 3.11: Aspirin inhibits cell motility in HCT116 cells. Representative 
chemotaxis plots of single cell movement illustrating movement of 10 cells (A). 
Graphs of accumulated and euclidean distance in HCT116 cells in 10% serum (B) 
and 0.5% serum (C). Combined data for 80 cells per treatment from three 
independent experiments. Error bars represent standard error. P-value determined 





Figure 3.12: Aspirin inhibits cell motility in Colo205 cells. Representative 
chemotaxis plots of single cell movement illustrating movement of 10 cells (A). 
Graphs of accumulated and euclidean distance in Colo205 cells in 10% serum (B) 
and 0.5% serum (C). Combined data of 80 cells per treatment from three 
independent experiments. Error bars represent standard error. P-value determined 
by students unpaired t-test. * p-value < 0.05 
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3.6: Aspirin inhibits the ROCK1 motility pathway in CRC cell lines 
 
The reduction in cell motility detected after exposure to aspirin indicated aspirin 
may be effecting the motility pathways, such as the RhoA and Rac1 signalling 
pathways. I further investigated the effect of aspirin on these pathways using 
western blotting and immunofluorescence. The effect of aspirin on the RhoA and 
Rac1 signalling pathways was investigated by evaluating the expression of the 
downstream proteins. There were a few proteins which were undetectable at 
protein level in our HCT116, Colo205 and SW480 cells. These included p-MLC2, p-
LIMK2 and LIMK2. Therefore, the motility pathway markers which were evaluated 
were ROCK1, p-cofilin, total cofilin and F-actin.  
Aspirin exposure reduces ROCK1 expression in HCT116 and Colo205 cells after 24 
hours with no ROCK1 protein detectable in our batch of SW480 cells (Figure 3.13A). 
Aspirin reduces phosphorylated cofilin expression in HCT116, Colo205 and SW480 
cells after 24 hours (Figure 3.13B). In humans, both the cardiovascular benefits and 
cancer protection are observed with regular treatment with low dose aspirin. 
Therefore, along with the short treatments, 24 hours, I also performed daily dosing 
experiments where cells were exposed to 0.5mM aspirin daily for 96 hours. In 
HCT116 cells, daily dosing with low dose aspirin decreases phosphorylated cofilin 
(Figure 3.14). The effect of daily dosing with low dose aspirin on phosphorylated 
cofilin in Colo205 cells is inconsistent which may be due to alterations to cellular 
density as maintaining a consistent cell density over a 96hour period is challenging 
and variations will occur. Based on these results, it can be concluded that aspirin is 













Figure 3.13: Aspirin decreases ROCK1 and p-cofilin expression in CRC cell 
lines. Western blots for ROCK1 expression in HCT116 and Colo205 cells (A). 
Western blots for phosphorylated cofilin and total cofilin expression in HCT116, 
Colo205 and SW480 cells (B). Densitometry figures are presented as fold change of 
untreated control as normalised to loading control. Representative images of three 
independent experiments illustrating aspirin’s reduction in ROCK1 and 











Figure 3.14: Daily dosing with aspirin decreases p-cofilin expression in CRC 
cell lines. Western blots of phosphorylated cofilin and total cofilin in HCT116 (A) 
and Colo205 (B) cells. Daily treatments with 0.5mM aspirin for 96 hours. 
Densitometry figures are presented as fold change of untreated control as 








3.7: Aspirin decreases F-actin expression 
 
To establish the link between the observed decrease in cell motility and 
ROCK1/cofilin inhibition I investigated the effect of aspirin on the actin filaments. 
Filamentous actin (F-actin) is composed of monomeric globular actin molecules 
termed G-actin which are constantly associating and disassociating so fibres are 
continually growing and shrinking (Van Troys et al., 2008). This is termed actin 
treadmilling and produces a propulsive force in the lamellipodia and filopodia of 
cells (Van Troys et al., 2008). The cofilin proteins are responsible for maintain this 
actin treadmilling and inactivation of cofilin, by LIMK mediated phosphorylation, 
results in an inhibition of F-actin binding and F-actin severing causing F-actin 
stabilization (Van Troys et al., 2008). Therefore, cofilin inhibition should result in a 
reduction in F-actin expression and turnover. The expression and morphology of F-
actin was investigated by immunofluorescence. Low dose aspirin, 0.5mM, decreased 
the overall expression of F-actin in HCT116 and Colo205 cells after 24 hours (Figure 
3.15, 3.16). The alteration in expression was determined by calculation of the mean 
grey area per cell from 10x FITC images. There were no detectable differences in F-
actin morphology in either the HCT116 or Colo205 cells with both cell lines 
expressing predominately cortical F-actin. This was not unexpected as it has already 
been established that the CRC cell lines have low motility thus a low actin turnover 













Figure 3.15: Aspirin decreases the overall F-actin expression in HCT116 cells. 
Immunofluorescence staining of F-actin in HCT116 cells imaged with 10x (A) and 
40x (B) objective. Quantification of mean grey level per cell from thirty 10x images 
(C). Combined data from two independent experiments. Error bars represent 





Figure 3.16: Aspirin decreases the overall F-actin expression in Colo205 cells. 
Immunofluorescence staining of F-actin in Colo205 cells imaged with 10x (A) and 
40x (B) objective. Quantification of mean grey level per cell from thirty 10x images 
(C). Combined data from two independent experiments. Error bars represent 
standard error. P-values determined by students unpaired t-test. * p-value < 0.05.  
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The low basal levels of cellular motility and actin turnover restricts the investigation 
of aspirin-mediated changes in F-actin morphology. Stimulation of cells with 
growth factors have been demonstrated to increase motility, F-actin expression and 
stress fibre formation (Wu et al., 2014). Therefore, to further investigate the effects of 
aspirin on the F-actin morphology I attempted to induce stress fibre formation in 
HCT116 and Colo205 cells by exposure to growth factors. HCT116 cells were treated 
with platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and 
transforming growth factor-β (TGF-β) (Figure 3.17).  An increase in F-actin 
expression was observed after treatment with TGF-β only. Colo205 cells were 
treated with PDGF and TGF-β with both increasing the overall expression of F-actin 
(Figure 3.18). While there was an increase in the overall F-actin expression with 
some growth factors, there was no difference in stress fibre formation. Aspirin 
treatment after growth factor stimulation did not reduce F-actin expression 


















Figure 3.17: F-actin expression in stimulated HCT116 cells. 
Immunofluorescence staining for F-actin in HCT116 cells imaged with 10x (A) and 
40x (B) objective. Quantification of mean grey level per cell from fifteen 10x images 
(C). Data from one experiment. Error bars represent standard error. P-values 





Figure 3.18: F-actin expression in stimulated Colo205 cells. 
Immunofluorescence staining for F-actin in Colo205 cells imaged with 10x (A) and 
40x (B) objective. Quantification of mean grey level per cell from fifteen 10x images 
(C). Data from one experiment. Error bars represent standard error. P-values 
determined by students unpaired t-test. * p-value < 0.05 
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3.8: Chapter discussion 
 
Aspirin treatment consistently inhibited the migration of three CRC cell lines, 
HCT116, Colo205 and SW480, using wound healing assays. Wound healing assays 
are the primary method used to investigate cell migration in vitro and its use in 
CRC cell line migration has been previously documented (Gulhati et al., 2011). It has 
been reported that aspirin reduces the migratory capacity of the non-small cell lung 
carcinoma cell line, A549, in a dose dependent manner by downregulating slug and 
thus increasing E-cadherin expression (Khan et al., 2016).  This is the first 
demonstration of direct aspirin-mediated inhibition on CRC cell line migration with 
low concentrations of aspirin. A strength of this research is the replication in three 
cell lines. Although a potential weakness would be the lack of further research into 
the effect on proliferation versus migration.  
The inverse invasion assay is an elegant assay which allows the investigation of 
invasion and staining of the invading cells by immunofluorescence (Scott et al., 
2010).  Unfortunately, no CRC cell invaded the inverse invasion assay despite the 
presence of a strong chemoattractant. This was not unexpected as the primary cell 
lines used for inverse invasion assays are invasive breast cancer cell lines such as the 
MDA-MB-231 cell line (Scott et al., 2010). Therefore, it was decided to use the 
organotypic invasion assays as the assays should facilitate invasion due to a strong 
chemoattractant and would allow immunohistochemistry of invading cells. Aspirin 
treatment reduced the percentage and distance of cellular invasion in HCT116 and 
Colo205 cells. Aspirin has been demonstrated to reduce platelet-induced invasion in 
an ovarian cancer cell line, SK-OV-3 (Cooke et al., 2015). Incubation of SK-OV-3 cells 
with platelets increased their invasive capacity, investigated using matrigel coated 
invasion chambers, which is reduced when the platelets are pre-treated with low 
concentrations of aspirin, 20μM (Cooke et al., 2015). Aspirin has been reported to 
reduce invasion of the SW480 CRC cell line in a matrigel based invasion assay but 
this was completed with high concentrations, between 2.5mM and 10mM, of aspirin 
(Yu et al., 2002). This project is the first description of direct aspirin-mediated 
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reduction in the invasive capacity of CRC cell lines with low-dose aspirin. A 
strength of this work is the use of low aspirin concentrations, 0.1mM, which is 
physiologically achievable. 
The use of organotypic invasion assays allowed immunohistochemistry staining for 
markers of invasion and EMT. It was observed that invading cells had less E-
cadherin expression and some cells exhibited vimentin expression which was 
expected due to loss of cell-cell contacts. The fact that only a few cells expressed 
vimentin indicates that not all cells must undergo full EMT in order to invade as 
previously described with collective cell invasion (Mayor and Etienne-Manneville, 
2016). 
Aspirin has been reported to reduce cell migration in numerous cancers but the 
effects of aspirin on single cell motility have not been investigated (Maity et al., 
2015). Here we show that aspirin reduces cellular motility of HCT116 and Colo205 
cells as observed using single cell motility assays. The use of single cell motility 
assays to investigate cellular movement with time-lapse imaging has been 
previously described and can be modified by the addition of a cell-derived matrix as 
reported in the literature (Scott et al., 2010). This assay varies from the wound 
healing migration assays as the cells are seeded sub-confluent to avoid interference 
by neighbouring cells and inhibition of cell movement due to high cell density. The 
primary weakness of this work was the lack of basal motility as aspirin-mediated 
differences may have been more striking if the basal motility was higher. 
The RhoA and Rac1 GTPases are commonly implicated in cancer cell motility and 
EMT regulation (Chen et al., 2014; Gulhati et al., 2011). It has been reported that 
aspirin treatment can induce Rac1 signalling in HT29 cells although there is no 
evidence of this occurring in our experiments (Hardwick et al., 2004). Aspirin has 
been demonstrated to reduce RhoA signalling in vascular smooth muscle cells by 
both inhibiting synthesis and increased protein degradation (Li et al., 2012a). 
Directly measuring the activity of RhoA and Rac1 can be achieved using glutathione 
S- transferase (GST)-tagged Rho-binding domain of Rhotekin and GST-tagged p21 
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binding domain of PAK1 pull down assays respectively as previously demonstrated 
(Gulhati et al., 2011). However, this can be technically challenging and I was 
advised early in the project to concentrate on the downstream effectors of the RhoA 
and Rac1 signalling pathways. Aspirin reduces expression of three of these effectors; 
ROCK1, phospho-cofilin and F-actin. The lack of expression of other motility 
proteins restricted the investigation with no LIMK, phospho-LIMK or phospho-
MLC2 protein detected in the CRC cell lines. There are no published reports 
detailing the protein expression of LIMK or p-LIMK in these CRC cell lines but 
phospho-MLC2 protein has been detected in HCT116 cells (Sun et al., 2013). The 
lack of detection in our cell lines may reflect low expression in our batch of CRC cell 
lines or poor sensitivity of the phospho-MLC2 antibody.  
F-actin expression has previously been detailed in HCT116 cells, with 
predominantly cortical expression which is consistent with our observations (Sun et 
al., 2013). Aspirin reduced the overall expression of F-actin in HCT116 and Colo205 
cells with no detectable changes in morphology. The induction of EMT by TGF-β 
stimulation in NMuMG cells increased overall F-actin expression and increased the 
number of F-actin stress fibre bundles (Wu et al., 2014). However, no alterations in 
F-actin morphology were detected in our cell lines with growth factor stimulation 
which may suggest insufficient EMT induction. The lack of dynamic F-actin 
turnover limited the investigation as only alterations to overall F-actin expression 
could be quantified. A weakness of this work is the lack of dependency which could 
have been investigated with the use of ROCK1 inhibitor to determine if the 
reduction in cofilin, F-actin and subsequent cellular motility were dependent on 
aspirin-mediated ROCK1 inhibition. A strength of this work is the use of two CRC 
cell lines, HCT116 and Colo205, demonstrating a consistent decrease in three key 
markers of cellular motility. This is the first description of aspirin-mediated 
reduction in ROCK1, phosphorylated cofilin and F-actin expression in any cancer 
cell line. I have demonstrated that aspirin reduces CRC cell migration, invasion and 
single cell motility whilst reducing protein expression of several members of the 
RhoA/Rac1 signalling pathways.  
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Chapter 4: The effect of aspirin on the epithelial-





The epithelial-mesenchymal transition (EMT) is characterised by the loss of 
epithelial characteristics, such as apical-basal polarity and cell-cell junctions, and the 
gain of mesenchymal characteristics, such as increased motility and expression of 
extracellular matrix degradation proteins (Kalluri and Weinberg, 2009). These 
alterations facilitate cell migration, invasion and subsequent metastasis of epithelial 
tumours (Chambers et al., 2002). EMT can be subdivided into three types; 
developmental EMT, EMT in wound healing and fibrosis and EMT in cancer 
progression. An important observation is the occurrence of the reversed process; 
mesenchymal-epithelial transition (MET) (Kalluri and Weinberg, 2009). Migratory 
tumour cells will revert back to an epithelial population after establishing a 
secondary site by undergoing MET so the metastases are composed of epithelial 
cells (Thiery, 2002).  
The markers of EMT and the regulatory signalling pathways remain consistent 
between the three different subtypes of EMT. The primary epithelial markers are 
members of the adherens and tight junctions, specifically E-cadherin, α-catenin and 
zona-occludens 1. E-cadherin is a component of the adherens junctions which links 
neighbouring cells to the actin cytoskeleton (Baum and Georgiou, 2011). E-cadherin 
is bound to the actin filaments by α-catenin and β-catenin with p120-catenin 
involved in stabilisation of the adherens junctions (Dufour et al., 2013). In addition 
to roles at the adherens junctions, β-catenin is an effector of the Wnt signalling 
pathway and upon Wnt activation is translocated to the nucleus to initiate 
transcription of Wnt target genes (Niehrs, 2012). The tight junctions, composed of 
claudins, occludins and zona-occludins, are another source of EMT markers with 
zona-occludin 1 (ZO-1) and claudin-1 used as an epithelial and mesenchymal 
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marker respectively. ZO-1 is predominately used as an epithelial marker but it has 
been observed that ZO-1 can shuttle to the nucleus during cancer progression and 
influence EMT progression (Polette et al., 2007). Claudin-1 expression is 
upregulated in colon cancer and has been associated with Wnt activation and β-
catenin/TCF signalling (Dhawan et al., 2005).  
In addition to claudin-1, other mesenchymal markers include vimentin and the EMT 
transcription factors. Vimentin is an intermediate filament which is important to 
maintain structural integrity of mesenchymal cells and is required for cellular 
motility (Ivaska et al., 2007). Several transcription factors are increased during EMT 
progression including snail, slug, twist and ZEB1 (Moreno-Bueno et al., 2008). These 
transcription factors have a common function which is to repress E-cadherin 
transcription by binding to the gene’s promoter (Naber et al., 2013). Overexpression 
of these transcription factors induces EMT by repression of E-cadherin and 
activation of mesenchymal marker transcription. These transcription factors are the 
key regulators of EMT induction and can be activated by numerous signalling 
pathways including EGF, FGF, TGF-β, PDGF, Wnt, Notch, Akt, Ras, NF-κB, HIF-1α 
and mTOR (Tania et al., 2014). 
The induction of EMT has been demonstrated in CRC by analysis of gene expression 
and histology in CRC tumours with EMT correlating with poor prognosis (Loboda 
et al., 2011). The presence of EMT in CRC correlates with increased invasion and 
metastasis and ultimately a poor prognosis (Galván et al., 2015). This highlights the 
need to understand the mechanisms of EMT in CRC and the therapeutic value of an 
EMT inhibitor. The focus of the project was to determine the effects of aspirin on the 







4.2: Cellular density influences EMT marker expression 
 
It is important to consider cellular density when investigating EMT in cell lines as 
this can confound results. An increase in cell-to-cell contacts will promote an 
epithelial phenotype and suppress the mesenchymal marker expression (Conacci-
Sorrell et al., 2003). To control for this variable in future experiments, density 
experiments were performed in HCT116, Colo205 and SW480 cells (Figure 4.1). 
Cells were seeded at varying cellular densities and treated with either 0.5mM or 
5mM aspirin for 24 hours. In HCT116 cells aspirin increased E-cadherin expression 
at low and moderate cell density but this was reversed in the highest seeding 
densities. A similar effect was observed in Colo205 cells with the greatest aspirin-
mediated increase in E-cadherin expression occurring in cells with the lowest 
seeding density. Expression of an alternative epithelial marker, α-catenin, mirrored 
the expression prolife of E-cadherin in Colo205 cells. Mesenchymal markers, 
claudin-1 and α-smooth muscle actin (α-SMA), were decreased at all densities in 
HCT116 and Colo205 cells respectively. Aspirin exposure decreased both E-cadherin 
and vimentin protein expression in SW480 cells at all cell densities which was 
unexpected and may represent an overall increase in cell death. In addition, the β-
actin protein expression in SW480 cells was inconsistent which may be due to 
technical error in loading protein samples or inefficient whole cell lysis. The 
medium cell densities provided the most consistent and reliable results so a density 











Figure 4.1: Cellular density effects EMT marker expression. Expression of EMT 
markers in untreated and aspirin treated cells seeded at varying densities in 
HCT116 (A), Colo205 (B) and SW480 (C) cell lines. Representative images from 
two independent experiments. Densitometry figures presented as fold change of 
untreated controls and normalised to loading control. 
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4.3: Aspirin increases epithelial marker and decreases 
mesenchymal marker protein expression in CRC cell lines 
 
There are a number of epithelial markers which can be used to investigate EMT 
progression such as zona-occludens 1 (ZO-1) and α-catenin but ultimately the 
hallmark of EMT is the loss of E-cadherin expression. Epithelial marker expression 
can be measured in CRC cell lines at the protein level by western blotting and 
immunofluorescence. Aspirin increases E-cadherin and α-catenin expression in 
HCT116 cells after 16 and 24 hour treatments with 3mM and 5mM (Figure 4.2). Low 
dose aspirin, 0.5mM, increases E-cadherin and α-catenin expression in HCT116 cells 
after 16 hours but there is a slight decrease in both epithelial markers after 24 hours. 
An increase in E-cadherin and ZO-1 protein expression was detected by 
immunofluorescence in HCT116 cells exposed to 0.5mM and 1mM aspirin for 24 
hours (Figure 4.3). Aspirin increased E-cadherin and α-catenin protein expression in 
Colo205 cells after 24hour treatment with 3mM and 5mM (Figure 4.4). There was a 
decrease in both epithelial markers detected in all aspirin concentrations, 0.5mM, 
3mM and 5mM, after 16 hour treatments. Taken together these results indicate that 
aspirin is promoting an epithelial phenotype illustrated by an increase in three 
different epithelial markers, E-cadherin, α-catenin and ZO-1. However, there are cell 
line differences with the strongest response to aspirin after 16 hours in HCT116 but 















Figure 4.2: Aspirin increases epithelial marker expression in HCT116 cells on 
western blot. Western blots for E-cadherin (A) and α-catenin (B) expression. 
Densitometry figures presented as fold change of untreated control and normalised 
to loading control. Representative images of five independent experiments 











Figure 4.3: Aspirin increases epithelial marker expression in HCT116 cells on 
immunofluorescence. Immunofluorescence staining for E-cadherin (A) and ZO-1 
(B). Quantification of mean grey area per cell from thirty 10x images for E-cadherin 
(C) and ZO-1 (D). Combined data from two independent experiments. Error bars 









Figure 4.4: Aspirin increases epithelial marker expression in Colo205 cells. 
Western blots for E-cadherin and α-catenin expression. Densitometry figures 
presented as fold change of untreated controls and normalised to β-actin 
expression. Representative images of three independent experiments illustrating a 
modest but reproducible increase in E-cadherin and α-catenin expression with 















The predominant mesenchymal markers are the EMT transcription factors, such as 
snail, slug and twist, and cytoskeletal markers, such as vimentin and α-smooth 
muscle actin. In addition, there are junctional proteins which are associated with a 
mesenchymal phenotype including N-cadherin and claudin-1. Investigating the 
effects of aspirin on the mesenchymal markers in HCT116 and Colo205 cells proved 
challenging due to low basal expression. Vimentin and N-cadherin protein was 
undetectable in our HCT116 and Colo205 cell lines. Claudin-1 protein expression 
was detectable in whole cell lysates but the small transcription factor, snail, required 
concentrated nuclear extractions. Fractionation of the cells into cytoplasmic and 
nuclear lysates allowed the detection of Snail protein. The purity of the fractions 
was confirmed by the presence of GAPDH in the cytoplasmic fraction and lamin-B 
in the nuclear fraction. Snail is purely nuclear and is decreased with 0.5mM aspirin 
in HCT116 and Colo205 cells after 16 hour and 24 hours respectively (Figure 4.5A). 
Claudin-1 protein was observed in whole cell lysates with expression reduced 16 
and 24 hour treatments with 5mM aspirin in HCT116 cells (Figure 4.5B). A 
reduction in cludin-1 protein expression was observed in Colo205 cells treated with 



















Figure 4.5: Aspirin decreases mesenchymal marker expression in CRC cell 
lines. Western blots for Snail (A) and claudin-1 (B) expression in HCT116 and 
Colo205 cells. GAPDH and Lamin-B expression to assess purity of fractions. 
Densitometry figures presented as fold change of untreated controls and normalised 
to loading control. Snail expression data is representative of three independent 






As mentioned previously, the clinical effects of aspirin are apparent following 
prolonged treatment with a low concentration of aspirin. To replicate this in vitro 
cells were exposed to 0.5mM aspirin every 24 hours for 96 hours. This experiment 
was susceptible to variations in cell density and inducing cell stress by passaging 
the cells during experimentation. Despite these confounding factors, aspirin 
exposure exhibited similar effects to the short duration experiments with an 
increase in E-cadherin and decrease in claudin-1 protein expression in HCT116 cells 
(Figure 4.6A). The daily low dose aspirin exposure consistently increased E-
cadherin protein expression in Colo205 cells but there was only a small reduction in 
claudin-1 protein expression detected (Figure 4.6B).  This may indicate a higher 
concentration of aspirin is required to alter claudin-1 expression in Colo205 cells.  
The growth curve and IC50 data from chapter 3.2 demonstrates that the SW480 cells 
are more sensitive to aspirin compared to the HCT116 or Colo205 cell lines. This can 
be observed on a western blot with 5mM aspirin decreasing both epithelial marker, 
mesenchymal marker and loading control expression which may indicate lack of 
viable cells and increased cell death. Exposure to 5mM aspirin decreased E-cadherin 
and vimentin protein expression after 16 and 24 hours (Figure 4.7). A reduction in β-
actin expression is observed with 5mM aspirin treatment at both 16 and 24 hours 
which may be a technical error or demonstrate the reduction in viable cells in the 
5mM aspirin treated SW480 cell population. Exposure to 0.5mM of aspirin increased 
both E-cadherin and vimentin expression at 16 hours and reduced both after 24 
hours. The β-actin expression is more consistent than the 5mM treated samples but 
there is a defect in the 16hour aspirin treated sample which may have confounded 
the densitometry results and would explain the increased vimentin expression after 
16 hours. Whilst the SW480 cells express mesenchymal markers, such as vimentin, 
which is a benefit in the investigation of EMT, their sensitivity to aspirin provides 








Figure 4.6: Daily dosing with low-dose aspirin increases E-cadherin and 
decreases claudin-1 expression in CRC cell lines. Western blots for E-cadherin 
and Claudin-1 expression in HCT116 (A) and Colo205 (B) cells. Densitometry 
figures presented as fold change of untreated controls and normalised to β-actin. 














Figure 4.7: SW480 EMT marker expression is dependent on aspirin 
concentration. Western blots of E-cadherin and Vimentin expression in SW480 
cells treated with either 0.5mM or 5mM aspirin. Densitometry figures presented as 
fold change of untreated controls and normalised to β-actin. Representative images 















4.4: Aspirin increases E-cadherin and decreases Snail RNA 
expression in CRC cell lines 
 
The increase in E-cadherin can be explained by increased synthesis due to increased 
transcription or increased protein stabilisation due to reduced protein degradation. 
The reduced protein expression of the EMT transcription factor, snail, suggests that 
the E-cadherin expression changes are a consequence of reduced snail mediated 
transcription. To investigate this hypothesis further I evaluated the expression of the 
E-cadherin gene, CDH1, from HCT116 and Colo205 RNA extracts. Exposure to 
3mM aspirin for either 24 or 48 hours increased CDH1 expression in HCT116 cells 
(Figure 4.8A). However, low dose aspirin, 0.5mM, reduces CDH1 expression in 
HCT116 cells. This particular pattern of results is only observed with HCT116 cells 
and mirrors some of the protein expression results in which 0.5mM of aspirin for 24 
hours decreased E-cadherin protein expression (Figure 4.2A). These results suggest 
the effects of 0.5mM aspirin on HCT116 cells are most apparent at earlier time-
points such as 16 hours. Exposure to 0.5mM and 3mM aspirin increased CDH1 
expression in Colo205 cells after 24 and 48 hours (Figure 4.8B). The is a cumulative 
effect of aspirin on CDH1 expression in the low dose daily treatment experiments. 
In HCT116 cells, daily exposure to 0.5mM aspirin consistently increases CDH1 
expression at every time-point, except 24 hours, with a 6-fold increase after 96 hours 
(Figure 4.8C). In Colo205 cells, daily exposure to 0.5mM aspirin increases CDH1 
expression at every time-point with a 5-fold increase after 96 hours (Figure 4.8D). 
Primers for the EMT transcription factors, snail, slug and twist, were obtained and 
expression quantified in HCT116 and Colo205 RNA extracts. Unfortunately, I was 
unable to detect any slug or twist expression in HCT116 or Colo205 cell lines. 
Considering the lack of slug or twist protein expression in concentrated nuclear 
extracts from HCT116 and Colo205 cells, I suspect there is minimal expression of 
either EMT transcription factor. Snail expression was detected in HCT116 cells but 
not in the Colo205 cells which was unexpected considering the presence of snail 
protein in Colo205 extractions. A possible explanation would be the presence of a 
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SNP or mutation in the Colo205 cells preventing the binding of the snail primers 
and subsequent detection of snail expression. As with CDH1 expression in HCT116 
cells, snail expression seemed to be dose dependent with 3mM aspirin reducing 
snail at both 24 and 48 hours. However, 0.5mM aspirin increased snail expression 
after 24 hours to mirror the CDH1 reduction. This increase in snail RNA expression 




























Figure 4.8: RNA expression of CDH1 and Snail in CRC cell lines. CDH1, gene 
encoding E-cadherin, RNA expression fold change in dose response experiment 
with 0.5mM and 3mM aspirin in HCT116 (A) and Colo205 (B) cell lines. CDH1 RNA 
expression fold change in daily dosing experiment with 0.5mM aspirin in HCT116 
(C) and Colo205 (D) cell lines. Snail RNA expression in HCT116 cells with 0.5mM 
and 3mM aspirin treatment (E). All RNA expression normalised to GAPDH 
expression. Combined data from three independent experiments. Error bars 




4.5: Induction of EMT in CRC cell lines 
 
The inherent problem with CRC cell lines is their epithelial nature and lack of 
mesenchymal marker expression. This means investigating EMT based on 
alterations to basal epithelial and mesenchymal marker expression is difficult as 
essentially aspirin treatment is causing an epithelial population to become more 
epithelial. To combat this issue, I attempted to induce an EMT phenotype in the 
CRC cell lines by treatment with growth factors. Induction of EMT would then 
allow the completion of both prevention and reversal experiments. Transforming 
growth factor-β (TGF-β) is a commonly used EMT inducer in various cell lines 
(Chen et al., 2015b). HCT116, Colo205 and SW480 cells were treated with either 
5ng/ml or 10ng/ml of TGF-β for 24hours. TGF-β treatment increases E-cadherin and 
decreases claudin-1 protein expression in all CRC cell lines (Figure 4.9). An increase 
in cell proliferation which leads to increased cell density would explain the 
alterations in E-cadherin and claudin-1 expression due to increased cell-cell 
contacts. Clearly, TGF-β is not inducing an EMT phenotype in HCT116, Colo205 or 
SW480 cells after 24hour treatment. The lack of TGF-β induced EMT in HCT116 and 
Colo205 cell lines can be explained by mutations to the TGFBR2 gene. Microsatellite 
instable cell lines, HCT116 and Colo205, have been demonstrated to be 
unresponsive to TGF-β stimulation (Pino et al., 2010). The SW480 cell line is 
microsatellite stable and thus should respond to TGF-β stimulation and this lack of 
response may be due to the duration of treatment with prolonged exposure to TGF-













Figure 4.9: TGF-β treatment in CRC cell lines. Western blots for E-cadherin and 
claudin-1 expression in HCt116, Colo205 and SW480 cell lines. Densitometry 
figures presented as fold change of untreated controls and normalised to β-actin 


















The lack of response to TGF-β induction in CRC cell lines highlighted the need to 
test other growth factors for EMT induction. The loss of E-cadherin expression is the 
hallmark of EMT induction. With this is mind, I screened a number of prospective 
EMT inducers using immunofluorescence to detect changes in E-cadherin protein 
expression. HCT116 and Colo205 cells were treated with either 20ng/ml PDGF, 
50ng/ml EGF or 10ng/ml TGF-β for 48 hours (Figure 4.10). Immunofluorescence 
staining was quantified as mean grey area per cell for each condition. There was no 
change in E-cadherin expression in HCT116 cells with any growth factor. PDGF 
decreased E-cadherin expression in Colo205 cells with EGF and TGF-β having no 
effect.   
As PDGF treatment decreased E-cadherin expression in Colo205 cells, I was 
interested if aspirin treatment would reverse this process. Colo205 cells were treated 
with 20ng/ml PDGF for 48 hours. Aspirin was added to the cells 24 hours post 
PDGF treatment and left for the following 24 hours. There was still a decrease in E-
cadherin expression with 20ng/ml PDGF but no increase in E-cadherin expression 
after addition of 0.5mM and 3mM aspirin (Figure 4.11).  Aspirin treatment may 
need to be prolonged to reverse the effects of PDGF induction or alternatively can 
pre-treat cells with aspirin to prevent the PDGF mediated decrease in E-cadherin. 
Unfortunately, apart from a modest decrease in E-cadherin expression on 
immunofluorescence there were no other indications, such as phenotype changes, to 
suggest PDGF was inducing a robust EMT. Optimising the induction of EMT with 
growth factors to ensure a consistent induction would be time consuming and it 
was decided other areas of the project could benefit more from additional time 









Figure 4.10: Growth factor screening for EMT induction in CRC cell lines. 
Immunofluorescence images of E-cadherin expression after growth factor treatment 
in HCT116 (A) and Colo205 (B) cell lines. Corresponding graphs of 
immunofluorescence quantification of mean grey area per cell from fifteen 10x 
images in HCT116 (C) and Colo205 (D) cell lines. Data from one experiment. Error 
bars represent standard error. P-value determined by students unpaired t-test. * p-





Figure 4.11: PDGF treatment decreases E-cadherin expression in Colo205 
cells. Immunofluorescence images of E-cadherin expression in Colo205 cells with 
PDGF treatment and combination of PDGF and aspirin treatment (A). 
Corresponding graph of immunofluorescence E-cadherin expression quantification 
as mean grey area per cell from fifteen 10x images. Data from one experiment. 
Error bars represent standard error. P-value determined by students unpaired t-test. 
* p-value < 0.05 
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4.6: Chapter Discussion 
 
Aspirin has been demonstrated to inhibit EMT and reduces the migratory capacity 
in lung cancer by reducing slug expression (Khan et al., 2016). In breast cancer, 
aspirin treatment induced the mesenchymal-epithelial transition and inhibited cell 
migration (Maity et al., 2015). Recently, aspirin has been reported to prevent platelet 
induced EMT and migration in CRC cell lines (Guillem-Llobat et al., 2016). This 
research documented that pre-treatment of platelets with aspirin could prevent 
platelet induced EMT but did not investigate the direct effects of aspirin of EMT 
markers in CRC cell lines.  
Aspirin increases protein expression of epithelial markers, specifically E-cadherin 
and α-catenin, and decreases protein expression of mesenchymal markers, 
specifically claudin-1 and snail, in CRC cell lines. There was a lack of mesenchymal 
marker expression in our HCT116 and Colo205 cells. This is not consistent with the 
literature as HCT116 cells have been reported to contain vimentin, N-cadherin and 
twist (Gulhati et al., 2011; Wang et al., 2013a).  I was unable to detect any protein 
expression of these markers in HCT116 cells despite having effective antibodies for 
detection on western blot. A possible explanation for these discrepancies is that the 
batch of HCT116 cells I had obtained was particularly epithelial and thus did not 
express the common mesenchymal markers. The EMT marker RNA expression 
profile of Colo205 cells has been reported but protein expression has not been 
evaluated (Ghoul et al., 2009). Originally, the SW480 cell line was less favoured than 
the HCT116 or Colo205 cell lines due to the poor growth rates, sensitivity to aspirin 
treatment and the presence of two slightly different cell populations. The primary 
concern was the lack of consistent results due to the presence of two seemingly 
different cellular populations which has not been previously reported and may be 
specific to this batch of SW480 cells.  
The effects of cell density on the EMT marker proteins can be a confounding factor 
in the investigation of EMT in cell lines (Conacci-Sorrell et al., 2003). Therefore, it 
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was critical that cells were seeded at a consistent cell density and all cell culture 
conditions remained constant. This was achievable for 24 hour treatments but more 
difficult to control when cells were treated for prolonged periods such as the daily 
dosing experiments. Naturally there were variations in cell density between time 
points but cell density was consistent across control and treated cells. The daily 
dosing experiments illustrate an increase in E-cadherin and a decrease in claudin-1 
expression in response to low dose aspirin treatment. These daily treatments with 
low-dose aspirin demonstrated a cumulative effect of aspirin exposure with 96 
hours of aspirin increasing CDH1 RNA expression 5 and 6 fold in Colo205 and 
HCT116 cells respectively. This is the first report of aspirin treatment having a 
cumulative effect on E-cadherin expression in cell lines.  
Aspirin exposure increased CDH1 RNA expression in HCT116 and Colo205 cells 
over short duration experiments. However, in HCT116 cells there was a decrease in 
CDH1 RNA expression with 0.5mM aspirin for 24 hours which was mirrored by an 
increase in Snail expression. An increase in E-cadherin protein could be explained 
by either an increased synthesis or decreased turnover (Kowalczyk and Nanes, 
2012). The RNA expression results suggest that low dose aspirin is increasing E-
cadherin protein by stabilisation rather than synthesis with synthesis important in 
longer treatments and those of higher dose. The spike in snail RNA expression in 
HCT116 cells treated with 0.5mM aspirin for 24 hours would explain the mirrored 
reduction in E-cadherin synthesis. However, the reasons behind this increase in 
Snail RNA are unclear and is not replicated in protein as Snail protein is consistently 
decreased by aspirin after 24 hours. Snail expression can be increased following 
metabolic stress due to an increase in reactive oxygen species (ROS) but this seems 
unlikely as the increased snail was only noted in low-dose aspirin concentration and 
was not replicated in protein expression (Ch et al., 2011).  
The primary challenge with the CRC cell lines was their epithelial nature. To 
overcome this, I attempted to induce EMT and thus produce a more motile, 
mesenchymal phenotype with growth factor stimulation. Induction of EMT with 
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growth factors has been reported in the literature, including the four growth factors 
used in this project; TGF-β, PDGF, EGF and Thrombin (Boyer et al., 2000). The 
microsatellite instable cell lines, HCT116 and Colo205, have been reported to be 
unresponsive to TGF-β induced EMT due to a TGFBR2 mutation (Pino et al., 2010). 
The SW480 cell lines is microsatellite stable so in theory should respond to TGF-β 
stimulation which may indicate an increase in concentration or duration is required 
to induce EMT (Pino et al., 2010). The only growth factor to show any signs of EMT 
induction was PDGF, in which a modest decrease in E-cadherin protein was 
detected by immunofluorescence in Colo205 cells. However, there were no 
indication of an induction of a mesenchymal phenotype and it was decided to 
pursue other aspects of the project rather than optimising EMT induction. A 
possible explanation for this lack of growth factor induced EMT is the inherent 
epithelial nature of this batch of CRC cell lines which is noted by the lack of basal 
mesenchymal markers.  
With hindsight, induction of EMT by overexpressing an EMT transcription factor, 
such as Snail, would have been the most consistent and reliable method of 
investigating aspirin’s effects on EMT. Overexpression of snail in CRC cell lines has 
been demonstrated to induce EMT, increase migration and invasion and inducing a 
cancer stem cell phenotype (Fan et al., 2012).  Although, that method would have its 
own challenges as an investigation of aspirin’s effect on EMT would then be limited 
to aspirin’s effect on Snail induced EMT. Another method to induce EMT in 
epithelial cell lines is co-culture with platelets (Guillem-Llobat et al., 2016).  The co-
culture of platelets and the HT29 CRC cell line induced EMT, increased motility and 
increased metastasis (Guillem-Llobat et al., 2016).  Co-culture of an ovarian cancer 
cell line, SK-OV-3, with platelets induced cellular invasion and EMT in vitro (Cooke 
et al., 2015). Pre-treatment of platelets with aspirin prevented the induction of 
cellular invasion but did not prevent the induction of EMT (Cooke et al., 2015). The 
lack of induction of EMT prevents investigation of aspirin-mediated prevention or 
reversal of EMT. However, this is the first description of direct aspirin-mediated 
promotion of the mesenchymal-epithelial transition in CRC cell lines.  
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Chapter 5: The effect of aspirin on mouse in vivo 





Modelling CRC pathogenesis is possible due to the known common genetic 
mutations observed in both hereditary and sporadic CRC. The loss of Apc, due to a 
truncating mutation, is often the initiating mutation in sporadic CRC with around 
80% of sporadic CRC tumours containing Apc mutations (Cancer Genome Atlas 
Network, 2012). Mutations in the KRAS, PI3KCA and TP53 are also commonly 
observed in sporadic CRC (Cancer Genome Atlas Network, 2012). The 20% of 
sporadic CRC tumours which do not contain mutated Apc, usually contain a 
mutation of the mismatch repair genes similar to the hereditary Lynch syndrome 
(Cancer Genome Atlas Network, 2012). The other hereditary CRC syndrome is 
familial adenomatous polyposis (FAP) which is a consequence of a germline Apc 
mutation (O’Sullivan et al., 1998). Given the known common genetic mutations in 
both sporadic and hereditary CRC it is possible to create mouse models with a 
similar mutation background.  
Given the high mutation rate of the Apc gene in sporadic CRC and the germline 
Apc mutation in FAP patients, the majority of CRC pathogenesis in vivo models 
contain an Apc mutation. The multiple intestinal neoplasia (ApcMin/+) model has an 
autosomal dominant mutation at codon 850 of the Apc gene resulting in a non-
functional truncated protein (Heyer et al., 1999). Loss of heterozygosity (LOH) 
spontaneously occurs during adulthood resulting in the development of numerous 
adenomas throughout the intestines with the overwhelming majority located in the 
small intestines (Heyer et al., 1999). Clinical symptoms of tumour burden are a 
result of intestinal bleeding such as blood in faeces and signs of anaemia such as 
pale feet (Heyer et al., 1999). The ApcMin/+ mouse differs from a FAP patient as the 
vast majority of adenomas are restricted to the small intestine in the mouse and the 
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colon in a human FAP patient. It has been observed that colon adenomas develop in 
older, 18-25 week old, ApcMin/+ mice (Li et al., 2012b). The environment can affect 
adenoma progression in ApcMin/+ mice with both diet and gut microbiota 
demonstrated to influence adenoma burden. ApcMin/+ mice maintained in a germ-free 
environment, thus no commensal gut bacteria, had a significant reduction in 
intestinal adenomas (Li et al., 2012b). Similarly, ApcMin/+ mice on a calorie restricted 
diet had a significant reduction in intestinal adenoma development (Mai et al., 
2003). Therefore, mouse maintenance conditions can influence the number of 
intestinal adenomas which highlights the need for consistent experimental 
conditions.  
The use of mouse intestinal tumorigenesis models is crucial in the investigation of 
CRC initiation and progression. The use of CRC cell lines is important in the initial 
investigation of the effects of aspirin of EMT and the underlying signalling 
pathways but it is known that EMT can be induced by stromal cells within the 
tumour which are absent in the in vitro models. Using ApcMin/+ models, we can 
investigate the effects of aspirin on adenoma initiation in terms of adenoma number 
and size. The ApcMin/+ mouse experiments will also provide adenoma tissue to 














5.2: 4-week treatment cohort 
 
Treatment of the 4-week treatment cohort commenced at 6 weeks and lasted for 4 
weeks. Therefore, it is expected adenoma initiation had already occurred in the mice 
and that any effects of aspirin would be on adenoma progression. Adenomas were 
counted and sized from the methylene blue stained intestines from 5 control and 4 
aspirin treated mice (Figure 5.1A, B). There were no significant differences in the 
number of adenomas in the small intestine with a mean of 16.3 and 14 adenomas in 
control and aspirin treated mice respectively (Figure 5.1C). There was no difference 
in colon adenoma number with a mean of 2 and 2.25 adenomas in control and 
aspirin treated mice (Figure 5.1D). There were no significant changes in adenoma 
size in either small intestine or the colon (Figure 5.1E, F). Whilst there were no 
significant changes in the number or size of adenomas, there was a trend for 
decreasing adenoma number and size in aspirin treated mice. This lack of significant 
results may be explained by a lack of adenomas in the mice. The ApcMin/+ mice from 
this cohort had relatively low numbers of adenomas, around 15-20, which was due 
to the termination of experiment when mice were 10 weeks. The ApcMin/+ mice 
exhibited no clinical signs, pale feet or blood in faeces, of tumour burden during the 
4-week treatment. Based on this lack of adenomas and lack of symptoms in the mice 
I believe the duration of the experiment could have been prolonged which may 








Figure 5.1: 4-week treatment cohort. Sections of ApcMin/+ mouse small intestine 
(A) and colon (B) stained with methylene blue dye. Red dashed circle highlights 
ApcMin/+ adenomas. Mean number of adenomas per treatment group in small 
intestine (C) and colon (D). Mean number of adenomas separated by size in small 
intestine (E) and colon (F). All counts and sizes determined from 5 control (2M/3F) 
and 4 aspirin treated mice (1M/3F). Mice treated with 400mg/kg aspirin for 4-weeks. 
Error bars represent standard error. P-values determined by students unpaired t-
test. * p-value < 0.05 M/F: number of male and female mice per group 
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5.3: 7-day treatment cohort 
 
Treatment of the 7-day treatment cohort commenced on the emergence of pale feet, 
a clinical sign indicating high tumour burden and intestinal bleeding, and lasted 7 
days. In this cohort, the adenoma burden is established prior to treatment. 
Differences in survival statistics were observed between the control and aspirin 
treated mice with all 5 aspirin treated mice surviving until the end of treatment at 
day 7 whilst only 1 mouse from the 7 control mice survived until day 7 (Figure 
5.2A). The other 6 control mice had to be culled for ethical reasons as symptoms 
worsened. There was no significant change in the number of small intestinal 
adenomas with a mean of 86 and 69 adenomas for control and aspirin treated mice 
respectively (Figure 5.2B). There was a significant increase in the number of colon 
adenomas with a mean of 0.67 and 1.57 adenomas for control and aspirin treated 
mice (Figure 5.2C). There were no significant changes in the adenoma sizes in either 
small intestine or colon (Figure 5.2D, E). Similar to the 4-week treatment cohort, 
there were no significant changes in small intestine adenoma number but again 
there was a trend of decreasing numbers. There was no change in the average 
weight of the mice between the control and aspirin treated groups at day 0 and day 
7 (Figure 5.2F). Due to the lack of control mice from this treatment cohort to survival 
until day 7, weight data from another cohort of control mice was substituted. The 
consistency in body weight between control and aspirin treated mice demonstrates 
that mice were still eating and drinking as normal despite the presence of aspirin in 









Figure 5.2: 7-day treatment cohort. Survival curves from 7 control (6M/1F) and 5 
aspirin treated (4M/1F) mice after emergence of pale feet (A). Mean number of 
adenomas per treatment group in small intestine (B) and colon (C). Mean number of 
adenomas separated by size, less than 1.5mm diameter (D) and over 1.5mm 
diameter (E). Average weights from 3 control (3M) and 7 aspirin treated mice 
(5M/2F) at day 0 and day 7 of treatment (F). All counts and sizes determined from 
18 control (8M/10F) and 7 aspirin treated mice (5M/2F). Mice treated with 2.6mg/ml 
aspirin in drinking water for 7days. Error bars represent standard error. P-values 
determined from students unpaired t-test. * p-value < 0.05. M/F: number of male and 
female mice per group 
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5.4: Ageing cohort 
 
Treatment of the ageing cohort commenced after the emergence of clinical signs of 
tumour burden, specifically pale feet due to intestinal bleeding and anaemia. The 
ageing cohort mice were maintained after the emergence of pale feet until 
symptoms worsens and the mice had to be culled for ethical reasons. There is a 
significant increase in survival rates in the aspirin treated mice compared to the 
controls (Figure 5.3A). Control mice have a median and mean survival of 5 and 5.4 
days respectively after the emergence of pale feet. The aspirin treatment mice have a 
median and mean of 21 and 32 days respectively after the emergence of pale feet 
and thus commencement of aspirin treatment. Aspirin treatment significantly 
decreases the number of small intestine adenomas from a mean of 86 adenomas in 
control mice to a mean of 51 adenomas in aspirin treated mice (Figure 5.3B). There 
was still a significant increase in the number of colon adenomas from a mean of 0.67 
adenomas in control mice to a mean of 1.71 adenomas in aspirin treated mice 
(Figure 5.3C).  Aspirin significantly decreases the number of small, ,1.5mm, 
adenomas but no changes in the number of large, >1.5mm, adenomas in the small 
intestine (Figure 5.3D, E). Control mice had a mean of 60 and 26 adenomas <1.5mm 
and >1.5mm respectively. Aspirin treatment mice had a mean of 25 and 26 
adenomas <1.5mm and >1.5mm respectively. There was no significant difference in 













Figure 5.3: Ageing treatment cohort. Survival graphs of 15 control (8M/7F) and 23 
aspirin treated (17M/6F) mice after emergence of pale feet (A). Mean number of 
adenomas in small intestine (B) and colon (C). Size of adenomas separated into 
less than 1.5mm diameter (D) and over 1.5mm diameter (E). All counts and sizes 
were determined from 18 control (8M/10F) and 17 aspirin treated (11M/6F) ApcMin/+ 
mice. Mice treated with 2.6mg/ml aspirin in drinking water from emergence of pale 
feet until culled. Error bars represent standard error. P-values determined from 





5.5: Aspirin inhibits EMT in ApcMin/+ mouse small intestine 
adenomas 
 
Prior to evaluating aspirin-mediated effects on EMT protein expression, it is 
important to determine baseline expression differences between normal mucosa and 
adenoma tissue. ApcMin/+ mouse small intestine and colon tissue was stained for EMT 
marker expression (Figure 5.4A). Adenomas have reduced E-cadherin and increased 
vimentin expression associated with EMT progression. These differences in baseline 
expression were also noted in human tissue, specifically normal mucosa and 
adenoma tissue from familial adenomatous polyposis (FAP) patients (Figure 5.4B). 
Immunohistochemistry of the formalin fixed paraffin embedded (FFPE) tissue from 
the ApcMin/+ mice cohorts allow investigation of the expression and localisation of 
proteins in the normal mucosa and the adenomas. The adenoma tissue was of most 
interest for studying the effects aspirin had on adenoma progression with E-
cadherin and vimentin used as markers of EMT. Aspirin increased the overall E-
cadherin protein expression in small intestine adenomas in the 4-week treatment 
cohort (Figure 5.5). Vimentin expression is limited to stromal cells in normal small 
intestine tissue but there were a few epithelial cells in adenoma tissue which 
expressed vimentin. Aspirin decreased the number of vimentin positive cells in the 
small intestine adenomas in the 4-week treatment cohort (Figure 5.5). For 
immunohistochemistry analysis of the 4-week treatment cohort, I compared grading 
scores from all control adenomas to that of all aspirin treated adenomas rather than 
mean score per mouse. This method was preferred for this cohort as there were 
significantly lower numbers of adenomas compared to the 7-day and ageing cohorts 
and for some mice the mean score didn’t reflect the variation in adenoma staining. 
Evaluation of the effects in colon adenomas was not feasible due to the lack of colon 
adenomas. These in vivo results mirror the aspirin-mediated increase in E-cadherin 







Figure 5.4: Expression differences in ApcMin/+ mouse and human FAP tissue. 
Immunohistochemistry staining of ApcMin/+ small intestine and colon (A) and FAP 
normal colonic mucosa and colonic adenoma (B). Haematoxylin & Eosin (H&E), E-
cadherin and vimentin staining. Images captured by nanozoomer slide scanner with 











Figure 5.5: EMT marker expression in 4-week treatment cohort. Images of 
immunohistochemistry staining for E-cadherin and vimentin in small intestine (A). 
Grading of E-cadherin staining intensity in 37 control and 23 aspirin treated small 
intestine adenomas (B). Counts of number of positive stained vimentin cells per 
mm2 of 29 control and 16 aspirin treated small intestine adenomas (C). Adenomas 
from 5 control (2M/3F) and 4 aspirin treated (1M/3F) mice. Mice treated with 
400mg/kg aspirin for 4 weeks. Error bars represent standard error. P-values 
determined from students unpaired t-test. * p-value < 0.05 M/F: number of male and 







5.6: Chapter discussion 
 
The in vivo mouse models for intestinal carcinogenesis are an important research 
tool in the investigation of aspirin’s clinically relevant effects. The mutation and loss 
of functional Apc is commonly the initiating step in sporadic CRC with 80% of 
sporadic CRC tumours containing Apc mutations (Cancer Genome Atlas Network, 
2012). Therefore, CRC initiation can be modelled in vivo by the loss of Apc which is 
commonly achieved by use of the ApcMin/+ mice which contain a germline mutation 
and thus develop intestinal adenomas (Heyer et al., 1999). The three ApcMin/+ aspirin 
experiments had a dual purpose of investigating the effect of aspirin on adenoma 
initiation and progression whist providing tissue to investigate aspirin’s effects on 
signalling pathways within adenomas.  
The administration of 400mg/kg of aspirin in utero has been demonstrated to 
increase survival of ApcMin/+ mice but no effect was observed when aspirin was 
administered post weaning (Sansom et al., 2001). Survival in ApcMin/+ mice has been 
increased with administration of other therapies such as rapamycin, an inhibitor of 
the mTOR pathway (Faller et al., 2015). Aspirin treatment increased survival in the 
7-day treatment and ageing cohorts when administered upon the presence of 
clinical signs of tumour burden, specifically pale feet. In the short duration 
experiments where survival is increased by a few days this may be explained by 
aspirin’s analgesic effects which allows the mouse to look less distressed and 
continue to eat and drink normally, thus avoiding cull due to ethical reasons. 
However, the aspirin treated mice in the ageing cohort survived for a prolonged 
period after initial presentation of symptoms suggesting aspirin treatment 
suspended adenoma growth and progression.  
Aspirin has been reported to decrease the number of small intestine adenomas in 
ApcMin/+ mice by 44% at a dose of 200mg/kg (Mahmoud et al., 1998). This reduction 
in small intestine adenoma number and size was also demonstrated in another 
study after 7 weeks of aspirin treatment with both 250mg/kg and 500mg/kg doses of 
167 
 
aspirin (Barnes and Lee, 1998). However, there was no reduction in the number of 
colon adenomas with either dose (Barnes and Lee, 1998). There was no reduction in 
adenoma number or size in ApcMin/+ treated for 4 weeks with aspirin once tumour 
burden established, which suggests that the effects of aspirin on adenoma number 
and size require early and prolonged treatment with aspirin (Reuter et al., 2002). 
Aspirin has been detailed to suppress adenoma formation when 400mg/kg of 
aspirin administered in utero but not post weaning confirming that early aspirin 
intervention is required to limit adenoma initiation and formation (Sansom et al., 
2001).  
There was no difference in the number or size of adenomas in aspirin treated mice 
from the 7-day treatment cohort which was expected due to the limited treatment 
time and the presence of an established adenoma burden at time of treatment. There 
was a reduction in the number of small adenomas in the aspirin treated mice from 
the ageing cohort which suggests that prolonged aspirin treatment may prevent the 
initiation of further adenomas. The 4-week treatment cohort mice had lower 
numbers of adenomas compared to the 7-day treatment and ageing cohort mice 
indicating that the experiment could have been lengthened which may have 
revealed changes in adenoma size and number. Despite the lack of a significant 
decrease in adenoma size and number in all cohorts there was trend of a decreased 
number of small intestine adenomas after aspirin exposure. The reason this was not 
significant may be due to the numbers of mice per cohort resulting in low statistical 
power. 
These cohort experiments provided small intestine and colon tissue to investigate 
the effects of aspirin on the signalling pathways involved in adenoma initiation and 
progression. These experiments were not specifically designed to investigate EMT 
and invasion in vivo but did provide an opportunity to investigate EMT marker 
expression within mouse adenomas. Despite the lack of invasion observed in 
ApcMin/+ mouse models, EMT was present in adenomas as detected by decreased E-
cadherin expression in adenomas and the presence of vimentin positive adenoma 
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cells. Aspirin treatment decreased the number of vimentin positive cells per mm2 of 
adenoma tissue while increasing E-cadherin protein expression. These results 
confirm the phenotype observed in CRC cell lines with aspirin promoting the 
mesenchymal-epithelial transition in colorectal tissue. To further investigate EMT in 
vivo, an invasive CRC model is required. The loss of PTEN and activation of KRAS 
in mice has been demonstrated to induce the formation of invasive 
adenocarcinomas and liver metastasis (Davies et al., 2014). The intravenous injection 
of CRC cells in the tail vein has also been reported in the investigation of signalling 
pathways involved in CRC metastasis (Gulhati et al., 2011). While this allows 
investigation of the establishment of secondary metastasis, it does not account for 
the mechanisms and underlying signalling required to facilitate the initial 
movement of cells from tumour to the circulatory system.  
A challenge of in vivo experimentation is controlling the variables of the 
experiment. There is variation between the housing and diet of the three treatment 
cohorts but all mice within each cohort were maintained in the same conditions. The 
4-week treatment cohort was specifically designed to limit variation in the 
experiment. This was achieved by designing an experiment where all mice were 
culled and processed together thus reducing experimental variation. Therefore, 
treatment commenced early so mice should survive the 4 weeks without 
succumbing to anaemia due to tumour burden. A benefit of this 4-week treatment 
cohort experiment was the administration of aspirin solution by oral gavage rather 
than drinking water to remove the variation of aspirin concentration consumed. All 
control mice were given distilled water by oral gavage to control for any stress 
associated with the technique.  
A strength of this research was the replication of aspirin-mediated promotion of the 
mesenchymal-epithelial transition in mouse small intestine adenomas. Although the 
ApcMin/+ mouse model is not an invasive CRC metastasis model, it did allow 
verification of the CRC cell line results in vivo. The survival statistics from the 7-day 
treatment and ageing cohorts illustrate the potential clinical benefits of aspirin 
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treatment post adenoma initiation although the mechanism for this increased 
survival has not been determined. Weaknesses of this research is the lack of 
significant results regarding the effect of aspirin on the adenoma number and size 
which may be due to low statistical power. All three cohorts are designed to 
investigate adenoma progression rather than initiation. To investigate the 
prevention of adenoma initiation aspirin would need to be administered to young 
mice before adenoma development. This is the first demonstration of an aspirin-
mediated promotion of the mesenchymal-epithelial transition in mouse small 






















Chapter 6: The effect of aspirin on organoids of 





The discovery of the intestinal stem cells and the understanding of the stem cell 
niche was critical in the development of a crypt culture protocol in vitro (Sato et al., 
2009). Clevers and Sato designed a protocol for the culture of Lgr5+ stem cells in 
vitro which form crypt-villus like structures termed organoids (Sato et al., 2009). 
Single Lgr5+ cells or whole crypts from the mouse small intestine were embedded in 
matrigel with growth factors added to the culture media to mimic the stem cell 
niche (Sato et al., 2009). The organoids can be cultured for months and maintain all 
epithelial cell lineages including Paneth cells, goblet cells, enterocytes and 
enteroendocrine cells (Sato et al., 2009). Although no stromal cells are present in the 
organoid culture thus any growth factors or ligands provided by stromal cells must 
be added to the culture media (Sato et al., 2009).  
Organoids from human colon, adenoma and adenocarcinoma have been described 
in the literature (Sato et al., 2011b). The culture of organoids from human tissue 
required additional reagents to facilitate organoid growth and survival (Sato et al., 
2011b). A screening of growth factors, vitamins and hormones revealed an increased 
organoid efficiency with addition of gastrin, nicotinamide, A83-01 (Alk inhibitor) 
and SB202190 (p38 inhibitor) (Sato et al., 2011b). However, nicotinamide and 
SB202190 inhibits the differentiation of goblet and enteroendocrine cells which may 
be important is experiments require the presence of all cell types (Sato et al., 2011b). 
Whilst there are limitations associated with organoid culture such as the lack of 
stromal cells and the dependence on external growth factors, they do provide an 
intermediate step between CRC cell lines and in vivo CRC pathogenesis mouse 
models. Due to the established crypt-villus structure in organoids, they are an 
excellent model to investigate stem cell effects.  
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While organoids from human colon and adenomas has been demonstrated in the 
literature, the majority of CRC research relies on mouse small intestine organoids. 
There are a number of reasons for this such as mouse small intestinal organoids are 
easier to propagate and require less growth factors. Organoids can be established 
from mice with different genetic backgrounds and mouse tissue is easier to obtain 
than human. As organoid culture is a relatively new technique, the focus of my 
research was to first establish a protocol for both mouse and human organoid 
culture. Once a protocol for human colonic normal mucosa and adenoma organoid 
culture had been established, the effects of aspirin on the motility and EMT markers 





















6.2: Characterisation of organoids 
 
Optimisation and characterisation of colonic organoid culture was completed with 
mouse colon before attempting organoid culture from human tissue. The primary 
difference between colon organoid and small intestine organoid culture is the 
requirement for WNT3a in the colon organoid culture media. WNT ligands are 
provided by the Paneth cells in the small intestine which are maintained in small 
intestine organoid culture (Sato and Clevers, 2013). However, Paneth cells are not 
present in the colon with the stromal cells beneath he intestinal crypts and C-kit+ 
goblet cells hypothesised as an external source of WNT ligands in the colon 
(Rothenberg et al., 2012). Mouse colonic organoids grow slower than those of the 
small intestine with budding occurring around day 5-6 opposed to day 2-3 in the 
small intestine (Figure 6.1A). It is noteworthy that some colonic organoids do not 
bud but at remain as spheroids. The colonic organoids are highly epithelial with 
high expression of E-cadherin at cell junctions and cortical actin detected by 
immunofluorescence with no vimentin or slug protein expression detected (Figure 
6.1B). Imaging of organoids by confocal sections allows the visualisation of the 
budding organoid in three-dimension (Figure 6.1C). 
 The passage of the mouse organoids was the main step requiring optimisation as a 
number of organoid cultures failed to propagate following optimisation. Mechanical 
disruption of organoids using a p200 pipette was insufficient to fragment the mouse 
organoids so an additional disruption with a 21-gauge needle was added to the 
protocol. It was also observed that organoid growth was most noticeable in the 
smaller droplets of matrigel which may be due to closer contact between organoids 
and growth factors. Therefore, 5 small 10μl droplets of matrigel were seeded per 
well instead of 1 large 50μl matrigel droplet.  The combination of these alterations to 
the protocol improved the survival of the mouse organoids beyond the first passage 




Following the optimisation of the mouse colonic organoid culture protocol, I 
cultured organoids from human colonic mucosa. Normal mucosa from human colon 
was collected during the surgical resection of colorectal tumours. Human colonic 
organoids require some additional growth factors which are detailed in chapter 2.5. 
Human colonic organoids grow well with budding occurring around day 6-7 
(Figure 6.2A). Human organoid culture success can vary between patients which 
may be due to the age of patient, duration of surgery or other underlying medical 
conditions. In addition to receiving tissue from patients undergoing colorectal 
tumour resection surgeries, I also received tissue from familial adenomatous 
polyposis (FAP) patients. Surgical removal of the colon in FAP patients allows the 
collection of normal mucosa and adenomas from an individual patient. The 
presence of an Apc mutation in the FAP adenoma cells means the adenoma 
organoids do not require external WNT3a in the media and the organoids grow as 
cystic rather than budding structures (Figure 6.2B). Unfortunately, a challenge with 
organoid culture from FAP patient tissue is the presence of micro adenomas which 
are undetectable macroscopically. Their presence only becomes apparent later in 
culture as a mixed population of cystic and budding organoids. This was a common 















Figure 6.1: Characterisation of mouse colonic organoids. Timeline of mouse 
colonic organoid growth and budding (A). Magnification noted in the bottom left 
corner of image. Immunofluorescence of E-cadherin and F-actin expression in 
mouse colonic organoids with inverse and confocal microscopy (B). Three-
dimensional image of mouse colonic organoid formed by stacking confocal sections 








Figure 6.2: Characterisation of human colonic organoids. Timeline of human 
colonic organoid growth and budding (A). Images of human colonic mucosa, FAP 
normal mucosa and FAP adenoma organoids (B). Magnification noted in bottom left 









6.3: Aspirin promotes a less motile epithelial phenotype in 
organoids 
 
Organoids from human colonic mucosa, FAP normal mucosa and FAP adenoma 
were exposed to aspirin to evaluate the effects of aspirin on the motility and EMT 
markers using western blotting. Five different patient samples were used to 
establish organoids as indicated in figure 6.3. The organoids were exposed to aspirin 
for either 4 hours or 48 hours to evaluate both short and long term responses to 
aspirin. There was a different expression pattern between the time points in all EMT 
and motility markers. In the short term experiments, 4 hours, the alterations in 
protein expression are variable suggesting the 4 hours may be too early a time-point 
to determine the effects of aspirin on the EMT and motility markers (Figure 6.3A). 
Aspirin increases E-cadherin and reduces both claudin-1 and phosphorylated cofilin 
protein expression after exposure to aspirin for 48 hours (Figure 6.3B). Aspirin 
increases CDH1, gene encoding E-cadherin, RNA expression consistently with the 
largest fold change of 3.5 observed in a daily dosing experiment where organoids 
were treated with 0.1mM of aspirin daily for 96 hours (Figure 6.3C & D). There is 
some variability across the organoid results which is expected due to patient 
variability and the number of external factors such as quality of growth factors 
which may be susceptible to batch variation. However, most results seen in the 
organoid experiments, especially the longer duration treatments, mirror those 
results from CRC cell lines. These results illustrate that aspirin is decreasing motility 











Figure 6.3: Aspirin promotes a less motile epithelial phenotype in human 
colonic organoids. Western blots of E-cadherin, claudin-1 and phosphorylated 
cofilin after 4hours (A) and 48hours (B) of aspirin treatment. Densitometry figures 
presented as fold change of untreated control and normalised to loading control. 
CDH1, gene encoding E-cadherin, RNA expression in human colonic mucosa 
normalised to GAPDH RNA expression after 4hours (C) and longer duration (D) of 
aspirin treatment. Data presented from five individual patients thus no repeats or 
error bars. FAP, familial adenomatous polyposis, NM, normal mucosa. Number in 
brackets indicates patient number. 
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6.4: Chapter discussion 
 
Following the identification of the intestinal stem cells and the associated signalling 
pathways required for the stem cell niche and efficient intestinal homeostasis, the 
culture of organoids could be established (Sato and Clevers, 2013). Isolation of the 
Lgr5+ stem cells and growth in vitro in a matrigel matrix with the addition of 
growth factors results in the formation of organoids (Sato et al., 2009). Organoids 
grow as crypt-villus budding structures with the buds representing the inverse 
formation of a single crypt (Sato et al., 2009). The additional factors essential for 
mouse organoids are EGF, noggin and R-spondin for small intestine with Wnt3a 
also required for colon culture (Sato et al., 2009). EGF and R-spondin are ligands for 
the EGF and Wnt pathways respectively with noggin an inhibitor of the BMP 
signalling pathway (Sato et al., 2009). Human organoids have an increased plating 
efficiency when other reagents such as the hormone gastrin is added to the culture 
(Sato et al., 2011b).  
Despite receiving protocols from the Sato and Clever’s laboratory, my initial 
organoid experiments did not grow as consistently as required for experimentation. 
The majority of organoid batches died following the first passage indicating that the 
passage protocol required optimisation. I added another mechanical disruption step 
to the protocol which involved aspirating the organoids with a 21-gauge needle to 
fully break the organoid structure. It was observed that organoids grew better in 
small matrigel droplets which may be due to the closer contact with growth factors 
in the media. Therefore, the organoids were plated in multiple 10μl matrigel 
droplets rather than one 50μl droplet per well. These additional steps aided the 
long-term culture of organoids from mouse and human tissue with both surviving 
several months in the laboratory.  
The culture of organoids provides an intermediate step between CRC cell lines and 
in vivo CRC pathogenesis models. Organoids in culture retain the characteristics of 
the normal intestinal epithelium with a single Lgr5+ stem cell capable of producing 
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an organoid which contains goblet cells, Paneth cells, enteroneurocrine cells and 
enterocytes (Sato et al., 2009). This allows the experimentation on intestinal 
epithelial cells in vitro from mouse and human tissue. There is also the opportunity 
to grow organoids from mice with different genetic backgrounds and investigate the 
effects of mutations to specific genes. The development of CRISPR (clustered 
regularly interspaced short palindromic repeats) technology has been transferred to 
organoid culture with the induction of mutations directly to organoids currently 
being used to model human CRC (Matano et al., 2015). Organoids can be grown 
from adenomas and carcinomas which may be a useful tool in screening of potential 
anticancer therapies. The increased use of organoids in the investigation of CRC 
pathogenesis should reduce the number of mice required as there is less reliance on 
in vivo experiments. Whilst there are a number of advantages to using organoids to 
investigate CRC, there are also limitations. There are no stromal cells present in 
organoid culture so there is no cross signalling between mesenchymal and epithelial 
cells (Sato et al., 2009).  There is a dependence on external growth factors which can 
be subject to batch variation and is also expensive to maintain organoids in culture 
for prolonged durations.  
Characterisation of the organoids revealed an epithelial population with high levels 
of E-cadherin expression and no detectable vimentin or snail protein. This epithelial 
population has previously been reported (Sato et al., 2009). Aspirin exposure 
increases E-cadherin protein and RNA expression in organoids whilst decreasing 
claudin-1 and phosphorylated cofilin protein expression. These results are 
consistent with the effects demonstrated in CRC cell lines. To the best of my 
knowledge there are no previous report on the effects of EMT marker and motility 
marker expression in intestinal organoids. There is no reported EMT induction 
protocol for organoids and it is likely that mutations to tumour suppressors or 
oncogenes would be required as EMT is observed in aggressive CRC tumours 
(Spaderna et al., 2006). This is the first description of the effects of aspirin on human 
colonic organoids and the first demonstration of an aspirin-mediated promotion of 
the mesenchymal-epithelial transition in organoid culture.  
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Chapter 7: The effect of aspirin on organoid 





The Wnt signalling pathway was originally identified as a key pathway in 
drosophilia development and has since been proven to play a central role in normal 
mammalian development (Cadigan and Nusse, 1997). There are three distinct Wnt 
controlled signalling pathways including the canonical pathway and the two β-
catenin independent non-canonical pathways. The canonical pathway is the best 
studied of the three and centres around the regulation of β-catenin which plays a 
key role in activating the transcription of developmental genes (MacDonald et al., 
2009). Activation of canonical Wnt signalling is caused by the binding of Wnt 
ligands to the frizzed receptor. This binding disrupts the β-catenin destruction 
complex and allows the accumulation of cytoplasmic β-catenin which translocates 
to the nucleus to initiate transcription of Wnt target genes (MacDonald et al., 2009). 
There are two non-canonical pathways; one which controls cell polarity and has 
roles in cytoskeletal organization and the other is involved in intracellular calcium 
regulation (Kühl et al., 2000; Seifert and Mlodzik, 2007).  
The Wnt signalling pathway is often dysregulated in CRC with mutation of Apc, a 
key member of the β-catenin destruction complex, the most common initiating 
mutation in sporadic CRC (Cancer Genome Atlas Network, 2012). The importance 
of the Wnt signalling pathway in CRC initiation can be demonstrated by the loss of 
functional Apc with a hyperproliferative phenotype occurring in Apcflox/flox mice and 
intestinal adenoma formation in ApcMin/+ mice (Schneikert and Behrens, 2007). These 
effects translate to human CRC pathogenesis with a germline mutation to Apc, 
occurring in familial adenomatous polyposis, resulting in the formation of 
numerous adenomas throughout the colon (O’Sullivan et al., 1998). Therefore, the 
dysregulation of the Wnt signalling pathway causes an increase in cellular 
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proliferation to initiate colorectal adenoma formation (Schneikert and Behrens, 
2007). The Wnt signalling pathway is predominately discussed as an initiator of 
colorectal cancer with Wnt target genes, such as c-myc, promoting proliferation and 
tumour growth (Schneikert and Behrens, 2007). Along with roles in proliferation, 
the Wnt signalling pathway can play critical roles in the invasion and metastasis of 
CRC (Basu et al., 2016).  
The crypt base columnar cells (CBC cells), expressing Lgr5, have been identified as 
the stem cells in both the small intestine and colon by lineage tracing (Barker, 2014). 
The Wnt target gene, leucine-rich repeat containing G protein-coupled receptor 5 
(Lgr5), is expressed only in intestinal stem cells (Barker et al., 2007). In addition to 
Lgr5, TROY and OLFM4 can be used as markers of intestinal stem cells (Fafilek et 
al., 2013; van der Flier et al., 2009). The Wnt ligands are produced by the Paneth cells 
and stromal cells in the small intestine and colon respectively (Rothenberg et al., 
2012; Sato et al., 2011a). The loss of Paneth cells in small intestine and subsequent 
Wnt ligands results in a reduction in the Lgr5+ cellular population illustrating the 
Wnt signalling is required to maintain normal intestinal stem cell function (Sato et 
al., 2011a). 
A key technique for investigation of intestinal stem cells and the associated stem cell 
niche is the culture of intestinal organoids which represent the crypt-villus structure 
in vitro. Organoids with wild-type Apc grow as budding structure resembling the 
crypt-villus structure with each bud representing the formation of an inverse crypt 
(Sato et al., 2009). Organoids grow as three-dimensional structures with polarised 
epithelium surrounding a central lumen (Sato et al., 2009). The central lumen 
becomes filled with debris as the cells which in the normal intestine slough off the 
top of villi or crypts are collected in the centre of the organoid structure (Sato et al., 
2009). This characteristic budding structure relies on the localised Lgr5 and Wnt 
signalling which has been identified by labelling Lgr5+ CBC cells with a GFP tag 
(Sato and Clevers, 2013). This budding structure is lost upon dysregulation of the 
Wnt signalling pathway by loss of Apc (Sato and Clevers, 2013). Apc null organoids 
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grow as large cystic structures indicating there is a homogenous mix of stem and 
progenitor cells (Sato and Clevers, 2013). 
The induction of EMT is associated with the acquirement of a cancer stem cell 
phenotype in which cells gain characteristics of stem cells such as self-renewal and 
the ability to maintain a cellular population (Fan et al., 2012). The Wnt signalling 
pathway has been demonstrated to regulate EMT induction in CRC (Guo et al., 
2016). Aspirin has previously been demonstrated to inhibit the Wnt signalling 
pathway in vitro with reduction in β-catenin expression and Wnt target gene 
expression illustrated (Bos et al., 2006). Given the roles of the Wnt signalling 
pathway in CRC initiation, stem cell regulation and a potential EMT regulator, the 
focus was to determine the effects of aspirin on the intestinal stem cells and Wnt 
signalling in vivo. The aim of this research was to determine the effects of aspirin on 
organoid budding and the intestinal stem cell population using both mouse and 

















7.2: Aspirin rescues the Apc null driven cystic phenotype  
 
Organoids grown from Apc null tissue grow as cystic rather than budding 
organoids which is observed in organoids from ApcMin/+ mice, Apcflox/flox mice and 
human FAP tissue. Organoids were grown from two ApcMin/+ mice from the 4-week 
treatment cohort, a control and an aspirin treated mouse. No additional aspirin was 
added to the organoids during culture with the only aspirin exposure occurring in 
vivo. Small intestinal and colonic organoids from the control ApcMin/+ mouse grew as 
cystic organoids which was expected due to the Apc mutation. Interestingly, the 
aspirin treated small intestine and colonic organoids grew as budding organoids 
rather than cystic structures (Figure 7.1). As the only aspirin exposure was in vivo, 
the altered phenotype may be a result of aspirin-mediated selection rather than 






















Figure 7.1: Aspirin rescues the Apc null driven cystic phenotype in ApcMin/+ 
organoids. Brightfield images of organoids from ApcMin/+ small intestine and colon 
from the 4-week treatment cohort. Mice were treated with 400mg/kg aspirin for 
4weeks with no further treatment added to organoids. Images captured with 10x 













To investigate if aspirin was capable of reversing this cystic phenotype, organoids 
were grown from human FAP normal mucosa and adenoma. The expectation was 
that normal mucosa from FAP patients would grow as a budding population as 
cells should retain a functional copy of Apc and thus regulated WNT signalling. 
However, the normal mucosa organoids grow as a mixed population which 
suggests the presence of micro adenomas in the sample which were macroscopically 
undetectable. The FAP adenoma organoids grew as a predominately cystic 
population. The FAP organoids were exposed to 0.5mM aspirin in media daily for 
26 days before any alteration in phenotype was observed. After 29 days of culture in 
0.5mM aspirin, the percentage of budding organoids in the FAP normal mucosa 
population was increased from 15.98% to 22.97% (Figure 7.2). Exposure to 0.5mM 
aspirin for 29 days increased the percentage of budding organoids in the FAP 
adenoma population from 1.16% to 23.73%. This alteration in budding percentage 
may demonstrate an aspirin-mediated reversal of the cystic phenotype as the 
number of budding organoids present in aspirin treated wells is increased. 
However, there may also be elements of aspirin-mediated selection of the budding 
organoids as the total number of cystic organoids is halved with aspirin which may 
















Figure 7.2: Aspirin rescues the Apc null driven cystic phenotype in human 
FAP organoids. Brightfield images of organoids from FAP normal colonic mucosa 
and FAP adenomas (A). Images captured with 10x objective. Corresponding graph 
of the percentage of budding organoids per treatment group with 12 wells of 
organoids counted per treatment group (B). Data from a single experiment. Error 
bars represent standard error. P-values determined by students unpaired t-test. * p-
value < 0.05 
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Investigating the capability of aspirin to reverse the cystic phenotype in ApcMin/+ 
organoids and FAP organoids highlighted the challenge of determining if the 
increased budding was reversal or selection. To overcome this challenge a third 
model of CRC pathogenesis, the Apcflox/flox organoids, were obtained. The Apcflox/flox 
organoid population is 100% cystic so any changes observed must be a result of the 
reversal of a cystic phenotype. Small intestinal organoids from wild-type mouse was 
obtained as a control for the Apcflox/flox experiment. The wild-type mouse small 
intestinal organoids grow as a 100% budding population. Small intestinal organoids 
from wild-type and Apcflox/flox mice were exposed to 0.5mM aspirin daily for 27 days. 
There were no detectable changes in organoid budding with 0.5mM aspirin. This 
lack of observable budding may indicate that results from previous experiments, 
ApcMin/+ organoids and FAP organoids, were due to aspirin-mediated selection 
rather than reversal.  
The Apcflox/flox organoids were exposed to a higher aspirin concentration, 2mM, daily 
for 12 days. After 12 days of 2mM aspirin there was an increase in the percentage of 
non-cystic organoids in the Apcflox/flox organoids (Figure 7.3). The non-cystic 
organoid population was composed of those budding and those with an irregular 
ruffled border unlike the perfect sphere observed with cystic organoids (Figure 
7.3C). There were no changes detected in the budding phenotype of wild-type 
organoids. There were a small percentage, 5.22%, of Apcflox/flox control organoids 
which exhibited a non-cystic phenotype. This may suggest that the irregular ruffled 
edges may be a result of cell stress due to long passage and not only indicate the 
emergence of organoid budding. Although, there were established budding 
organoids present, in addition to the ruffled edged organoids, in the aspirin treated 
Apcflox/flox population. The Apcflox/flox results suggest aspirin is reversing the cystic 
phenotype but the experiment should be repeated for a longer duration. This would 
require a lower concentration of aspirin as there was evidence of cell death, 






Figure 7.3: Aspirin rescues the Apc null driven cystic phenotype in mouse 
Apcflox/flox organoids. Brightfield images of organoids from wild-type and Apcflox/flox 
mouse small intestine (A). Images captured with 10x objective. Corresponding graph 
of the percentage of non-cystic organoids per treatment group (B). Counts from 12 
wells per treatment group. Representative images of cystic organoids and organoids 
with ruffled edges (C). Data from a single experiment. Error bars represent standard 
error. P-values determined by students unpaired t-test. * p-value < 0.05 
189 
 
7.3: Aspirin reduces stem cell marker expression 
 
Aspirin-induced promotion of the budding phenotype suggests aspirin may be 
altering the stem cell population in the organoids. The hallmark of an intestinal stem 
cell is the expression of Lgr5. Other markers, such as TROY and OLFM4, have 
overlapping expression profiles to Lgr5 and can be used as substitute markers. RNA 
was extracted from the isolated ApcMin/+ mouse crypts prior to the establishment of 
the organoid culture. RNA was extracted from the FAP and Apcflox/flox organoids at 
day 29 and 12 respectively. Lgr5, TROY and OLFM4 RNA expression was reduced 
in aspirin treated ApcMin/+ mouse crypts from the small intestine and colon compared 
to the control ApcMin/+ mouse (Figure 7.4A). Aspirin treatment, 0.5mM, of FAP 
colonic normal mucosa and adenoma organoids reduced Lgr5 RNA expression after 
29 days (Figure 7.4B). TROY expression in FAP normal mucosa organoids was not 
significantly altered and no changes were detected in the FAP adenoma organoids 
due to low expression. The Apcflox/flox control organoids have increased Lgr5 and 
TROY expression compared to the wild-type mouse control organoids which is 
expected due to the presence of dysregulated Wnt signalling (Figure 7.4C). 
Exposure to 2mM aspirin for 12 days decreased both Lgr5 and TROY expression in 















Figure 7.4: Aspirin decreases stem cell marker RNA expression. RNA 
expression of Lgr5, TROY and OLFM4 from isolated crypts of ApcMin/+ mice after 
400mg/kg aspirin for 4 weeks in vivo (A). RNA expression of Lgr5 and TROY from 
FAP organoids treated with 0.5mM aspirin for 29 days (B). RNA expression of Lgr5 
and TROY from wild-type control organoids and Apcflox/flox control and aspirin treated, 
2mM aspirin for 12 days, organoids (C). Three technical replicates for RNA 
expression of each independent experiment. Error bars represent standard error. P-
values determined from students unpaired t-test. * p-value < 0.05. NM, normal 
mucosa, FAP, familial adenomatous polyposis, WT, wild-type 
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Lgr5 protein expression can be detected, using western blotting, in human organoid 
lysates but proved difficult to detect in CRC cell line lysates which may reflect low 
basal expression. Aspirin exposure reduced Lgr5 protein expression consistently in 
human colonic organoids (Figure 7.5). This reduction in Lgr5 protein expression 
was observed with 2mM aspirin after 4 and 48 hours. Lgr5 protein expression was 




























Figure 7.5: Lgr5 protein expression in human colonic organoids. Western blots 
of Lgr5 protein expression in human colonic organoids. Densitometry figures 
presented as fold change of untreated control normalised to loading control. Data 
from individual patients thus no repeats. Number in brackets indicates patient 















Unfortunately, there is no specific Lgr5 antibody suitable for 
immunohistochemistry. Therefore, in order to evaluate Lgr5 expression in FFPE 
tissue from the previous ApcMin/+ mouse experiments I performed RNAscope assays 
on the complete 4-week treatment cohort. RNAscope technology allows detection 
and quantification of Lgr5 RNA transcripts. As expected, only a few cells per crypt 
expressed Lgr5. Quantification of crypt Lgr5 expression is possible but unless strict 
crypt orientation guidelines are adhered the results will not be true reflection for 
Lgr5 expression (Figure 7.6A). As seen in the figure spots are only observed in well 
orientated crypts, so an abundance of poorly orientated crypts would lead to an 
underestimation of the true number of Lgr5 transcripts. Lgr5 expression is 
upregulated in ApcMin/+ adenomas. Although, there is variation in Lgr5 expression 
throughout adenomas with the highest expression in the cells nearest the crypt base 
with decreasing peripheral expression as cells reach the lumen (Figure 7.6B). There 
was no observable change in Lgr5 expression between control and aspirin treated 
mice (Figure 7.7). Although, due to the heterogeneity of the Lgr5 expression in 




















Figure 7.6: Lgr5 RNAscope expression in ApcMin/+ mouse tissue. Brightfield 
images illustrating the lack of Lgr5 transcripts detected in poorly orientated crypts 
(A). Brightfield images of small intestine and colon adenoma illustrating expression 
differences between crypt (c) and peripheral (p) adenoma cells (B). All images 










Figure 7.7: Lgr5 RNAscope expression in adenomas. Example RNAscope 
stained small intestine adenomas from ApcMin/+ mice. Representative images from 
control mice and those treated with 400mg/kg aspirin for 4 weeks. Images captured 


















In addition to Lgr5, OLFM4 and TROY, I also investigated the expression of SOX9 
which is another protein associated with the intestinal stem cell signature. SOX9 is a 
downstream gene of Wnt signalling which is required for Paneth cell differentiation 
in the small intestine (Lü et al., 2008). Overexpression of Sox9 in colorectal cancer is 
common and associated with a poor prognosis (Lü et al., 2008). SOX9 
immunohistochemistry staining was completed by Tam Jamieson at the Beatson 
institute on the ApcMin/+ 7-day treatment cohort. There was an increase in SOX9 
expression in small intestinal adenomas compared to normal mucosa. Aspirin 
increased SOX9 expression in small intestinal adenomas (Figure 7.8). This may 
reflect different stem cell populations as SOX9 is reported to be expressed in both 
Lgr5+ stem cells and Lgr5- reserve stem cells (Roche et al., 2015). An increase in 
reserve stem cells to compensate for the reduction in Lgr5+ stem cells could explain 























Figure 7.8: Sox-9 expression in small intestine adenomas. 
Immunohistochemistry staining for Sox-9 expression in mouse small intestine 
normal mucosa and adenoma from the 7-day treatment cohort (A). All images 
captured with a 10x objective. Corresponding graph of small intestine adenoma 
grading (B). Grading calculated as the average per mouse with mean determined 
from 5 control (5F) and 4 aspirin treated (1M/3F) mice. Mice treated with 2.6mg/ml 
aspirin in drinking water for 7 days. Error bars represent standard error. P-values 
determined by students unpaired t-test. * p-value < 0.05. M/F: number of male and 







7.4: The effect of aspirin on spheroid formation assays 
 
Spheroid formation assays permit the formation of spheres in suspension from 
normally adherent CRC cell lines. The process of sphere formation involves EMT 
with an increase in mesenchymal markers and decreased E-cadherin described in 
the literature (Han et al., 2013). The ability of cell lines to form spheres or spheroids 
is reported to correlate with stem cell population (Han et al., 2013). Aspirin 
exposure prevented the formation of spheroids following 3days exposure to 0.1mM, 
0.5mM or 1mM (Figure 7.9A). Protein expression alterations between adherent 
control cells, untreated spheroids and aspirin-treated spheroids were determined by 
western blotting (Figure 7.9B). There were difficulties in determining alterations in 
protein expression due to the lack of a consistent loading control. This may be a 
technical error in the western blotting protocol or a result of inefficient whole cell 
lysis. Densitometry was completed comparing protein of interest to the β-actin 
expression. This densitometry showed inconsistent results in epithelial markers, E-
cadherin and α-catenin, across both HCT116 and Colo205 cell lines which could be 
traced back to the loading control. There was a lack of mesenchymal marker 
expression in the spheroids with no vimentin, snail or slug protein detected in either 
adherent cells or spheroids. There was around a 3-fold increase in phospho-cofilin 
from adherent cells to untreated spheroids. Aspirin treatment reduced all markers 












Figure 7.9: Spheroid formation assays. Brightfield images of spheroid formation 
assays of HCT116 cells treated for 3 days with aspirin using 4x objective (A). 
Western blotting of EMT and motility markers in HCT116 and Colo205 cells (B). 
Densitometry figures presented as fold change of adherent untreated cells and 




7.5: Aspirin inhibits the Wnt signalling pathway 
 
That aspirin exposure can promote the budding phenotype in organoids with 
dysregulated Wnt signalling, due to Apc loss, and reduce Lgr5 expression suggests 
that aspirin is modulating the Wnt signalling pathway either directly or indirectly. 
Aspirin has previously been demonstrated to reduce β-catenin protein expression 
and the transcription of Wnt signalling genes by β-catenin/Tcf4 complex (Bos et al., 
2006; Lan et al., 2011). Aspirin has also been demonstrated to reduce the number of 
adenomas formed in ApcMin/+ mice and reduce the β-catenin expression in ApcMin/+ 
mice (Mahmoud et al., 1998).  I hoped to confirm these reported findings in our CRC 
cell lines and in vivo experiments. 
To investigate the Wnt signalling effects, β-catenin protein expression was 
determined in cell lines and mouse tissue. Exposure to aspirin, 3mM and 5mM, 
reduced β-catenin protein expression in HCT116 whole cell extracts (Figure 7.10A). 
Aspirin exposure, 0.5mM and 3mM, reduced β-catenin protein expression in 
Colo205 whole cell extracts. Fractionation of HCT116 cells into cytoplasmic and 
nuclear fractions was completed to determine any alterations to β-catenin nuclear 
shuttling. Firstly, it must be noted that cytoplasmic β-catenin appears as a triplicate 
band in HCT116 cells on western blot. As far as I am aware this has not been 
reported previously and may be specific to this extraction protocol. Aspirin 
treatment decreases the nuclear β-catenin expression in HCT116 cells after 4, 16 and 
24 hours (Figure 7.10B). Expression of cytoplasmic β-catenin protein was increased 
at 4 hours then decreased at 16 and 24 hours. This suggests there may be a reduction 
in nuclear shuttling at 4 hours with an overall reduction in β-catenin after 16 and 24 
hours. Expression of β-catenin in ApcMin/+ mice adenomas was determined by 
immunohistochemistry There is increased β-catenin expression in ApcMin/+ adenomas 
compared to normal mucosa. Aspirin treated mice from the 4-week treatment cohort 
demonstrated a significant reduction in β-catenin expression levels of the small 








Figure 7.10: Aspirin decreases β-catenin protein expression in CRC cell lines. 
Western blots illustrating β-catenin expression in HCT116 and Colo205 whole cell 
extracts (A). Western blots illustrating β-catenin expression in HCT116 
cytoplasmic/nuclear extractions. Densitometry figures presented as fold change of 
untreated controls and normalised to β-actin expression. Data representative of 














Figure 7.11: Aspirin decreases β-catenin protein expression in vivo. 
Immunohistochemistry staining for β-catenin expression in small intestine normal 
mucosa and adenomas in the 4-week treatment cohort (A). Corresponding graph of 
β-catenin grading calculated from 21 control and 30 aspirin treated small intestine 
adenomas (B). Adenomas from 5 control (2M/3F) and 4 aspirin treated (1M/3F) 
mice. Mice treated with 400mg/kg aspirin for 4 weeks. Magnification noted in bottom 
left corner of image. Error bars represent standard error. P-values determined by 








In addition to a decrease in stem cell marker and β-catenin expression, I noted a 
decrease in expression of the β-catenin signalling gene Tcf7 (Figure 7.12). The T-cell 
factor-7 (Tcf7) gene encodes the Tcf-1 protein which is the binding partner of 
nuclear β-catenin and facilitates the transcription of Wnt signalling genes. Aspirin 
treatment decreased Tcf7 RNA expression in both small intestine and colon ApcMin/+ 
mouse crypts from the 4-week treatment cohort. Exposure to aspirin reduced Tcf7 
RNA expression in the Apcflox/flox mouse organoids which were treated with 2mM 
aspirin for 12 days. These were the same samples which showed an increased 




Figure 7.12: Aspirin decreases TCF7 RNA expression in mouse crypts and 
organoids. Fold change of TCF7 RNA expression from ApcMin/+ mouse crypts and 
Apcflox/flox mouse organoids normalised to GAPDH RNA expression. Data from three 
technical replicates from a single independent experiment. ApcMin/+ and Apcflox/flox 
organoids treated with 400mg/kg aspirin for 4 weeks in vivo or 2mM aspirin for 12 
days in vitro respectively. Error bars represent standard error. P-values determined 
by students unpaired t-test. * p-value < 0.05 
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Paneth cells are an important cell within the innate immune system as the cells 
produce and secrete antimicrobial peptides including defensins and lysozyme 
(Clevers and Bevins, 2013).. The Paneth cells also provide the niche environment for 
the Lgr5 stem cells by producing Wnt ligands and other growth factors (Roth et al., 
2012). Loss of Paneth cells reduces the Lgr5+ population and the addition of Paneth 
cells to organoid culture greatly increases the efficiency of organoid growth from 
Lgr5+ cells (Clevers and Bevins, 2013; Farin et al., 2012). Paneth cells have been 
reported to modulate the stem cell population based on the availability of nutrients 
in calorie restricted mice (Yilmaz et al., 2012).  
Lysozyme expression has been widely used as a marker of Paneth cells (Yilmaz et 
al., 2012). Lysozyme immunohistochemistry staining was completed by Tam 
Jamieson at the Beatson institute on the 7-day treatment cohort. Aspirin exposure 
corresponded with a reduction in the number of lysozyme positive cells per mm2 of 
adenoma tissue (Figure 7.13). This can be interpreted as a decrease in Paneth cell 
number. To confirm this altered expression in lysozyme is a consequence of reduced 
Paneth cell number and not a reduction in lysozyme production, additional stains 
such as phloxine-tartrazine ,which staining the cytoplasmic granules of Paneth cells 
















Figure 7.13: Aspirin decreases Paneth cell number in vivo. 
Immunohistochemistry staining of Paneth cell marker, Lysozyme, in small intestine 
normal mucosa and adenoma in the 7-day treatment cohort (A). Corresponding 
graph of the number of Lysozyme stained cells per mm2 of small intestine adenoma 
tissue (B). Grading calculated as the average per mouse with mean determined 
from 5 control (5F) and 4 aspirin treated (1M/3F) mice. Mice treated with 2.6mg/ml 
aspirin in drinking water for 7 days. Magnification noted in bottom left corner of 
image. P-values determined by students unpaired t-test. * p-value < 0.05. M/F: 








7.6: Chapter discussion 
 
The benefit of growing organoids was that it enabled the investigation of the 
intestinal stem cell population in vitro. The growth of organoids as budding 
structures reflects the inverse formation of crypts so allows the stem cells and the 
stem cell environment to be studied (Sato et al., 2009). Aspirin treatment promoted a 
budding phenotype in Apc null organoids from ApcMin/+ mice, Apcflox/flox mice and 
human FAP tissue. The increase in the percentage of budding organoids may be a 
consequence of aspirin-mediated reversal of the cystic phenotype or aspirin-
mediated selection of the budding phenotype. The Apcflox/flox experiment suggests 
that aspirin can reverse the cystic phenotype as no budding organoids were 
apparent before aspirin treatment commenced. Although, the presence of irregular 
ruffled edged non-cystic organoids in untreated Apcflox/flox organoids was 
unexpected.  A possible explanation may be that the organoid is responding to 
cellular stress and the irregular ruffled edged organoids are in the process of 
rupturing rather than budding. This would suggest a proportion of the non-cystic 
organoids in aspirin treated Apcflox/flox organoids are also undergoing cell death thus 
the true percentage of budding organoids is reduced. To confirm this theory 
expression of apoptosis markers could be investigated or imaging of individual 
organoids on time-lapse microscopy to determine if irregular ruffled edges 
consistently results in organoids budding. This is the first report of aspirin 
promoting a budding phenotype in Apc null organoids.  
Aspirin exposure reduced the stem cell marker expression in all three organoid 
budding experiments. A reduction in Lgr5, OLFM4 and TROY RNA expression was 
observed in isolated crypts from the ApcMin/+ mice. Aspirin reduced Lgr5 RNA 
expression in the FAP colonic normal mucosa and adenoma organoids. There was 
no increase in Lgr5 or TROY detected between FAP normal mucosa and FAP 
adenoma organoids which would be expected due to dysregulated Wnt signalling. 
Lgr5 expression has been demonstrated to be increased in human adenomas and 
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adenocarcinomas after loss of Apc and subsequent dysregulation of Wnt signalling 
(Baker et al., 2015). A possible explanation for the lack of difference in stem cell 
marker expression between normal mucosa and adenoma is the presence of a mixed 
population in normal mucosa organoids. The normal mucosa organoids grew as a 
mixed cystic and budding population which likely indicates the presence of 
macroscopically undetectable micro adenomas on the normal mucosa. There was an 
increase in Lgr5 and TROY RNA expression between wild-type mouse organoids 
and Apcflox/flox mouse organoids. Aspirin exposure subsequently decreases both Lgr5 
and TROY RNA expression in Apcflox/flox organoids. A reduction in Lgr5 protein 
expression was observed in human organoids after a short 4hour treatment.  
The lack of an effective Lgr5 immunohistochemistry antibody was a challenge but 
fortunately the detection of Lgr5 transcripts in colorectal adenomas using 
RNAscope had recently been published (Baker et al., 2015). Adenomas had higher 
expression of Lgr5 which was decreased in aspirin treated ApcMin/+ mice. There was a 
noticeable heterogeneity in Lgr5 expression in adenomas which has been previously 
described in human adenomas (Baker et al., 2015).  There are no published reports 
of the effects of aspirin in intestinal stem cells or Lgr5 expression. This is the first 
description of aspirin reducing stem cell marker expression both in vivo, ApcMin/+ 4-
week treatment experiment, and in vitro, FAP and Apcflox/flox organoids. A strength 
of this research is the replication in three separate experiments including both in 
vivo and in vitro experiments and mouse and human tissue. 
While Lgr5, TROY and OLFM4 expression was consistently decreased after aspirin 
treatment, SOX9 expression was increased. SOX9 is a Wnt target gene and 
transcription factor with roles in cell proliferation and can activate the promoter of 
the stem cell marker Bmi-1 (Espersen et al., 2015). SOX9 positive cells exhibit self-
renewal and the ability to maintain a cellular population which confirms its validity 
as an intestinal stem cell marker (Espersen et al., 2015). SOX9 expression was 
increased in ApcMin/+ adenomas with an increase in expression detected after 7-day 
aspirin treatment. This was unexpected and may be due to the short duration of 
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treatment or may reflect a true aspirin-mediated increase. A possible explanation for 
the SOX9 expression pattern to vary from the other stem cells is the reported 
expression of SOX9 in reserve stem cells which do not express Lgr5 (Roche et al., 
2015). The loss of Lgr5 positive stem cells is reported to result in an increased 
reserve stem cell population as a compensatory mechanism (Tian et al., 2011). The 
expression of SOX9 by these reserve stem cells would explain the increased SOX9 
expression in the 7-day treatment cohort. To evaluate this theory, 
immunohistochemistry of markers of reserve stem cells, such as Bmi-1, could be 
completed on the adenomas (Sangiorgi and Capecchi, 2008). Additionally, SOX9 
expression should be evaluated in the ageing and 4-week treatment cohorts to 
determine the effects of longer duration of aspirin treatment on SOX9 expression. 
It was anticipated that the spheroid formation assays would bridge the link between 
EMT and stem cell phenotype as it had been demonstrated in the literature that 
spheroids undergo EMT thus are a more mesenchymal population (Han et al., 2013). 
The CRC cell spheroids are reported to have increased expression of the stem cell 
marker, Lgr5, and reduced epithelial cell marker, CK20 (Han et al., 2013). The 
spheroids display increased motility and invasion using in vitro assays (Han et al., 
2013). Spheroids expressed high expression of mesenchymal markers, vimentin and 
α-SMA, with decreased E-cadherin expression (Han et al., 2013). In our experiment, 
there was no alteration to the EMT markers between adherent cells and spheroids 
which suggests a failure to efficiently induce spheroid formation. The increased 
motility was noted by an increase in phosphorylated cofilin between adherent cells 
and spheroids. The primary challenge with the spheroids was the lack of a 
consistent loading control. This inconsistency in the cytoskeletal markers may be a 
consequence of poor whole cell lysis or a technical error in the western blotting. The 
conditions of our spheroid formation experiments were consistent with those 
reported in the literature. However, the time the spheroids were in culture for initial 
spheroid establishment was not reported (Han et al., 2013). Despite observing 
spheroids 3-days after seeding adherent cells in low attachment culture plates, the 
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alterations in EMT and stem cell marker expression may require a prolonged 
duration in culture.  
Aspirin-mediated Wnt inhibition has been demonstrated before as a decrease in 
nuclear β-catenin and reduction in Wnt target gene expression (Bos et al., 2006; Lan 
et al., 2011). The importance of the Wnt signalling pathway in intestinal stem cells is 
illustrated by the dependency of Wnt ligands in the culture of organoids from 
intestinal crypts (Sato et al., 2009). Organoids grown from Apc deficient tissues and 
thus increased Wnt signalling activity grow as cystic structures rather than the 
characteristic budding structures observed in organoids derived from normal 
intestinal mucosa (Sato et al., 2011b). The organoid budding and stem cell marker 
results are indicative of aspirin’s inhibition on the Wnt signalling pathway. Aspirin 
treatment reduces β-catenin expression in CRC cell lines with a specific reduction in 
nuclear β-catenin detected in HCT116 cells after 16 and 24 hour treatments. Aspirin 
treatment decreased the β-catenin expression in small intestinal adenomas in the 4-
week treatment cohort. In addition to the reduction in β-catenin expression in vitro 
and in vivo, aspirin decreased RNA expression of the β-catenin binding partner, 
Tcf7. Tcf7 gene encodes the TCF-1 protein which along with β-catenin activates the 
transcription of Wnt target genes (Cadigan and Waterman, 2012). Expression of the 
nuclear β-catenin binding proteins, TCF/LEFs, can be regulated directly by Wnt 
signalling (Cadigan and Waterman, 2012). The mechanisms responsible for the 
decrease in β-catenin and Tcf7 expression have not been determined but it is clear 
that aspirin is decreasing Wnt signalling. This may explain both the promotion of 
organoid budding and reduction in stem cell expression.  
Paneth cells are an important cell type in the innate immune system with the 
secretion of antimicrobial peptides such as defensins and lysozyme (Clevers and 
Bevins, 2013). In addition to the antimicrobial role, Paneth cells are also key in 
regulating the intestinal stem cell environment (Clevers and Bevins, 2013). Paneth 
cells produce EGF and ligands for the Wnt and notch signalling pathways, Wnt3 
and DII4 respectively, to maintain the stem cell niche (Clevers and Bevins, 2013). 
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The presence of Paneth cells in organoid culture greatly improves the ability of Lgr5 
cells to form budding organoid structures (Clevers and Bevins, 2013).  A recent 
paper detailed a shift in the intestinal crypt cell population, in response to calorie 
restriction, with an increase in stem cells and decrease in transit amplifying cells 
observed (Yilmaz et al., 2012).  This was demonstrated to be in response to Paneth 
cell modulation as calorie restricted Paneth cells promoted organoid formation to a 
greater extent than those from mice on an ab lib diet (Yilmaz et al., 2012). Activation 
of mTORC1 signalling in the Paneth cells prevented the increase in stem cells 
despite calorie restriction while inhibition of mTORC1, with rapamycin treatment, 
increased both intestinal stem cells and Paneth cells (Yilmaz et al., 2012). Therefore, 
decreased mTORC1 activity, due to calorie restriction, increased the frequency of 
Paneth cells and intestinal stem cells (Yilmaz et al., 2012).  
Aspirin treatment decreased the number of lysozyme positive cells in ApcMin/+ small 
intestine adenomas after a 7-day treatment which mirrors the reduction in stem cell 
marker expression. Lysozyme expression has been routinely used as a specific 
marker of Paneth cells (Yilmaz et al., 2012). However, to confirm a reduction in 
Paneth cells and not simply a reduction in lysozyme production, other histological 
stains could be used including phloxine-tartrazine which staining the cytoplasmic 











Chapter 8: The effect of aspirin on the mTOR 
signalling pathway  
 
 
8.1: Introduction     
 
The mechanistic target of rapamycin (mTOR) pathway is a key signalling hub 
involved in cellular metabolism, proliferation, motility and survival (Laplante and 
Sabatini, 2009). The signalling pathway is composed of two complexes; mTORC1 
and mTORC2 (Laplante and Sabatini, 2009).There is an elevated expression of 
mTORC1 and mTORC2 components in colorectal cancer with knockdown of either 
complex resulting in decreased proliferation and inhibition of tumour growth in 
vivo from xenografts (Gulhati et al., 2009). This increase in mTOR signalling was 
also detected in adenomas formed after Apc deletion with inhibition of mTORC1 
decreasing both the number and size of adenomas formed (Fujishita et al., 2008). 
The activation of mTORC1 signalling and subsequent mediation of translation 
elongation is crucial for cell proliferation and tumorigenesis following Apc loss 
(Faller et al., 2015). It is clear that mTOR signalling pathway is critical in colorectal 
cancer initiation and progression. In addition to the effects of mTOR in colorectal 
pathogenesis, mTORC1 activity can regulate the intestinal stem cells by modulating 
Paneth cell activity, highlighting the importance of the mTOR signalling pathway in 
intestinal regeneration and stem cell maintenance.  (Yilmaz et al., 2012).  
The mTORC1 is the best characterized complex and its roles in protein synthesis, 
lipid synthesis and cell survival are well studied (Figure 8.1A). mTORC1 has a 
positive effect on cellular growth by increasing protein synthesis via the 
phosphorylation of S6 kinase 1(S6K1) and eukaryotic translation factor 4E binding 
protein 1 (4E-BP1) results in increased synthesis of mRNA, translation initiation and 
translation elongation (Laplante and Sabatini, 2012). mTORC1 controls lipid 
synthesis by regulating the sterol regulatory element-binding protein 1/2 
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(SREBP1/2) transcription factors which are responsible for expression fatty acid and 
cholesterol synthesis genes (Lamming and Sabatini, 2013). mTORC1 inhibits 
autophagy and promotes cell survival by inhibited of the initiation of autophagy by 
suppression of the ULK1/Atg13/FIP200 (unc-51-like kinase 1/ mammalian 
autophagy-related gene 13/ focal adhesion kinase family-interacting protein of 
200kDa) complex (Laplante and Sabatini, 2012). 
mTORC1 activity can be influenced by several upstream signalling pathways with 
the majority acting via the TSC1/2 complex, composed of tuberous sclerosis 1 (TSC1 
or Hamartin) and tuberous sclerosis 2 (TSC2 or Tuberin), which negatively regulates 
mTORC1 activity (Laplante and Sabatini, 2012). Downstream signalling from the 
Ras, PI3K and Wnt signalling pathways can all regulate mTORC1 activity (Figure 
8.1B) (Laplante and Sabatini, 2012). mTORC1 activity can also be regulated by 
inflammation, energy balance, hypoxia and DNA damage (Inoki et al., 2012). 
Adenosine monophosphate-activated protein kinase (AMPK) is an energy sensor 
which can inhibit mTORC1 signalling by enhancing TSC2 activity and an inhibitory 
phosphorylation of the Raptor subunit (Inoki et al., 2012). Hypoxia can suppress 
mTORC1 activity by several mechanisms including the inhibition of TSC1/2 and 
mTORC1 by AMPK dependent and independent mechanisms (Wouters and 
Koritzinsky, 2008). Therefore, mTORC1 regulates cellular growth and survival 
based on the available nutrients and growth factor signalling. 
The second mTOR complex, mTORC2, is primarily thought to regulate cell motility 
and cell survival, although due to the feedback between the mTOR complexes, 
mTORC2 can also indirectly regulate mTORC1 activity (Laplante and Sabatini, 
2012). mTORC2 phosphorylates and activates protein Kinase C alpha (PKCα) 
resulting in activation of the small GTPases Rac1, RhoA and Cdc42 which are 
critical mediators of cell motility and actin cytoskeleton organization (He et al., 2013; 
Jacinto et al., 2004; Morrison et al., 2015).  The upstream signalling of mTORC2 is 
not well understood, but it is known that PI3K signalling, glycogen synthase kinase 
3β (GSK3-β) and S6K1 can all regulate mTORC2 activity (Chen et al., 2011);(Dibble 
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et al., 2009). This overlap in signalling between mTORC1 and mTORC2 is important 
when considering which complex is responsible for cellular effects. 
The epithelial-mesenchymal transition can be regulated by the mTOR pathway in 
both colon and prostate cancer (Chen et al., 2014; Gulhati et al., 2011). The knockout 
of raptor and rictor, components of mTORC1 and mTORC2 respectively, inhibited 
the induction of EMT in CRC cell lines and prevented metastasis in vivo (Gulhati et 
al., 2011). In both colon and prostate cancer cells, these effects were determined to be 
RhoA and Rac1 dependent (Chen et al., 2014; Gulhati et al., 2011). In renal cell 
carcinoma, induction of both Akt and mTOR signalling pathways were correlated 
with induction EMT (Yang et al., 2016). The mTOR pathway has been demonstrated 
to be critical in the initial proliferation following Apc loss and adenoma formation 
and also important in EMT and CRC metastasis.   
Previous work in our group has demonstrated that aspirin can reduce mTOR 
signalling and subsequently induce autophagy in CRC cell lines (Din et al., 2012). 
Aspirin inhibited the phosphorylation of S6K1 and 4E-BP1 which are the 
downstream components of mTORC1 involved in protein synthesis (Din et al., 
2012). The aspirin-mediated inhibition of mTOR signalling was determined to a 
result of both AMPK-dependent and AMPK-independent mechanisms (Din et al., 
2012). Whilst the effects of aspirin on the mTOR signalling pathway in vitro has 
been determined, there is a lack of confirmation by in vivo experiments. The aim of 
this research is to investigate the effects of aspirin on the mTOR signalling pathway 
in vivo using models of intestinal tumorigenesis including ApcMin/+ and Apcflox/flox 














Figure 8.1: mTORC1 signalling pathway. Simplified diagram of mTORC1 effects 
on protein synthesis, lipid synthesis and cell survival (A). Overview of mTORC1 
regulation in the cell with activity dependent on energy balance, inflammation, 



































8.2: Baseline mTOR expression in adenomas 
 
In conjunction with the host group’s study into aspirin-mediated inhibition of the 
mTOR signalling pathway, I completed immunohistochemistry staining and 
grading of mTOR marker expression in small intestinal ApcMin/+ adenomas and 
Apcflox/flox tissue. The three markers of mTOR signalling studied were p-4E-BP1, p-S6 
and p-eEF2. All three markers are phosphorylated by mTORC1 signalling. 
Phosphorylation of 4E binding protein 1 (4E-BP1) and S6 ribosomal protein results 
in an activation of cap-dependent translation and an increase in translation of 
mRNA transcripts respectively. Eukaryotic elongation factor 2 (eEF2) catalyses the 
peptidyl-tRNA translocation on the ribosome with phosphorylation of eEF2 
inhibiting this activity and inhibiting peptide chain elongation. 
Before evaluating aspirin-mediated effects on protein expression, it is important to 
determine baseline expression differences between normal mucosa and adenoma 
tissue. ApcMin/+ mouse small intestine and colon tissue was stained for mTOR marker 
expression (Figure 8.2A). Adenomas have an increase in p-4E-BP1 and p-S6 
expression with minimal p-eEF2 expression which indicates an increase in mTOR 
signalling. The difference in mTOR signalling between normal colonic mucosa and 
colonic adenomas was determined in human FAP patients (Figure 8.2B). In human 
tissue there is little difference in p-4E-BP-1 and p-S6 expression but there is 














Figure 8.2: Expression differences in ApcMin/+ mouse and human FAP tissue. 
Immunohistochemistry staining of ApcMin/+ small intestine and colon (A) and FAP 
normal colonic mucosa and colonic adenomas (B). Phospho-S6, phospho-4E-BP1 
and phospho-eEF2 staining. Images captured by nanozoomer slide scanner with 






8.3: Aspirin inhibits the mTOR pathway in ApcMin/+ mouse small 
intestine adenomas 
 
Aspirin treatment decreases p-4E-BP1 and increases p-S6 and p-eEF2 protein 
expression in small intestinal adenomas in both the 4-week treatment cohort (Figure 
8.3) and the 7-day treatment cohort (Figure 8.4). The reduction in p-4E-BP1 and 
increase in p-eEF2 protein expression in the small intestinal adenomas suggests 
aspirin-mediated inhibition of the mTOR signalling pathway. However, the 
increased p-S6 protein expression after aspirin exposure in both cohorts was 
unexpected and may suggest an increased concentration of aspirin or increased 
duration of treatment is required for inhibition of p-S6.  
Aspirin exposure decreases both p-4E-BP1 and p-S6 protein expression in small 
intestinal adenomas in the ageing cohort along with increasing p-eEF2 expression 
(Figure 8.5). Exposure to aspirin decreases the percentage of BrdU positive cells per 
adenoma illustrating a reduction in proliferation in the small intestine adenomas of 
the ageing cohort. The results from the ageing cohort demonstrate that aspirin 

















Figure 8.3: mTOR marker expression in 4-week treatment cohort. Images of 
immunohistochemistry staining for p-4E-BP1, p-S6 and p-eEF2 in small intestine 
(A). Grading of staining intensity in 31 control and 22 aspirin treated small intestine 
adenomas for p-4E-BP1 (B). Grading of staining intensity in 35 control and 37 
aspirin treated small intestine adenomas for p-S6 (C). Grading of staining intensity in 
31 control and 22 aspirin treated small intestine adenomas for p-eEF2 (D). 
Adenomas from 5 control (2M/3F) and 4 aspirin treated (1M/3F) mice. Mice treated 
with 400mg/kg aspirin for 4 weeks. Error bars represent standard error. P-values 
determined by students unpaired t-test. * p-value < 0.05. M/F: number of male and 






Figure 8.4: mTOR marker expression in 7-day treatment cohort. Images of 
immunohistochemistry staining for p-4E-BP1, p-S6 and p-eEF2 in small intestine 
(A). Grading of staining intensity in small intestine adenomas for p-4E-BP1 (B), p-S6 
(C) and p-eEF2 (D). Staining and counts calculated as the average per mouse with 
mean determined from 5 control (5F) and 4 aspirin treated (1M/3F) ApcMin/+ mice. 
Mice treated with 2.6mg/ml aspirin in drinking water for 7 days. Error bars represent 
standard error. P-values determined by students unpaired t-test. * p-value < 0.05. 







Figure 8.5: mTOR marker expression in ageing treatment cohort. Images of 
immunohistochemistry staining for p-4E-BP1, p-S6, p-eEF2 and BrdU in small 
intestine (A). Grading of staining intensity in small intestine adenomas for p-4E-BP1 
(B), p-S6 (C) and p-eEF2 (D). Counts of percentage BrdU positive cells per small 
intestine adenoma (E). Staining and counts calculated as the average per mouse 
with mean determined from 8 control (6M/2F) and 8 aspirin treated (6M/2F) ApcMin/+ 
mice. Mice treated with 2.6mg/ml aspirin in drinking water at emergence of pale feet 
until culled Error bars represent standard error. P-values determined by students 
unpaired t-test. * p-value < 0.05. M/F: number of male and female mice per group. 
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8.4: The effect of aspirin on the Apcflox/flox mouse cohorts 
 
The loss of Apc is a common initiating mutation in sporadic CRC with 80% of 
sporadic CRC tumours containing a mutation in the Apc gene (Cancer Genome 
Atlas Network, 2012). In addition to the previously described ApcMin/+ mouse model, 
a commonly used model of CRC initiation is the Apcflox/flox mouse model (Jackstadt 
and Sansom, 2016). Using cre-lox tecghnology both alleles of the Apc gene can be 
conditionally knocked out which results in a crypt progenitor phenotype, 
characterised by the aberrant cell proliferation in the crypt (Sansom et al., 2004). 
mTOR signalling activity is increased in Apcflox/flox mice with mTORC1 activity 
required for development of the crypt progenitor phenotype (Faller et al., 2015). 
Therefore, the use of the Apcflox/flox mouse model allows the study of the effect of 
aspirin on the mTOR signalling pathway following the loss of Apc. 
Tissue from 2 wild-type, 2 Apcflox/flox control and 3 Apcflox/flox aspirin treated mice 
were processed for immunohistochemistry. Deletion of the Apc gene in the small 
intestine initiates a hyperproliferative phenotype observed as an increase in crypt 
height and increased percentage of the BrdU positive cells per crypt (Sansom et al., 
2004). Aspirin treatment for 4 days, after deletion of Apc, significantly decreases the 
crypt height in the small intestine (Figure 8.6). Aspirin treatment decreases the 
percentage of positive BrdU cells in the small intestine crypts indicating a decrease 
in cellular proliferation in the Apcflox/flox mice. These results demonstrate that aspirin 
treatment inhibits the hyperproliferative phenotype observed by deletion of the Apc 
gene in the small intestine.  
An investigation of the effects of aspirin on the mTOR signalling pathway was 
evaluated by immunohistochemistry. Due to the limited number of floxed mice in 
the study it was difficult to evaluate if expression differences were a result of aspirin 
exposure or individual mouse variation. The increase in β-catenin with Apc deletion 
was observed in the Apcflox/flox mice but no changes in β-catenin expression observed 
with aspirin exposure (Figure 8.7). This may be due to a short, 4day, treatment and a 
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prolonged treatment duration may be required or a reflection of the few mice per 
treatment group. There was an increase in mTOR signalling in the Apcflox/flox mice 
observed as an increase in p-4E-BP1 and p-S6 and decrease in p-eEF2 expression.  
Aspirin increased p-S6 and p-eEF2 expression with no changes to p-4E-BP1 
expression.  
Combining the in vivo mouse model data, aspirin is increasing p-eEF2 expression 
consistently across ApcMin/+ and Apcflox/flox treatment cohorts. Aspirin treatment has 
decreased p-4E-BP1 expression in all ApcMin/+ cohorts but no change detected in 
Apcflox/flox mice. The effect of aspirin on p-S6 expression in vivo has been variable 
with increased expression noted in the short-term experiments such as the 7-day 
ApcMin/+ cohort and Apcflox/flox cohort but decreased expression observed with longer 
treatment in the ageing cohort. Aspirin exposure has resulted in reduced cellular 
proliferation in adenomas and crypts in ApcMin/+ and Apcflox/flox models respectively. 
This reduction in proliferation may be a consequence of mTOR signalling inhibition 
as mTORC1 signalling has been demonstrated to be required for the crypt 
















Figure 8.6: Aspirin inhibits the hyperproliferative phenotype in small intestine 
of Apcflox/flox mice. Haematoxylin & Eosin (H&E) and BrdU staining of small intestine 
(A). Crypt height measured from H&E images with fifty 10x images per treatment 
cohort (B). Percentage of BrdU positive cells per crypt measured from fifty crypts per 
treatment cohort (C). Images from 2 wildtype (2M), 2 Apcflox/flox control (2M) and 3 
Apcflox/flox aspirin treated (3M) mice. Mice treated with 2.6mg/ml aspirin in drinking 
water for 4 days after recombination. Images captured by nanozoomer slide scanner 
wither either 10x or 20x magnification as indicated. Error bars represent standard 
error. P-values determined from students unpaired t-test. * p-value < 0.05. M/F: 





Figure 8.7: Immunohistochemistry staining of Apcflox/flox mouse small intestine. 
Representative images of β-catenin, p-4E-BP1, p-eEF2 and p-S6 staining of wild 
type and both control and aspirin treated Apcflox/flox small intestine. Apcflox/flox mice 
were treated with 2.6mg/ml aspirin in drinking water for 4 days following 
recombination. Images captured by nanozoomer slide scanner with either 10x or 
20x magnification as indicated.  
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8.5: Chapter discussion 
 
Analysis of expression of mTOR signalling components in human colorectal tissue 
demonstrated an increased expression of p-mTOR, p-S6K1 and p-4E-BP1 in both 
human colorectal adenomas and carcinomas indicating increased mTOR activity 
(Zhang et al., 2009). Inhibition of mTOR decreased cell growth in CRC xenograft 
models (Zhang et al., 2009). It has been previously reported that the mTOR 
signalling pathway activity is increased in small intestine adenomas after Apc loss 
with inhibition of mTORC1 shown to reduce the number and size of adenomas 
(Fujishita et al., 2008). This increase in mTORC1 signalling was confirmed in our 
ApcMin/+ mouse cohorts and human FAP tissue. There was an increase in p-4E-BP1 
and p-S6 expression and decreased p-eEF2 expression indicating increased 
mTORC1 activity in ApcMin/+ and FAP adenomas compared to normal mucosa.  
Aspirin’s inhibition of the mTOR signalling pathway has previously been 
demonstrated in our laboratory with aspirin treatment decreasing cell proliferation 
and promoting autophagy (Din et al., 2012). This previous research was completed 
in CRC cell lines with the purpose of this project to investigate the effects of aspirin 
in ApcMin/+ mouse adenomas. The effect of aspirin treatment on the mTOR signalling 
pathway within ApcMin/+ adenomas was established by immunohistochemistry for 
mTOR marker expression and cellular proliferation. Aspirin treatment consistently 
decreased p-4E-BP1 and increased p-eEF2 expression in ApcMin/+ adenomas in all the 
treatment cohorts. Aspirin’s effect on p-S6 expression was varied with increased 
expression detected in Edinburgh 4-week and Beatson 7-day treatment cohorts but 
decreased in the Beatson ageing cohort. This may due to the duration of treatment 
with only the longest treated mice, the ageing cohort, showing a reduction in p-S6 
expression. Aspirin exposure also decreased proliferation in the ApcMin/+ adenomas 
from the ageing mice cohort as detected by BrdU staining. This reduction in cellular 
proliferation is most likely a consequence of mTOR inhibition but mTOR 
dependency has not been confirmed.   
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Conditional knockout of Apc, using cre-lox technology, in the small intestine results 
in an increase in cellular proliferation and alters the crypt-villus architecture 
(Sansom et al., 2004). This was observed as an increased crypt height and increased 
percentage of BrdU positive cells, due to aberrant cellular proliferation, which is 
termed the crypt progenitor phenotype (Sansom et al., 2004). Following acute Apc 
loss in Apcflox/flox mouse models the mTORC1 signalling pathway is activated (Faller 
et al., 2015). Inhibition of mTORC1 activity, by either rapamycin or raptorflox/flox, 
reduced the crypt height and thus prevented the crypt progenitor phenotype (Faller 
et al., 2015). mTORC1 mediated translation elongation is crucial for cell proliferation 
and the development of the crypt progenitor phenotype (Faller et al., 2015). 
Aspirin treatment for 4 days was sufficient to reduce the crypt height and 
percentage of positive BrdU cells per crypt. These results indicate that aspirin is 
reducing cellular proliferation following Apc loss and subsequently reducing the 
crypt progenitor phenotype. The results with aspirin treatment resemble the 
reported effects of mTORC1 inhibition as demonstrated by rapamycin treatment 
and knockout of raptor protein. An increase in p-eEF2 protein expression was 
detected in aspirin treated Apcflox/flox mice indicating a reduction in protein 
translation which is consistent with mTORC1 inhibition. The other mTOR markers, 
p-4E-BP1 and p-S6, did not show a decreased expression which may be due to the 
short duration of aspirin treatment. The small sample size and individual mouse 
variation was a challenge when evaluating the effect of aspirin on the mTOR 
markers in the Apcflox/flox mouse cohort and this experiment could be improved by 
the addition of mice to each treatment group. The combination of decreased mTOR 
signalling in ApcMin/+ adenomas demonstrates aspirin-mediated mTOR inhibition. 
The reduction in cellular proliferation in both ApcMin/+ and Apcflox/flox mouse models is 





Chapter 9: Summary and discussion 
 
In this thesis, I have demonstrated that aspirin exposure reduces the migration, 
invasion and single cell motility of CRC cells. Aspirin inhibits the ROCK1 signalling 
pathway in CRC cell lines and human colonic organoids whilst promoting the 
mesenchymal-epithelial transition in CRC cell lines, human colonic organoids and 
in vivo. Aspirin reverses the cystic phenotype and reduces the stem cell population 
in Apc deficient organoids of both mouse and human origin. Aspirin also reduces 
the Paneth cell number in ApcMin/+ small intestine adenomas. Aspirin inhibits both 
the Wnt and mTOR signalling pathways in vivo. Whilst the signalling pathway 
responsible for these effects has not been determined it is clear that aspirin is 
promoting a less motile epithelial phenotype and reducing the stem cell population 
which may explain, in part, the post-diagnosis benefits of aspirin treatment in 
colorectal cancer.  
The epithelial-mesenchymal transition is a physiological process most commonly 
associated with embryogenesis and organ development. There has been minimal 
research investigating the effect of aspirin on developmental EMTs although it has 
been demonstrated that aspirin-triggered resolvin D1 can inhibit EndMT (Shu et al., 
2016). The endothelial-mesenchymal transition (EndMT) is a similar process to EMT 
and involves the transformation of vascular endothelial cells into mesenchymal cells 
(Thiery, 2003). EndMT is important for embryonic development, tissue repair and 
disease pathogenesis including cancer progression (Thiery, 2003). In cancer 
progression the EndMT can induce the formation of cancer-associated fibroblasts 
which contributes to tumour progression and metastasis and can be regulated by 
TGF-β signalling (Shu et al., 2016). TGF-β induced EndMT, increased migration in 
Human umbilical vein vascular endothelial cell lines (HUVECs) which was reversed 
with aspirin-triggered resolvin D1 (AT-RvD1) (Shu et al., 2016). Resolvins are 
involved in the resolution of inflammation with AT-RvD1 often reported to 
modulate allergic responses and reduce inflammation (Rogerio et al., 2012). This 
research does not investigate the direct effect of aspirin on EndMT induction or the 
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migration of HUVECs. There are numerous developmental EMTs occurring during 
embryogenesis and organ development but aspirin exposure has not been 
investigated previously in this context. Considering that aspirin inhibits cell 
migration and promotes the mesenchymal-epithelial transition in cancer cells, the 
effects of aspirin on developmental EMTs should be determined as may contradict 
the administration of aspirin during embryogenesis.  
The effect of aspirin of cell migration, invasion and EMT has predominately been 
studied in regards to platelet effects. Platelet-cancer interactions have been reported 
to aid the formation of metastasis and subsequent tumour growth. A key 
mechanism is the aggregation of platelets by tumour cells, termed tumour cell-
induced platelet aggregates (TCIPA) (Jurasz et al., 2004). The ability of tumour cells 
to induce formation of TCIPA is advantageous for metastasis as TCIPA aids the 
survival of tumour cells in the circulatory system, facilitates adhesion to vascular 
endothelium and stimulates tumour growth by secretion of growth factors (Jurasz et 
al., 2004). The presence of platelets helps survival in the circulatory system by 
coating the tumour cells thus allowing evasion from the immune system and 
protecting tumour cells from the shearing forces in flowing blood (Jurasz et al., 
2004). The presence of platelets is associated with the induction of EMT and 
secretion of MMPs which facilitates tumour cell invasion, extravasation and tumour 
growth (Santilli et al., 2016).  
Platelets secrete α-granules containing platelet-derived growth factor (PDGF) and 
transforming growth factor-β (TGF-β) which can induce EMT and increase invasion 
in epithelial tumours (LOU et al., 2014). Exposure to platelets induced EMT and 
increased the invasive capacity of colon carcinoma cell lines by activating the TGF-β 
signalling pathways in the tumour cells (Labelle et al., 2011). Platelet-derived TGF-
β1, released upon platelet activation, is required for the formation of lung metastasis 
in vivo (Labelle et al., 2011). Platelet-derived growth factor receptor (PDGFR) 
expression correlates with platelet activation, TGF-β signalling, EMT induction and 
liver metastasis in human CRC (Steller et al., 2013). Aspirin irreversibly inhibits 
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platelet cyclo-oxygenase 1 (COX-1) leading to the suppression of thromboxane 
production and subsequent platelet aggregation (Patrono, 2015). Thromboxane 
expression promotes platelet activation, aggregation and release of α-granules (LOU 
et al., 2014). Therefore, it has been hypothesised that the aspirin-mediated reduction 
in cancer mortality is a consequence of platelet inhibition and thus inhibition of 
EMT, invasion and metastasis. 
Therefore, investigations into the effects of aspirin on EMT has focused 
predominately on the role of platelets. Co-culture of platelets with the metastatic 
ovarian cancer cell line, SK-OV-3, induced EMT and increased invasion (Cooke et 
al., 2015). EMT was observed as loss of cell-cell junctions, decreased E-cadherin and 
increased vimentin expression which was attributed to the increase in the EMT 
transcription factor, snail (Cooke et al., 2015). The mechanism responsible for the 
platelet induced EMT has been attributed to the formation of TCIPA (Cooke et al., 
2015). Pre-treatment of platelets with low-dose aspirin, 20μM, reduced the invasive 
capacity compared to non-treated platelets (Cooke et al., 2015). However, there were 
no changes in EMT induction (Cooke et al., 2015).  
In CRC, the co-culture of platelets with the HT-29 cell line, enhanced the metastatic 
ability of the CRC cells (Guillem-Llobat et al., 2016). In vivo metastasis models were 
achieved by injection of CRC cells into the tail vein of immune-deficient nude mice 
which resulted in lung metastasis (Guillem-Llobat et al., 2016). A proaggregatory 
phenotype, defined as enhanced platelet activation, was observed in vivo after 
injection of HT-29 cell exposed to platelets (Guillem-Llobat et al., 2016). Exposure to 
platelets induced EMT in HT-29 cells as observed by reduced E-cadherin and 
increased twist expression (Guillem-Llobat et al., 2016). Platelets pre-treated with 
aspirin inhibited the induction of EMT, reduced the metastatic potential of HT-29 
cells and prevented the proaggregatory phenotype (Guillem-Llobat et al., 2016). The 
effects on EMT were attributed to aspirin COX-1 inhibition and subsequent 




In addition to these effects, platelets have been demonstrated to influence the stem 
cell population by PDGF signalling. PDGF is reported to be critical for the initiation 
and maintenance of cancer stem cells in gliomas (Jiang et al., 2011). PDGF signalling 
is required for self-renewal, proliferation and differentiation of cancer stem cells 
with inhibition of PDGF reducing tumorigenic capacity of cancer stem cells in vivo 
(Jiang et al., 2011). There is growing evidence to suggest aspirin-mediated platelet 
inhibition may be responsible for inhibition of EMT, decreased invasion and 
reduced metastasis in epithelial cancers.  However, this thesis demonstrates that 
aspirin reduces invasion, promotes the mesenchymal-epithelial transition and 
reduces stem cell population in the absence of platelets. Combined, these results 
indicate that aspirin can promote a less invasive epithelial phenotype in tumour 
cells by both platelet-dependent and platelet-independent mechanisms.  
Prostaglandin E2 (PGE2) is downstream of cyclooxygenase (COX) and expression 
has been reported to both induce and inhibit EMT. PGE2  is inactivated by 
prostaglandin dehydrogenase (PGDH) (Mann et al., 2006). Epidermal growth factor 
(EGF) represses PGDH protein expression in CRC cell lines by increasing snail, an 
EMT transcription factor, expression (Mann et al., 2006). Snail specifically represses 
PGDH expression by binding to the PGDH promoter (Mann et al., 2006). These 
results suggest that increased PGE2 expression may be a consequence of EMT 
induction rather than the cause. PGDH expression is decreased in multiple human 
cancers, including liver and lung, compared to normal mucosa with lowest 
expression in metastatic tumours (Mann et al., 2006). Increased expression of PGE2 
and reduced PGDH activity correlated with snail expression (Mann et al., 2006). 
PGE2 and hypoxia both individually induced EMT in LIM1863 cells, a CRC cell line 
(Young et al., 2013). Hypoxia also reduced PGDH expression in LIM1863 to suggest 
that hypoxic regions of tumours can reduce PGDH activity, increase PGE2 
expression and induce EMT (Young et al., 2013). However, exposure to PGE2 can 
also inhibit both cell migration and the induction of EMT. PGE2 exposure initially 
increased cell migration in human bronchial epithelial cells (HBECs) although after 
EMT induction, exposure to PGE2 reduced cell migration (Li et al., 2015). PGE2 
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exposure completely inhibited induction of EMT in Madin-Darby canine kidney 
(MDCK) cells, a renal cell line, due to inhibition of reactive oxygen species (ROS) 
(Zhang et al., 2006). The literature suggests that PGE2 exposure induces EMT in 
cancer cell lines but inhibits EMT in non-cancerous epithelial cell lines such as 
MDCK cells. 
PGE2 has a role in regulating the stem cell population with PGE2 exposure 
increasing Lgr5+ crypt viability and proliferation as observed by organoid culture 
(Fan et al., 2014). PGE2 exposure results in increased numbers of Lgr5+ cells and 
increased Wnt signalling activity, detected by Axin2 and β-catenin expression, in 
organoid culture (Fan et al., 2014). PGE2 modified the Wnt signalling pathway in 
hematopoietic stem cells by stabilising β-catenin via phosphorylation of GSK3β and 
β-catenin (Goessling et al., 2009). Inhibition of PGE2 inhibited Wnt signalling in 
hematopoietic stem cells (Goessling et al., 2009). PGE2 can also activate the Wnt 
signalling pathway by inactivation of GSK3β in a PI3K/Akt signalling dependent 
manner (Castellone et al., 2005). In ApcMin/+ mice, PGE2 exposure increases the stem 
cell population in adenomas and promotes liver metastasis after injection of tumour 
cells into the cecal wall of immunocompromised mice by activating the PI3K/Akt 
signalling pathway (Wang et al., 2015a). Inhibition of PGE2 by celecoxib, a specific 
COX-2 inhibitor, reduced the stem cell population and reduced liver metastasis 
(Wang et al., 2015a). Thus PGE2 exposure can induce migration, EMT and increase 
the stem cell population by several mechanisms including activation of Wnt and 
PI3K signalling.  
Aspirin is a potent inhibitor of prostaglandin synthesis which suggests aspirin 
would inhibit PGE2 stimulated EMT although this has not been reported. Inhibition 
of EMT in breast cancer cell lines was achieved by inhibition of COX-2 expression 
which was determined to be partially dependent on PGE2 expression (Cao et al., 
2014).  Specific COX-2 inhibitor, apricoxib, inhibited EMT and PGE2 expression in 
CRC cell lines (Kirane et al., 2012). This inhibition of EMT is not observed with all 
NSAIDs with indomethacin exposure inducing cell migration and EMT in non-small 
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cell lung carcinoma cells (Kato et al., 2011). Indomethacin is a COX-2 specific 
inhibitor and reduces PGE2 synthesis whilst inducing EMT in lung cancer cells (Kato 
et al., 2011). Indomethacin-mediated EMT is regulated by the activation of 
peroxisome proliferator-activated receptor γ (PPARγ) (Kato et al., 2011). These 
results demonstrate that EMT regulation by NSAIDs can occur by COX-dependent 
and COX-independent mechanisms. The effect of aspirin on cell invasion and EMT 
is often assumed to be a result of aspirin-mediated platelet inhibition or COX 
inhibition. However, there are a number of other signalling pathways targeted by 
aspirin which are implicated in EMT regulation including the Wnt, mTOR and NF-
κB signalling pathways. 
The presence of oncogenic K-ras corresponded with increased cell migration in non-
small cell lung carcinoma (NSCLC) cells (Khan et al., 2016). This was demonstrated 
to be oncogenic K-ras dependent by the use of a dominant negative mutant of RAS 
which reversed these effects (Khan et al., 2016). Oncogenic K-ras induces EMT by 
increasing slug expression which subsequently reduces E-cadherin expression 
(Khan et al., 2016). This increased slug was illustrated to be ERK signalling 
dependent via the transcription factor Elk-1 and p65NFκB (Khan et al., 2016). 
Extracellular signal-related kinase (ERK) pathway is downstream of Ras signalling 
and is associated with proliferation, apoptosis and migration (Dhillon et al., 2007). 
p65NFκB is a subunit of the nuclear factor kappaB (NFκB) signalling pathway 
which has roles in proliferation, invasion and metastasis (Kim et al., 2006). Aspirin, 
a known inhibitor of p65NFκB, reduces cell migration and increases E-cadherin 
expression by decreasing slug expression (Khan et al., 2016). In addition, aspirin 
reduced expression of vimentin, twist, MMP2 and MMP9 which are associated with 
an invasive mesenchymal phenotype (Khan et al., 2016).  
NF-κB signalling has been demonstrated to be involved in the regulation of EMT in 
breast cancer cells by increased snail expression (Kim et al., 2007). MMP2 and 
MMP9 facilitate invasion and have both been demonstrated to be regulated by NF-
κB signalling by transcriptional regulation and post-translational processing (Min et 
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al., 2008). NF-κB signalling is involved in the regulation of cancer stem cells with 
inhibition of NF-κB signalling reducing the crypt hyperproliferative phenotype 
observed in β-catenin floxed mice (Schwitalla et al., 2013). NF-κB can modulate β-
catenin activity by a direct interaction between p65NF-κB and β-catenin (Schwitalla 
et al., 2013). Thus inhibition of NF-κB signalling can subsequently reduce Wnt 
signalling by inhibiting β-catenin/Tcf transcription of Wnt target genes. As aspirin is 
a potent NF-κB inhibitor, the role of NF-κB signalling in our system should be 
further investigated.  
Wnt signalling is required for maintenance of the stem cell population with 
dysregulated Wnt observed by increased stem cell numbers and cystic organoids 
(Clevers et al., 2014). Aspirin exposure reversed the cystic phenotype in Apc 
deficient organoids, reduced the stem cell population and inhibited the Wnt 
signalling pathway both in vitro and in vivo. The Wnt signalling pathway has the 
ability to regulate the epithelial-mesenchymal transition thus aspirin-mediated Wnt 
inhibition could explain the increase in E-cadherin and decrease in mesenchymal 
and motility markers (Vincan and Barker, 2008). However, increased levels of E-
cadherin alone can act as buffer for excessive cytoplasmic β-catenin by binding at 
the adherens junction thus preventing nuclear β-catenin accumulation and 
associated transcription of Wnt targets (Huels et al., 2015b). Therefore, the decrease 
in β-catenin, in CRC cell lines and in vivo, may be a consequence of increased E-
cadherin rather than the cause. To investigate if Wnt signalling is responsible for 
these effects, I would first investigate the effects of aspirin on β-catenin knockout 
CRC cells. There is also the option of using E-cadherin knockout cells and organoids 
to determine if the aspirin-mediated reduction in β-catenin expression is reliant on 
increased E-cadherin expression. It is probable that there is a feedback loop in which 
inhibition of Wnt results in increased E-cadherin due to inhibition of EMT and this 
in turn further decreases Wnt signalling by removing free β-catenin. In addition, the 
Wnt signalling pathway can directly activate the mTOR signalling pathway via 
GSK-3β (Laplante and Sabatini, 2012). Therefore, inhibition of the Wnt signalling 
pathway could potentially explain the decrease in mTOR signalling.  
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The mTOR signalling pathway is another candidate pathway which may be 
regulating all the effects of aspirin demonstrated in this thesis. The mTOR pathway 
has been demonstrated to regulate CRC motility, invasion and EMT in colorectal 
cancer (Gulhati et al., 2011).  An inhibition of EMT and subsequent increase in E-
cadherin would explain the Wnt signalling and stem cell effects as a consequence of 
mTOR inhibition. Aspirin inhibits mTOR signalling and the associated cellular 
proliferation in CRC cell lines (Din et al., 2012) and I have demonstrated here that 
aspirin also inhibits mTOR signalling in adenomas in vivo. This is especially 
important given the reliance on mTOR signalling in cellular proliferation post Apc 
loss (Faller et al., 2015) thus an effective mTOR inhibitor would theoretically be 
clinically relevant in CRC treatment. Aspirin’s inhibition of the ROCK1 motility 
pathway, which is downstream of RhoA and Rac1 signalling, is another link to the 
mTOR signalling pathway as mTOR’s regulation of motility and EMT has been 
demonstrated to be RhoA/Rac1 dependent (Chen et al., 2014; Gulhati et al., 2011). 
Knockdown of raptor and rictor by siRNA can determine the dependency of 
mTORC1 and mTORC2 respectively. Although, feedback loops between the two 
complexes, such as TSC, Akt and S6K1, highlights the complexities involved in 
determining which, if any, complex is responsible.  
A weakness of this research was the failure to induce EMT in the CRC cell lines 
which limited the investigation of EMT inhibition and prevention. Attempts to 
induce EMT in CRC cell lines with growth factor stimulation were unsuccessful but 
induction of an EMT phenotype in CRC cells has been demonstrated previously in 
the literature by alternative methods. The LIM1863 cells are a colon carcinoma cell 
line which grow as spheroids in culture and undergo EMT to become a migrating 
monolayer of mesenchymal cells in response to TGF-β stimulation (Bates et al., 
2007). Culture on collagen-coated plastic with 20ng/µl TGF-β for 48 hours induces 
EMT in HT-29 cells as observed by a reduction in E-cadherin and increased ZEB-1 
expression (Kirane et al., 2012). Overexpression of snail induces EMT and a cancer 
stem cell phenotype in CRC cell lines (Fan et al., 2012). In hindsight, induction of 
EMT by overexpressing an EMT transcription factor, such as snail, would have been 
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the most consistent method of EMT induction. The co-culture of cancer cell lines 
with platelets induces EMT although I was interested in the effect of aspirin on CRC 
cells in the absence of platelets. Despite the failure to induce EMT, I was still able to 
demonstrate that aspirin promotes the mesenchymal-epithelial transition in CRC 
cell lines, organoids and in ApcMin/+ small intestine adenomas in vivo.  
The strength of this research was the replication of aspirin-mediated effects in CRC 
cell lines, organoids and in vivo experiments. Aspirin promoted a less motile 
epithelial phenotype in both mouse and human tissue. The reversal of a cystic 
phenotype and reduction in the stem cell population in Apc deficient organoids was 
replicated in both mouse and human tissue. Aspirin inhibits both the Wnt and 
mTOR signalling pathways although signalling dependency has not been 
established. Future research should focus on determining signalling dependency by 
using inhibitors and specific knockouts for key components of the Wnt and mTOR 
signalling pathway, such as raptor knockout to determine mTORC1 dependency. 
The potential clinical benefit of aspirin in CRC treatment was highlighted by the 
increased survival of ApcMin/+ mice after establishment of adenoma burden. To 
conclude, I have demonstrated aspirin reduces cell invasion, promotes the 
mesenchymal-epithelial transition and reduces the stem cell population in colorectal 
cancer which may help explain some of the post-diagnosis benefits of aspirin in 
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